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Abstract 
 
Identification and Characterization of the P53-Induced Long Noncoding RNA 
Isoform Pvt1b and Its Role in Stress-Specific Growth Inhibition via Myc 
Repression 
 
Christiane Elizabeth Olivero 
2021 
 
The tumor suppressor p53 and proto-oncogenic Myc transcription factors 
are frequently deregulated in cancer, with common loss-of-function and gain-of-
function mutations observed in the p53 and Myc networks, respectively. Referred 
to as the ‘guardian of the genome,’ p53 regulates genes important for curtailing 
cellular proliferation and tumorigenesis under conditions of stress, while the 
proto-oncogene Myc induces genes that, in contrast, promote cellular growth and 
can, in overcoming growth inhibitory signals, support cancer development. While 
previous literature has documented decreased Myc expression in response to 
cellular stress, researchers have long puzzled over identifying the specific 
regulatory lever responsible. The work presented here identifies a novel regulatory 
axis positioned at the intersection of the p53 and Myc pathways, which represses 
Myc and restricts cellular proliferation downstream of p53 activation. 
Long noncoding RNAs (lncRNAs) are a diverse class of transcripts lacking 
protein-coding potential and implicated in gene expression regulation. Here I 
present my work on the identification of an isoform of the lncRNA Plasmacytoma 
variant translocation 1 (Pvt1) and the characterization of its role in the p53-
mediated response to stress. I found that the stress-specific Pvt1b, expressed 50 
Kb downstream of the Myc locus, is induced by p53 in response to oncogenic and 
 ii 
genotoxic stress and accumulates at its site of transcription. I demonstrated that 
production of the Pvt1b RNA is necessary and sufficient to repress Myc 
transcription in cis without altering the chromatin organization of the locus. I 
investigated the functional outputs of Pvt1b-mediated Myc downregulation and 
found that inhibition of Pvt1b increased both Myc levels and transcriptional 
activity and promoted cellular proliferation. Notably, Pvt1b loss accelerated tumor 
growth, but not tumor progression, in an autochthonous mouse model of lung 
cancer. Further examination of the Pvt1b mechanism of action failed to identify 
Pvt1b-specific sequences required for its function, but uncovered a potential role 
for histone deacetylation in Pvt1b regulation of Myc. Finally, I initiated 
development of a suite of genetically engineered Pvt1 mouse models, the 
characterization of which will shed light on Pvt1 function in vivo and benefit future 
mechanistic studies. 
Taken together, this work conceptually advances our understanding of 
stress-induced growth inhibition orchestrated by p53. Specifically, I identify Pvt1b 
as the primary mediator of stress-specific Myc repression, providing insight into 
the long-standing question of how p53 activation triggers Myc downregulation. As 
such, this work has far-reaching implications not only for our understanding of cis-
acting lncRNAs, which can fine-tune local gene expression downstream of broadly 
active transcription programs, but also for the exciting therapeutic possibility of 
restricting Myc levels in cancer via Pvt1b modulation. 
 
 
Identification and Characterization of the P53-Induced Long Noncoding RNA 








Presented to the Faculty of the Graduate School 
of 
Yale University 
in Candidacy for the Degree of 








































© 2021 by Christiane Elizabeth Olivero 
All rights reserved. 
 v 
Acknowledgements  
 The work presented here would not have been possible without the 
enduring support of my colleagues, friends, and family. 
 My development as a scientist has been shaped, guided, and immeasurably 
enriched by exceptional female mentors. I am immensely grateful not only for their 
expertise, critiques, encouragement, and advice, but also for the opportunity to 
learn from the example they set as successful women in science. First and 
foremost, I would like to thank my thesis advisor, Nadya Dimitrova, for her 
passion, drive, and unfaltering enthusiasm for our work. She has challenged and 
inspired me in equal measure, and I am deeply appreciative of her dedicated 
mentorship and commitment to my intellectual growth. My dissertation research 
has also benefitted from the guidance of three outstanding scientists that comprise 
my thesis committee: Valerie Horsley, Josien van Wolfswinkel, and Joan Steitz. I 
am thankful for their discerning questions, insightful suggestions, and support of 
my professional aspirations. I would also like to thank my undergraduate research 
advisors, Priscilla Van Wynsberghe and Natasha Caplen, for fostering my budding 
scientific curiosity and encouraging me to pursue post-graduate education.  
 I feel infinitely lucky to have spent my time at the bench surrounded by 
people I now count as treasured friends. My colleagues in the Dimitrova lab built 
a community filled with camaraderie, humor, and mutual respect and admiration. 
I am deeply grateful to the current and former members of this uplifting 
environment: Ephrath Tesfaye, Lauren Winkler, Elena Martínez-Terroba, Peppe 
 vi 
Militello, Clara Liao, Rahul Nagvekar, Sonja Herter, Nina Grexa, Yee Nip, Ben 
Shao, and Meg Tian.  It is rare to stumble upon a group of people that can function 
as intellectual sounding board, emotional cheerleaders, and trusted confidantes in 
turn, and I credit our frequent coffee runs with maintaining my spirit and sanity 
through the hills and valleys of doctoral research.  
I would also like to thank the inclusive scientific community nurtured by the 
Molecular, Cellular, and Developmental Biology (MCDB) department at Yale. I am 
grateful for every MCDB seminar, retreat, and happy hour, and the many gifted 
colleagues I had the pleasure of interacting with during my time here. 
 My work was supported, in part, by the National Institutes of Health (NIH)- 
funded Training Program in Cellular, Molecular, and Quantitative Biology; I 
appreciate all the scientific and career development opportunities it afforded. 
 Finally, I am grateful for the lovely and kindhearted friends I’ve had the 
good fortune to meet at Yale, of which there are too many to name here. Above all, 
I would like to thank my family for the unconditional love and support they’ve 
given so freely over the past five years, and indeed, my entire life. To my 
grandparents, Jim and Arlene, thank you for your unwavering pride in your 
favorite granddaughter. To my brother, AJ, thank you for reminding me not to take 
myself too seriously. To my dad, Bob, thank you for endeavoring to solve any 
problem I faced, no matter how abstract or intractable. And to my mom, Kerin, 
thank you for your calming presence during my worst moments of self-doubt. To 
my parents especially, I would be lost without you both as my guideposts. 
 vii 
Table of Contents  
 
Abstract ................................................................................................ i 
Acknowledgements .......................................................................... v 
Table of Contents ............................................................................ vii 
Nonstandard Abbreviations .......................................................... ix 
List of Figures and Tables .............................................................. xv  
 
Chapter 1: Background ......................................................... 1  
Long noncoding RNAs in gene regulation ............................................ 1 
 Long noncoding RNA mechanisms of action …………………….….. 6 
Long noncoding RNAs in cancer ......................................................... 16 
The p53 and Myc duet in cancer ......................................................... 48  
The p53 tumor suppressor pathway .......................................... 50 
The proto-oncogenic Myc network ……...................................... 53 
Project framework: p53, Myc, and the missing lncRNA ….................. 54 
 
Chapter 2: 
p53 activates the long noncoding RNA Pvt1b to inhibit Myc and 
suppress tumorigenesis ………………………………………………….……….. 58 
 Introduction ……………………………………………………….………….. 58 
Results ……………………………………………………………………….….. 61 
Discussion …………………………………………………………….……….. 94 
 viii 
Chapter 3:  
Investigating the functional elements of the Pvt1b transcript …….... 99 
Introduction …………………………………………………………….…….. 99 
Results ……………………………………………………………………….….. 99 
Discussion …………………………………………………………………….. 107 
 
Chapter 4:  
Investigating the mechanism of Pvt1b-mediated Myc repression .. 109 
Introduction ………………………………………………………..……….. 109 
Results ………………………………………………………………………….. 110 
Discussion …………………………………………………………………….. 114 
 
Chapter 5:  
Generation of genetically engineered Pvt1 mouse models ………….. 116 
Introduction ………………………………………………………………….. 116 
Results ………………………………………………………………………….. 121 
Discussion …………………………………………………………………….. 125 
 
Chapter 6: Summary and Perspectives ................................. 127 
Final remarks ........................................................................... 139  
 
Chapter 7: Materials and Methods ......................................... 140 
 
Supplementary Tables ................................................................. 159  
References ...................................................................................... 167 
 ix 
Nonstandard Abbreviations  
 
AAH   atypical adenomatous hyperplasia 
AFAP1  actin filament-associated protein 1 
AFAP1-AS1  AFAP1 antisense RNA 1 
Airn   antisense of Igf2r ncRNA 
ALV   avian leukosis virus 
ANRIL  antisense noncoding RNA in the INK4 locus 
APC   adenomatous polyposis coli protein 
AR   androgen receptor 
Arf   alternate reading frame of Cdkn2a 
ARLNC1  AR-regulated long noncoding RNA 1 
ASO   antisense oligonucleotide 
BAC   bacterial artificial chromosome 
BANCR  BRAF-activated non-protein coding RNA 
BC   breast cancer 
BCAR4  breast cancer anti-estrogen resistance 4 
CARLo-5  cancer-associated region long noncoding RNA 5 
CASC14  cancer susceptibility candidate-14 
CCAT1/2  colon cancer-associated transcript 1/2 
CDKN2A  cyclin-dependent kinase inhibitor 2A/B 
ChIP   chromatin immunoprecipitation 
CHX   cycloheximide 
circRNA  circular RNA 
CLIP   crosslinking and immunoprecipitation 
CNV   copy number variation 
CON   control 
CRISPR  clustered regulatory interspaced short palindromic repeats 
CRISPRa  CRISPR activation 
CRISPRi  CRISPR inhibition 
 x 
CRISPR-SAM CRISPR synergistic activation mediator 
CRNDE  colorectal neoplasia differentially expressed 
CTL   cytotoxic T cell 
DANCR  differentiation antagonizing non-protein coding RNA 
DAPI   4’,6-diamidino-2-phenylindole 
DINO   damage-induced noncoding 
DMBA  7,12-Dimethylbenz[a]anthracene 
DNA-FISH  DNA fluorescence in situ hybridization 
DOXO  doxorubicin 
dRNA   ‘dead’ RNA 
ecDNA  extrachromosomal DNA 
EPIC1   epigenetically induced lncRNA 1 
ER   estrogen receptor; ERAR, ER agitation-related 
eRNA   enhancer RNA 
ETOP   etoposide 
EV   empty vector 
FAL1   focally amplified lncRNA 1 
FALEC  focally amplified long noncoding RNA in epithelial cancer 
Firre   functional intergenic repeating RNA element 
F1   first filial 
Gadd7   growth-arrested DNA damage-inducible gene 7 
GAPLINC gastric adenocarcinoma predictive long intergenic noncoding 
RNA 
GAS5   growth arrest-specific 5 
GATA6  GATA-binding protein 6 
GEMM  genetically engineered mouse model 
GFP   green fluorescent protein 
GOF   gain-of-function 
gRNA   guide RNA 
GWAS  genome-wide associated study 
Gy   gray 
HDAC   histone deacetylase 
 xi 
HDR   homology directed repair 
H&E   hematoxylin and eosin 
hnRNP  heterogeneous ribonucleoprotein 
HOTAIR  HOX transcript antisense RNA 
HOTTIP  HOXA distal transcript antisense RNA 
HPV   human papillomavirus 
HULC   highly upregulated in liver cancer 
IDR   intrinsically disordered region 
Igf2r   insulin-like growth factor receptor 2 
IκB   inhibitor of kappa B  
JAX   Jackson Laboratory for Genomic Medicine 
KC   K-rasLSL-G12D/+; Rosa26-Cas9LSL/LSL 
KI   knock-in 
KO   knock-out 
KPC   K-rasLSL-G12D/+; p53FL/FL; Rosa26-Cas9LSL/LSL 
KRAS   kirsten rat sarcoma viral oncogene homolog 
KPR   KrasLA2-G12D/+; p53LSL/LSL; Rosa26-CreERT2  
LAST   lncRNA-assisted stabilization of transcripts 
LED   lncRNA activator of enhancer domains 
LINC-PINT long intergenic non-protein coding RNA, p53-induced 
transcript 
LLPS liquid-liquid phase separation 
LNA   locked nucleic acid 
lncGATA6  lncRNA GATA6 
lncPRESS1  lncRNA p53-regulated and ESC-associated 1 
lncRNA  long noncoding RNA 
LOF   loss-of-function 
LOH   loss of heterozygosity 
LSAMP  limbic system-associated membrane protein 
LSL   loxP-STOP-loxP  
LUAD   lung adenocarcinoma 
MALAT1  metastasis-associated lung adenocarcinoma transcript 1 
 xii 
MAPK   mitogen-activated protein kinase 
MaTAR  mammary tumor-associated RNA 
MAX    Myc associated factor X 
MBP   Ms2 binding protein 
MCL1   myeloid cell leukemia sequence 1 
Mdm2  mouse double minute 2 
MEF   mouse embryonic fibroblast 
MEG3   maternally expressed 3 
miRNA  microRNA 
MITF   microphthalmia-associated transcription factor 
MMTV-PyMT mouse mammary tumor virus-polyomavirus middle T antigen 
Morrbid myeloid RNA regulator of Bim-induced death 
mRNA messenger RNA 
MYC myelocytomasis oncogene 
MYCLo  MYC-regulated lncRNA 
NANCI  Nkx2.1-associated noncoding intergenic RNA 
NBAT-1  neuroblastoma-associated transcript-1 
ncRNA  noncoding RNA 
NEAT1  nuclear enriched abundant transcript 1 
NF-κB  nuclear factor-kappa B 
NKILA  NF-κB interacting long noncoding RNA 
NKX2.1  NK2 homeobox 1 
NMD   nonsense-mediated decay 
NORAD  noncoding RNA activated by DNA damage 
OIS1   oncogene-induced senescence 1 
ORF   open reading frame 
Orilnc1  oncogenic RAS-induced lncRNA 1 
PAM   protospacer adjacent motif 
PANDA  p21-associated ncRNA DNA damage activated 
PANDAR  promoter of CDKN1A antisense DNA damage activated RNA 
PanINs  pancreatic intraepithelial neoplasias 
PAS   polyadenylation sequence 
 xiii 
PCa   prostate cancer 
PCA3   prostate cancer antigen 3 
PCATs  prostate cancer-associated ncRNA transcripts 
PCAT1/19  prostate cancer-associated transcript 1/19 
PcG   polycomb group 
PCGEM1  prostate cancer gene expression marker 1 
PDAC   pancreatic ductal adenocarcinoma 
PDX   patient-derived xenograft 
PHH3   phosphorylated histone H3 
PINCR  p53-induced noncoding RNA 
PRAL   p53 regulation-associated lncRNA 
PRC1/2  polycomb repressive complex 1/2 
PR-lncRNA  p53-regulated lncRNA 
PR MEF  p53LSL/LSL; Rosa-CreERT2 mouse embryonic fibroblast 
PRNCR1  prostate cancer- associated noncoding RNA 1 
PSA   prostate-specific antigen 
PTENP1  phosphatase and tensin homolog pseudogene 1 
PURPL  p53 upregulated regulator of p53 levels 
PVT1   plasmacytoma variant translocation 1 
p53BER  p53-bound enhancer regions 
p53RE  p53 response element 
qRT-PCR  quantitative reverse transcription polymerase chain reaction 
RAP-MS  RNA antisense purification mass spectrometry 
RBP   RNA binding protein 
RIP   RNA immunoprecipitation 
RNAi   RNA interference 
RNA Pol II  RNA polymerase II 
RNP   ribonucleoprotein 
SAHA   suberoylanilide hydroxamic acid 
SALNR  senescence-associated lncRNA 
SAMMSON survival-associated mitochondrial melanoma-specific 
oncogenic noncoding RNA 
 xiv 
SCC   squamous cell carcinoma 
SCNV   somatic copy number variation 
SHARP  SMART/HDAC1-associated repressor protein 
siRNA   small interfering RNA 
smRNA-FISH single molecule RNA fluorescence in situ hybridization 
SMRT silencing mediator of retinoic acid and thyroid hormone 
receptor 
SNHG15  small nucleolar RNA host gene 15 
snoRNA  small nucleolar RNA 
SNP   single nucleotide polymorphism 
SpCas9  Streptococcus pyogenes Cas9  
SPRY4  sprouty RTK signaling antagonist 4 
SPRY4-IT1  SPRY4 intronic transcript 1 
ssODN  single-stranded oligo donors 
TAD   topologically associated domain 
TAM   tamoxifen 
TCGA   The Cancer Genome Atlas 
THOR testis-associated highly conserved oncogenic long noncoding 
RNA 
TIDE tracking of indels by decomposition 
TPA   12-O-tetradecanoylphorbol-13-acetate 
TSA   trichostatin A 
TSS   transcription start site 
TWI   twister ribozyme 
UCA1   urothelial cancer associated 1 
Wnt   wingless/integrated 
WT   wild-type 
XCI   X-chromosome inactivation 
XIST   X-inactive specific transcript 
XRN2   5'-3' Exoribonuclease 2 
 
 xv 
List of Figures and Tables 
 
Figure 1: Cis- and trans- acting mechanisms of action by lncRNAs .................. 13  
 
Figure 2: Identification and functional characterization of MALAT1 ............... 34 
 
Figure 3: Identification and functional characterization of NEAT1 .................. 36 
 
Figure 4: Identification and functional characterization of PVT1 ..................... 39 
 
Figure 5: Identification and functional characterization of THOR ................... 46 
 
Figure 6: The p53 tumor suppressor pathway …................................................ 52 
 
Figure 7: The p53 and Myc transcription networks in cancer …......................... 57 
 
Figure 8: p53 suppresses Myc in response to genotoxic and oncogenic stress 
……………………………………………………………………………………………………………….. 63 
 
Figure 9: p53-dependent induction of the Pvt1 isoform, Pvt1b …...................... 66 
 
Figure 10: p53 activates the lncRNA isoform Pvt1b …....................................... 67 
 
Figure 11: p53 activation does not substantially alter chromatin architecture 
of the Myc-Pvt1 locus …......................................................................................... 69 
 
Figure 12: Accumulation of Pvt1 isoforms in the chromatin surrounding the 
Pvt1-Myc locus …................................................................................................... 72 
 
Figure 13: Co-localization of Pvt1a and total Pvt1 by smRNA-FISH ….............. 73 
 
Figure 14: Production of Pvt1b RNA suppresses Myc expression in cis …......... 77 
 
Figure 15: Effects of Pvt1b manipulation in cis and in trans on Myc protein 
levels ………….......................................................................................................... 79 
 
Figure 16: Genetic inhibition of Pvt1b leads to increased Myc levels …............ 82 
 
Figure 17: Genetic inhibition of Pvt1b rescues stress-dependent Myc 
repression in KPR clonal and MEF cell lines ….................................................... 83 
 
Figure 18: Effects of genetic inhibition of Pvt1b on the chromatin architecture 
of the Myc-Pvt1 locus and Myc transcription …................................................... 85 
 
 xvi 
Figure 19: Pvt1b suppresses Myc transcription and proliferative function ...... 88 
 
Figure 20: Tumor-specific editing in a lung cancer model reveals a role for 
Pvt1b in suppressing tumor growth, but not progression …................................. 92 
 
Figure 21: Mutagenesis of Gm26542-associated p53RE does not affect 
proliferation in vitro, tumor growth in vivo ………………………………..................... 93 
 
Figure 22: LncRNA Pvt1b mediates crosstalk between the Myc and p53 
transcriptional networks ….................................................................................... 98 
 
Figure 23: Probing the role of the Pvt1 ex1b sequence in p53-dependent Myc 
repression …......................................................................................................... 102 
 
Figure 24: Probing the role of spliced Pvt1b in p53-dependent Myc repression 
……………………………………………………………………………………………………………… 106 
 
Figure 25: Histone deacetylation may be required for stress-dependent Myc 
repression ….......................................................................................................... 112 
 
Figure 26: Schematic of Pvt1 GEMMs …………………………………….................... 120 
 
Figure 27: Pvt1-PAS, Pvt1b-PAS, and Pvt1b-TWI genotyping ……….….…........ 123 
 
 
Supplementary Table 1: ASO, dRNA, gRNA, HDR template, and smRNA 
FISH probe information 
 
Supplementary Table 2: qRT-PCR and PCR primer sequences 
 
Supplementary Table 3: Key plasmids and recombinant DNA used in this 
work 
 







Chapter 1: Background 
 
Long noncoding RNAs in gene regulation 
 Recent sequencing advances have revealed pervasive transcription of 
mammalian genomes, far exceeding the level of RNA production required for 
protein synthesis alone. Specifically, despite protein-coding sequences comprising 
just 2% of the human genome, as much as 75% of the genome is transcribed 
(Djebali et al., 2012). This discrepancy has largely upended one of the foundational 
tenets of molecular biology: that RNA (with a few notable exemptions) provides 
the cellular instructions, copied from DNA, to produce proteins (Rinn and Chang, 
2012). Why cells expend the energy to transcribe a majority of the genome is still 
not well understood, and some have speculated that these noncoding RNAs 
(ncRNAs), not being destined for translation, may amount to nothing more than 
extensive transcriptional noise. However, there is increasing evidence for 
noncoding transcripts with critical roles in cellular homeostasis, implicating these 
RNAs as having nuanced and previously unappreciated functions that go far 
beyond mere messenger (reviewed in (Statello et al., 2020)). 
Once simply referred to as “junk DNA,” recent years have seen a collective 
reframing of noncoding DNA sequences as mysterious genomic “dark matter” with 
unexplored functional depths. Breaking from a protein-centric view of cellular 
operations, there has been growing interest in how the RNAs produced from these 
enigmatic parts of the genome might impose an additional regulatory layer on 
cellular activities. Constituting perhaps the most nebulous of these ncRNA classes, 
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long noncoding RNAs (lncRNAs) encompass a heterogenous collection of 
RNA molecules broadly defined as transcripts exceeding 200 nucleotides in length 
and, like other ncRNAs, lacking protein-coding potential (Rinn and Chang, 2012). 
In contrast to other ncRNAs classes, such as miRNAs (microRNAs), with their 
comparatively well-defined role in post-transcriptional gene regulation, lncRNAs 
have far more varied and versatile roles in biology, stemming in part from their 
imprecise operational definition (Cech and Steitz, 2014). 
LncRNA transcription and processing share many similarities with those of 
protein-coding genes. For one thing, lncRNA genes possess chromatin marks 
consistent with other actively transcribed genes: H3K4me3, H3K9ac, H3K27ac 
(Guttman et al., 2009). Like mRNAs (messenger RNAs), many lncRNAs are 
transcribed by RNA Pol II, and are often subject to 5’-capping, splicing, and 
polyadenylation (Quinn and Chang, 2016). Following transcription, lncRNAs have 
comparable stability to mRNAs, with slightly shorter half-lives on average (Clark 
et al., 2012), and are also subject to nonsense-mediated decay (NMD), although 
perhaps with increased susceptibility over mRNAs (Mendell et al., 2004). 
However, there are several key features that distinguish lncRNAs from coding RNA 
transcripts, apart from their lack of open reading frame (ORF). First, the structures 
of lncRNA loci can vary widely, with lncRNA genes found overlapping, antisense 
to, or divergent from protein-coding genes, or located in intronic or intergenic 
regions (Rinn and Chang, 2012). Notably, lncRNAs can also undergo unique 
processing events, including RNase P 3’ end cleavage (as in MALAT1 processing) 
(Wilusz et al., 2008), RNA back-splicing to form circRNAs (circular RNAs) 
(Salzman et al., 2012), and the trimming of snoRNAs (small nucleolar RNAs) from 
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the introns of protein-coding genes (Yin et al., 2012) (reviewed in (Quinn and 
Chang, 2016)). Importantly, it is likely that our understanding of the full breadth 
of diversity in lncRNA form, structure, and processing is incomplete. 
LncRNA genes engulf protein-coding genes in abundance. While one study 
identified roughly 60,000 lncRNA genes in the human genome (Iyer et al., 2015), 
estimates of that number now approach 100,000, far outstripping the 21,000 
known protein-coding genes (Fang et al., 2018). Interestingly, some have noted a 
correlation between higher numbers of lncRNA genes and increasing organismal 
complexity, suggesting lncRNAs may have played an outsized role in recent 
evolutionary history (Jandura and Krause, 2017). Indeed, the ratio of noncoding 
to protein-coding DNA sequences increases as a factor of developmental 
complexity and is especially high in vertebrates (Mattick, 2004). This observation 
highlights the importance of the expansion of the noncoding genome, although it 
is still unknown whether this relationship between noncoding DNA and 
organismal intricacy is causal or simply incidental. 
 Analyses of the human transcriptional landscape have determined that 
lncRNAs are expressed with exquisite cell-type and disease-state specificity (Iyer 
et al., 2015). While this may point to critical lncRNA functions in normal and 
disease states, it is thus far from clear whether these specific lncRNA expression 
patterns are a cause or consequence of underlying biology. To date, examination 
of individual lncRNAs has revealed functions in cell cycle regulation (Dimitrova et 
al., 2014; Marin-Bejar et al., 2013), nuclear organization (Hacisuleyman et al., 
2014; Sunwoo et al., 2009), and differentiation (Jain et al., 2016; Kretz et al., 
2013), among myriad other ubiquitous cellular processes (reviewed in (Statello et 
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al., 2020)). As a result of lncRNA-specific expression signatures, the putative 
prognostic value of lncRNAs in disease is high. For example, several lncRNAs are 
expressed at higher levels in accordance with increased tumor stage or metastasis 
risk, and can provide valuable information about cancer severity (Lu et al., 2017; 
Shi et al., 2015). UCA1 (Urothelial Cancer Associated-1) and HULC (Highly 
Upregulated in Liver Cancer) have been proposed as biomarkers for bladder and 
liver cancer, respectively, in keeping with the tissues in which they were originally 
identified (Milowich et al., 2015; Xie et al., 2013). Surprisingly, the only lncRNA to 
be used in an FDA-approved diagnostic test to date is PCA3 (Prostate Cancer 
Antigen 3); its presence in patient urine samples enables prostate cancer diagnosis 
with a high degree of accuracy and sensitivity, surpassing the previous diagnostic 
standard, prostate-specific antigen (PSA) (Fradet et al., 2004; Hessels et al., 
2003). Continuing advances in our knowledge of the specificity of lncRNA 
expression patterns in disease will provide ample occasion for lncRNA-based 
diagnostic and prognostic test development moving forward. 
Of the lncRNAs which have been functionally characterized, many regulate 
gene expression, having described roles in modulating virtually every step of RNA 
production (Dimitrova et al., 2014; Marin-Bejar et al., 2013), processing (Tripathi 
et al., 2010; Yap et al., 2018), stability (Cao et al., 2017; Kretz et al., 2013), and 
translation (Carrieri et al., 2012; Zhang et al., 2013) (reviewed in (Statello et al., 
2020)). Gene regulation by lncRNAs is an extensive area of research; there has 
been significant interest in the role of lncRNAs in epigenetic modifications in 
particular, with several studies describing lncRNAs interacting with polycomb 
proteins to elicit gene repression (Khalil et al., 2009; Rinn et al., 2007; Tsai et al., 
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2010). While recent work demonstrating the promiscuous binding of PRC2 
(Polycomb Repressive Complex 2) to RNAs has cast doubt on the prevalence of this 
mechanism of action (Davidovich et al., 2013), lncRNAs have been shown to 
frequently associate with chromatin-modifying complexes to control transcription 
of target genes (reviewed in (Statello et al., 2020)). It is important to note that 
lncRNA functions are by no means restricted to gene regulation, and an increasing 
number of studies highlight regulatory roles for lncRNAs in organizing subcellular 
compartments and governing organelle activities (Clemson et al., 2009; Leucci et 
al., 2016; Yap et al., 2018). 
Despite immense growth in the field of lncRNA biology over the past three 
decades, efforts to distinguish bona fide functional lncRNAs from transcriptional 
noise have been bogged down by the sheer volume of uncharacterized lncRNA 
transcripts, raising questions about how to best prioritize them for additional 
study. Bioinformatic analyses have attempted to tackle this problem by examining 
the molecular features and regulation of lncRNAs to provide clues about their 
potential functions. One popular method involves assigning putative functions to 
lncRNAs based on their co-expression with protein-coding genes (Guttman et al., 
2009; Hung et al., 2011). These so-called “guilt by association” studies use what is 
known about different cellular pathways as a proxy for lncRNA function based on 
whether a lncRNA is co-regulated with protein-coding genes in the same network. 
The database decodeRNA catalogues lncRNAs based on this strategy (Lefever et 
al., 2017), although these functional projections should be approached with 
caution due to the correlative nature of these analyses. Others have attempted to 
predict function by evaluating lncRNA composition. For example, one recent study 
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grouped lncRNAs based on short sequence motifs called kmers, finding functional 
similarities between lncRNAs with related kmer profiles, despite an absence in 
linear sequence homology (Kirk et al., 2018). Notwithstanding these advances in 
computational methods, experimental validation of lncRNA candidates is the only 
way to confirm their functional importance. As such, recent genome-wide screens 
for functional lncRNAs that evaluate a specific cellular output following 
perturbation, such as those that have been performed using CRISPR/Cas9 genome 
editing, or its variants CRISPRa (CRISPR activation) or CRISPRi (CRISPR 
inactivation), can provide useful insights into function (Bester et al., 2018; Joung 
et al., 2017; Liu et al., 2017; Zhu et al., 2016). 
 
Long noncoding RNA mechanisms of action 
 The study of lncRNAs poses unique challenges, but perhaps the most 
irksome of these is the inability to define lncRNAs based on an unequivocal set of 
characteristics. Unlike mRNAs, or indeed some other ncRNA classes, there is no 
distinct (or even hazy) lncRNA model that can provide clear instructions for 
functional characterization, because any two lncRNAs can vary greatly in form, 
function, and mechanism of action. As a class, lncRNAs are extremely modular, 
able to bind DNA, proteins, and other RNAs, and multifaceted in their regulatory 
output, capable of eliciting either positive or negative feedback within a variety of 
cellular pathways (reviewed in (Statello et al., 2020)). Therefore, while the existing 
body of lncRNA literature can provide clues as to what a lncRNA might do, there 
is no standard path to follow when it comes to experimental design. Many 
frameworks have been developed which attempt to classify lncRNAs by their 
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modes of action (Rinn and Chang, 2012; Wang and Chang, 2011). For example, 
some have proposed dividing lncRNAs by “mechanistic themes” into those which 
act as either “decoys,” which interfere with DNA-protein interactions, “scaffolds,” 
which bring together two or more proteins in a complex, or “guides,” which localize 
proteins within a specific genomic area (Rinn and Chang, 2012).  While these 
groupings are certainly useful, there are many gray areas and potential for overlap 
that preclude precise categorization. 
One framework that is particularly helpful for initial lncRNA 
characterization without extensive a priori knowledge of mechanism involves 
broadly categorizing lncRNAs by their localization, or more specifically, based on 
the cellular compartment in which they reside. Subcellular fractionation and single 
molecule RNA fluorescence in situ hybridization (smRNA-FISH) are useful 
experimental tools for determining lncRNA location within the cell (Cabili et al., 
2015; Conrad and Orom, 2017). Notably, the majority of lncRNAs are nuclear-
enriched, perhaps reflecting the large number of lncRNAs involved in some aspect 
of gene expression regulation (Cabili et al., 2015; Derrien et al., 2012). LncRNA 
localization patterns have significant bearing on the spectrum of potential 
functions a lncRNA can execute, and can therefore guide further mechanistic 
studies. As such, lncRNA subcellular position informs an extremely related 
framework: categorization based on whether a lncRNA regulates in cis or in trans 
(Kopp and Mendell, 2018; Quinn and Chang, 2016). 
Cis-acting lncRNAs generally reside close to their site of transcription 
and regulate genes located in cis, or which are expressed from the same 
chromosome (Figure 1) (Gil and Ulitsky, 2020). These lncRNAs may act on their 
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nearest neighbor, or cross large linear distances to enact regulation, with spatially 
disparate genes brought in close proximity by long-range chromatin interactions 
(Cai et al., 2016). These distant contacts are often, but not always, facilitated 
between genes residing within the same topologically associated domain (TAD) 
(Groff et al., 2018). While many cis-regulatory lncRNAs exert control over one or 
more target genes, their effects can also be far more widespread. 
One lncRNA with extensive regulatory influence is XIST (X-Inactive-
Specific Transcript), a lncRNA which performs the critical task of dosage 
compensation in females by coordinating epigenetic repression of the entire X-
chromosome from which it is expressed in a process known as X-chromosome 
inactivation (XCI) (reviewed in (Loda and Heard, 2019)). XIST becomes 
upregulated in early development, eventually coating one of two X-chromosomes 
to induce widespread chromosomal reorganization and a heterochromatic state 
(Loda and Heard, 2019). Indispensable for gene silencing, XIST is responsible for 
coordinating the repression of >1000 genes through functions encoded in discrete 
and genetically separable elements of the XIST transcript (Loda and Heard, 2019). 
For example, the repeat A region of XIST is essential for gene silencing (Wutz et 
al., 2002), while other regions have been identified as necessary for recruitment of 
PRC1 (Polycomb Repressive Complex 1) or its localization on the inactive X-
chromosome, with some occasional redundancy (Colognori et al., 2019; Wutz et 
al., 2002). The XIST sequences and RNA binding proteins (RBPs) required for the 
establishment and maintenance of gene silencing, and the precise order of events 
in XCI, are incompletely understood. Attempts to identify XIST interactors have 
revealed numerous binding partners including various PcG (polycomb group) 
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proteins, hnRNPs (heterogeneous ribonucleoproteins), and others with unknown 
functional significance (Chu et al., 2015; McHugh et al., 2015). Different 
approaches have defined different, albeit overlapping, sets of XIST interacting 
proteins (Chu et al., 2015; McHugh et al., 2015). Notably, multiple studies have 
identified SHARP (SMART/HDAC1-Associated Repressor Protein; also known as 
Spen) as an XIST binding partner with a critical role in recruiting the nuclear 
corepressor SMRT and the histone deacetylase HDAC3 to remove activating 
histone acetylation marks from the X-chromosome (Chu et al., 2015; McHugh et 
al., 2015). However, a recent study demonstrated that HDAC3 is not essential to 
the establishment of XCI (Zylicz et al., 2019), raising questions about the role of 
the XIST-SHARP interaction in gene repression. While study of XIST dates back 
to the beginning of the lncRNA field itself (Brown et al., 1991), our understanding 
of XIST’s mechanism of action is still expanding and evolving, 30 years later. This 
highlights the complexity of lncRNA mechanisms and the importance of 
employing multiple orthogonal approaches in lncRNA functional characterization. 
The lncRNA Morrbid operates by a similar general mechanism of action, 
although with a far more restricted regulatory output than XIST. Expressed 
exclusively in a subset of myeloid cells, Morrbid influences cellular lifespan by 
repressing the pro-apoptotic gene Bim in cis (Kotzin et al., 2016). This negative cis-
regulation is mediated by Morrbid recruitment of PRC2 to the Bim promoter 
facilitated by chromatin contacts between the neighboring Morrbid and Bim loci. 
XIST and Morrbid exemplify an archetype of cis-acting lncRNAs, namely those 
that interact with chromatin-modifying complexes (either activating or repressive) 
to engage in epigenetic regulation of target gene(s). Many lncRNAs, cis-regulatory 
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or otherwise, execute their functions through their association with various RBPs 
(reviewed in (Statello et al., 2020)). However, lncRNA-mediated cis-regulation 
does not always require RNA-protein interactions, or indeed the RNA molecule 
itself. A notable example of this is Airn (Antisense Igf2r ncRNA), a lncRNA 
oriented overlapping and antisense to Igf2r (Insulin-like growth factor receptor 
2); both genes are encoded in a paternally imprinted gene cluster that also includes 
Slc22a2 and Slc22a3 (Statello et al., 2020). Airn expression from the paternal 
allele, specifically transcription through the Igr2r promoter region, is required for 
Igf2r silencing via transcriptional interference, a function which does not require 
the Airn RNA molecule, only its production (Latos et al., 2012; Sleutels et al., 
2002). In this way, the placement and architecture of the Airn locus confers its 
entire Igf2r-repressing function. However, the Airn RNA transcript has been 
shown to play a role in epigenetically repressing Slc22a3 through the recruitment 
of a histone methyltransferase G9a, revealing distinct transcript- and 
transcription- based mechanisms (Nagano et al., 2008). 
These difficulties in elucidating the mechanism by which Airn represses 
genes in the Igf2r locus emphasize a key and pervasive challenge in the lncRNA 
field; specifically, how can we accurately discern the element(s) of a lncRNA locus 
required for its function(s)? Gene regulation by cis-acting lncRNAs can be 
mediated by (1) DNA elements in the locus, (2) the act of transcription or RNA 
processing, (3) the RNA molecule itself, or some combination thereof (Figure 1) 
(Gil and Ulitsky, 2020). Employing either deletion of a lncRNA locus or insertion 
of a premature polyadenylation signal downstream of its transcriptional start site 
(TSS) can aid in dissociating the contributions of DNA elements in the locus from 
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both the act of transcription and the activity of the RNA molecule (Engreitz et al., 
2016; Paralkar et al., 2016). However, differentiating between the interconnected 
roles of transcription and the RNA transcript has proven a more thorny problem. 
Some experimental tools may be too intractable or imprecise to effectively isolate 
one lncRNA feature from the other and can produce muddled results. For example, 
recent work has demonstrated that antisense oligonucleotides (ASOs), often a 
preferred choice for RNA depletion in lncRNA studies (especially for nuclear-
enriched transcripts), can cause premature transcription termination and 
therefore do not constitute a loss-of-function (LOF) model specific to the RNA 
molecule (Lee and Mendell, 2020). Given such shortcomings in current 
technologies, necessity dictates that we continue to develop diverse and innovative 
experimental tools and approaches with lncRNA biology in mind. 
Cis-activating lncRNAs can be especially difficult to functionally dissect, as 
their transcription alone may be responsible for their ascribed regulatory outputs. 
Indeed, the transcription of protein-coding genes, like lncRNAs, has been shown 
to activate the expression of neighboring loci (Engreitz et al., 2016), perhaps 
because active transcription increases interactions mediated by cis-regulatory 
elements, thus supporting promoter-enhancer contacts (Gu et al., 2018). These 
observations may point to a widespread mechanism of transcription-facilitated 
cis-activation that is not specific to lncRNAs. Interestingly, many cis-activating 
lncRNAs are transcribed from enhancers and regulate neighboring genes by 
modulating enhancer availability through the act of their transcription or 
recruitment of the Mediator complex (Isoda et al., 2017; Lai et al., 2013). Yet, the 
role of other enhancer RNAs (eRNAs), such as the RNAs produced from p53-
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bound enhancer regions (p53BERs), is less clear, and may depend only on DNA 
elements to elicit gene expression changes (Melo et al., 2013). Other lncRNAs are 
not transcribed from enhancers per se, but may have enhancer elements associated 
with their loci. LincRNA-p21, for example, has been proposed to activate the 
transcription of its neighboring gene p21 through cis-regulatory DNA elements 
(Groff et al., 2016), despite other studies demonstrating a role for the RNA 
molecule (Dimitrova et al., 2014; Huarte et al., 2010). Controversies such as these 
highlight a need for robust characterization of cis-acting lncRNAs and clear 














Figure 1. Cis- and trans- acting mechanisms of action by lncRNAs. Long noncoding RNAs 
(lncRNAs) can function in either cis or trans. Cis-acting lncRNAs are nuclear-enriched and can 
regulate neighboring protein-coding genes (PCGs) through DNA elements in the lncRNA locus, the 
act of transcription, or the RNA transcript. Functions of the lncRNA transcript (blue) are mediated 
through interactions with target genes (red), RNA binding proteins (green and purple), or other 
RNAs (orange). Trans-acting lncRNAs can reside in the nucleus and regulate target genes 
expressed from different chromosomes in a similar manner, or can reside in the cytoplasm and 












In contrast to cis-acting lncRNAs, trans-acting lncRNAs can travel far 
from their site of transcription, and either regulate genes elsewhere in the nucleus 
or are exported to the cytoplasm, enabling a range of other activities (Figure 1) 
(reviewed in (Statello et al., 2020)). A notable example of a nuclear-enriched 
trans-acting lncRNA is HOTAIR (HOX Transcript Antisense RNA), expressed 
antisense to the HOXC gene cluster and proposed to epigenetically repress the 
distally located HOXD cluster via PRC2 recruitment (Rinn et al., 2007). However, 
this trans-acting mechanism has been called into question by a study noting 
nonspecific interactions between PRC2 and RNA (Davidovich et al., 2013). 
Additionally, the function of Hotair in the mouse has come under scrutiny after 
conflicting results were obtained using the same locus deletion model. One group 
documented homeotic transformations in response to Hotair loss (Li et al., 2013), 
while another group found no developmental defects whatsoever, and therefore 
concluded Hotair was dispensable for mouse development (Amandio et al., 2016). 
Despite these inconsistencies, there is functional evidence for HOTAIR 
overexpression in supporting breast cancer metastasis, highlighting a need for 
improved mechanistic elucidation (Gupta et al., 2010). 
Firre (Functional intergenic RNA repeat element), in contrast to other 
trans-acting nuclear-enriched lncRNAs, resides close to its site of transcription on 
the X-chromosome, but engages in various trans-chromosomal contacts in order 
to spatially concentrate distal genomic elements (Hacisuleyman et al., 2014). 
While the function of Firre was not initially clear, recent studies have proposed 
roles in hematopoiesis and XCI, potentially involving both trans- and cis- 
regulatory activities (Fang et al., 2020; Lewandowski et al., 2019). This unique 
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example illustrates that lncRNA location is not always a proxy for its function and 
that localization patterns in cis and trans may leave space for nuanced and 
unexpected mechanisms of action. 
Examples of trans-acting lncRNAs that function in the cytoplasm include 
NORAD (Noncoding RNA Activated by DNA Damage), which binds PUMILIO 
proteins to support genomic stability (Lee et al., 2016); LAST (LncRNA-Assisted 
Stabilization of Transcripts), which stabilizes the mRNA encoding Cyclin D1 
(CCND1) to promote cellular proliferation (Cao et al., 2017); and SAMMSON 
(Survival Associated Mitochondrial Melanoma Specific Oncogenic Noncoding 
RNA), which associates with the mitochondrial regulator p32 to increase its 
localization and function in mitochondrial homeostasis (Leucci et al., 2016). 
On the whole, cis-acting lncRNA mechanisms appear to be more prevalent 
than trans-acting. This idea is supported by enrichment of the majority of lncRNAs 
in the chromatin fraction, the low copy number of some lncRNAs, and the 
conservation of lncRNA genomic organization (or synteny) despite poor sequence 
conservation, all of which favor local cis-regulatory lncRNA modes of action 
(reviewed in (Gil and Ulitsky, 2020)). These observations in no way preclude 
abundant trans-acting lncRNA mechanisms, and indeed some lncRNAs have been 
suggested to regulate in both cis and trans. For example, in this work I describe a 
cis-acting role for an isoform of the lncRNA Pvt1 in negatively regulating the 
expression of a neighboring protein-coding gene (see Chapters 2-5). However, 
various trans-regulatory mechanisms for Pvt1 have been previously described, 
including a role in protein stabilization (Tseng et al., 2014), and one in which a 
circular form of Pvt1 (circPVT1) acts as a miRNA decoy (Panda et al., 2017). 
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Moreover, there is disagreement even with respect to the cis-activity of Pvt1, and 
whether it depends on the RNA or DNA elements in the locus (Cho et al., 2018). 
Such distinct regulatory functions described for Pvt1 and other lncRNAs may be 
cell-type specific and in keeping with observed differences in localization patterns. 
Another exciting possibility is that they reflect bona fide isoform-specific functions 




Long noncoding RNAs in cancer 
The work  in this section has been published as part of the following invited 
review: Olivero, C., and Dimitrova, N. Identification and characterization of 
functional long noncoding RNAs in cancer. (2020). The FASEB Journal 34, 
15630-15646. 
Introduction 
Cancer is a disease of aberrant cell growth arising from a complex genetic 
landscape of inherited and sporadic mutations and environmental factors. 
Historically, cancer research has prioritized examining alterations to protein-
coding genes in molecular pathways influencing the hallmarks of cancer (Hanahan 
and Weinberg, 2000, 2011). While these analyses have provided extensive insights 
into key players in tumorigenesis, protein-coding sequences account for only 2% 
of the genome (International Human Genome Sequencing, 2004). Both the 
pervasive transcription of the human genome (Djebali et al., 2012) and the 
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presence of cancer- associated mutations in noncoding regions (Freedman et al., 
2011) have suggested a potential wealth of unexplored cancer targets. Notably, the 
heterogeneous class of long noncoding RNAs (lncRNAs) occupies a significant 
space within the noncoding transcriptome, with recent estimates suggesting the 
existence of over 100,000 human lncRNA transcripts (Bertone et al., 2004; 
Carninci et al., 2005; Consortium, 2012; Kapranov et al., 2007).  
LncRNAs are operationally defined as RNA molecules exceeding 200 
nucleotides in length that lack protein-coding potential (Mercer et al., 2009; Rinn 
and Chang, 2012). Able to dynamically fold into intricate secondary structures 
(Qian et al., 2019) to interact with DNA, proteins and other RNAs, lncRNAs are 
diverse in their structure, localization, and pattern of expression, enabling them to 
regulate the flow of cellular information at many levels (Wang and Chang, 2011). 
Frequently the targets of transcriptional programs, lncRNAs influence many 
fundamental cellular processes including cell division, genome maintenance, and 
pluripotency (Lee et al., 2016; Loewer et al., 2010; Yap et al., 2010).  
As lncRNAs are expressed with exquisite cell-type and disease-state 
specificity, they are ideally positioned to act as biomarkers for a number of 
pathologies, including different cancers (Derrien et al., 2012; Iyer et al., 2015; Yan 
et al., 2015). Identifying lncRNA expression changes, or their association with 
recurrent copy number variations (CNVs) or cancer susceptibility single nucleotide 
polymorphisms (SNPs) have the potential to become useful tools in cancer 
diagnosis and treatment planning. Beyond their diagnostic and prognostic utility, 
over the past decade, individual lncRNAs have been mechanistically and 
functionally dissected, revealing critical roles in cancer-related pathways at the 
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cellular and organismal level. These studies have pointed to lncRNAs as operators 
within proto-oncogenic and tumor suppressive networks, suggesting that lncRNAs 
themselves may play active roles in promoting or limiting tumor development 
(Huarte, 2015; Prensner and Chinnaiyan, 2011; Wapinski and Chang, 2011). 
Despite growing data supporting the involvement of lncRNAs in 
tumorigenesis, it is often difficult to surmise whether changes in individual 
lncRNAs are bona fide drivers of human cancer development and whether 
targeting altered lncRNAs in patients would be expected to produce therapeutic 
benefit. Here, we present an overview of how functional lncRNAs in cancer are 
identified. We highlight promising therapeutic targets based on patient data and 
on experimental evidence from in vitro and in vivo cancer models. We also discuss 
important discrepancies to suggest a best-practice roadmap for further 
characterization of the roles of lncRNAs in cancer.  
 
Identification of cancer-associated lncRNAs 
Mining global human cancer genomic and transcriptomic data 
Integrating genomic and transcriptomic data from diverse human cancers 
has provided a starting point for the identification of lncRNAs with functional roles 
in cancer. In particular, recurrent genetic alterations have implicated many genes 
involved in oncogenesis, and the capacity to identify such genes has expanded in 
the last several years due to rapid advances in sequencing technologies. These 
studies have uncovered that many recurrent somatic copy number variations 
(SCNVs) map to noncoding regions (Beroukhim et al., 2010). Notably, analysis of 
5000 human tumor samples across 13 cancer types from The Cancer Genome Atlas 
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(TCGA) revealed that, on average, as many as one quarter of all lncRNAs manifest 
frequent cancer-related copy number gains or losses (Yan et al., 2015). A more 
recent study probed the copy number of over 10,000 lncRNAs in 80 cancer cell 
lines across 11 cancer types, identifying 136 lncRNAs involved in focal SCNVs 
(Volders et al., 2018). Importantly, 76 of these lncRNAs lacked copy number 
changes in flanking protein-coding genes, suggesting potential lncRNA-driven 
genomic alterations in cancer. Cancer risk SNPs in noncoding loci can also point 
to a potential role for specific lncRNAs in tumorigenesis. One study identified 
nearly 4000 lncRNAs overlapping disease-associated SNPs, while another 
estimated that roughly 12% of all cancer-associated SNPs mapped within 5 Kb of 
lncRNA loci (compared to 55% mapping near protein-coding genes) (Iyer et al., 
2015; Yan et al., 2015).  
Apart from harboring genomic alterations, lncRNAs have also been found 
to exhibit differential expression patterns in tumor samples compared to normal 
tissues. A comprehensive meta-analysis of over 7000 gene expression datasets, 
including a range of normal and cancer samples, identified as many as 60,000 
lncRNAs with altered expression (Iyer et al., 2015). Notably, many previously 
unannotated lncRNAs were found in disease-associated regions and the expression 
of roughly 8000 lncRNAs clustered with specific cancer or cell lineages, suggesting 
the potential for lncRNAs to execute cancer-specific functions (Iyer et al., 2015). 
Along similar lines, an analysis of seven cancer types revealed that, on average, 
26% of expressed lncRNAs were significantly deregulated in at least one cancer 
type (15% upregulated and 11% downregulated) with 60% of these altered lncRNAs 
demonstrating cancer specificity (Yan et al., 2015). In addition, a recent study of 
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lncRNA-associated epigenetic alterations across 20 different cancers identified 
over 2000 lncRNAs either epigenetically activated or silenced in at least one cancer 
type (Wang et al., 2018). Altogether, these studies led to the consensus that, as a 
class, lncRNAs are subject to frequent genetic and epigenetic alterations in cancer.  
 
LncRNA loci with recurrent SCNVs in cancer  
In addition to global patterns of lncRNA deregulation in cancer, several 
individual lncRNAs have been identified based on frequent large-scale genomic 
alterations. One of the first cancer-associated lncRNAs was identified in murine 
lymphomas due to the frequent translocations and viral insertions involving the 
as-yet uncharacterized Pvt1 (Plasmacytoma Variant Translocation 1) lncRNA 
(Cory et al., 1985; Graham et al., 1985), located approximately 72 Kb downstream 
of the MYC (Myelocytomatosis) proto-oncogene. Later studies extended these 
results to human cancer and demonstrated a correlation between PVT1 genomic 
amplification and poor prognosis in acute myeloid leukemia and in breast and 
ovarian cancers, among others (reviewed in (Colombo et al., 2015)). Significantly, 
PVT1 amplification is observed frequently in a range of cancer types including in 
33% of ovarian cancers, 20% of esophageal cancers, 13% of invasive breast 
carcinomas and 7% of lung adenocarcinomas based on TCGA data (Hoadley et al., 
2018). Moreover, PVT1 alterations are associated with a significant reduction in 
overall and disease-free survival (Cerami et al., 2012; Gao et al., 2013; Hoadley et 
al., 2018).  
Another prominent example of a lncRNA initially characterized by genomic 
alterations is FAL1 (Focally Amplified LncRNA 1, also known as FALEC) located 
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on chromosome 1q21 (Hu et al., 2014a). FAL1 copy number gains have been 
observed across many cancer types, including in approximately 10% of liver 
cancers, invasive breast carcinomas and lung adenocarcinomas according to TCGA 
data (Hoadley et al., 2018). FAL1 amplification and overexpression are associated 
with late stage tumors and with decreased survival of patients with ovarian cancer 
(Hoadley et al., 2018; Hu et al., 2014a). Similarly, the lncRNA SAMMSON 
(Survival Associated Mitochondrial Melanoma Specific Oncogenic Noncoding 
RNA) was identified in a region of focal amplification on chromosome 3p13-14 in 
10% of melanomas (Leucci et al., 2016). High SAMMSON copy number and 
expression levels are correlated with a reduction in disease-free survival of 
melanoma patients and associated with resistance to MAPK (Mitogen Activated 
Protein Kinase) inhibitors (Cerami et al., 2012; Gao et al., 2013; Hoadley et al., 
2018; Leucci et al., 2016).  
The locus of the lncRNA LOC285194 on chromosome 3q, on the other hand, 
is subject to recurrent monoallelic deletions in as many as 80% of osteosarcomas, 
often followed by loss of heterozygosity (LOH) (Pasic et al., 2010). Loss of 
LOC285194 is associated with decreased survival in osteosarcoma patients (Pasic 
et al., 2010). The focal deletion of PRAL (p53 Regulation-Associated LncRNA) on 
chromosome 17p in hepatocellular carcinoma has also been associated with 
reduced survival (Zhou et al., 2016). Similarly, recurrent loss of the 9p21 locus, 
where the lncRNA ANRIL (Antisense Noncoding RNA in the INK4 Locus) resides, 
is observed in over 50% of glioblastomas, more than 40% of mesotheliomas, and 
roughly 30% of bladder cancers (Hoadley et al., 2018). Interestingly, a 403 Kb 
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germline deletion encompassing the ANRIL locus is associated with a strong 
hereditary predisposition to melanoma development (Pasmant et al., 2007).  
Many regions of recurrent SCNVs, however, harbor both lncRNAs and 
protein-coding genes. Therefore, determining the specific contribution of the 
lncRNA has been challenging. For example, the presence of multiple overlapping 
transcripts in the ANRIL locus, including the p15INK4B (CDKN2B), p16INK4A 
(CDKN2A), and p19ARF tumor suppressors, has confounded the role of ANRIL 
(Yap et al., 2010). Analogously, PVT1 is co-amplified with MYC and the PVT1 gene 
body contains DNA regulatory elements, which promote MYC expression (Fulco et 
al., 2016). Likewise, SAMMSON is expressed near MITF (Microphthalmia 
Associated Transcription Factor), a key factor in melanocyte differentiation, 
whereas the commonly amplified genomic region in which FAL1 resides contains 
the proto-oncogene MCL1 (Myeloid Cell Leukemia Sequence 1). Finally, the 
LOC285194-associated region of deletion also harbors the tumor suppressor 
LSAMP (Limbic System-Associated Membrane Protein). Given the complex 
chromatin architecture and transcriptional profiles in these loci, further studies 
are needed to deconvolve the specific roles of the lncRNAs and to determine 
whether lncRNAs act in cooperation with or independently of their neighboring 
protein-coding genes.  
 
LncRNA loci with cancer-associated SNPs  
The link between inherited germline variants in lncRNA loci and cancer 
predisposition or prognosis has been probed extensively in large-scale genome-
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wide associated studies (GWAS). These studies have identified a plethora of 
lncRNA-linked SNPs associated with altered cancer risk or patient prognosis. 
As an example, the 2 Mb region mapping to 8q24 has emerged as a major 
hotspot for over a hundred SNPs strongly associated with multiple diseases, 
including cancers of the breast, colon, ovaries, prostate, and bladder (Easton and 
Eeles, 2008; Ghoussaini et al., 2008; Grisanzio and Freedman, 2010; Huppi et al., 
2012). Many of these SNPs are significantly correlated with cancer development 
and highly predictive of poor patient outcome (Bertucci et al., 2012; Garcia-Closas 
et al., 2008; Haiman et al., 2007; Yeager et al., 2007; Zhang et al., 2012b). While 
MYC is the dominant oncogene in the locus, many of the cancer risk SNPs are 
linked to the expression of lncRNAs in the surrounding region, including PVT1 
(Meyer et al., 2011), CCAT1 (Colon Cancer Associated Transcript 1, also known as 
CARLo-5) (Zhao et al., 2016), CCAT2 (Colon Cancer Associated Transcript 2) (Ling 
et al., 2013), PCAT1 (Prostate Cancer Associated Transcript 1) (Guo et al., 2016), 
PCAT19 (Prostate Associated Transcript 19) (Hua et al., 2018), and PRNCR1 
(Prostate Cancer Associated Noncoding RNA 1) (Huang et al., 2018b). The ANRIL 
locus is another example of a hotspot harboring more than 10 cancer risk SNPs, 
some of which are correlated with ANRIL expression (Cunnington et al., 2010; 
Khorshidi et al., 2017). Other lncRNAs linked to cancer SNPs include HOTAIR 
(HOX Transcript Antisense RNA) (Botti et al., 2018), HOTTIP (HOXA Distal 
Transcript Antisense RNA) (Huang et al., 2018b), MALAT1 (Metastasis-Associated 
Lung Adenocarcinoma Transcript 1) (Huang et al., 2018b), HULC (Highly 
Upregulated in Liver Cancer) (Huang et al., 2018b), MEG3 (Maternally Expressed 
3) (Dong et al., 2020), H19 (Hashemi et al., 2019), GAS5 (Growth Arrest Specific 
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5) (Dong et al., 2020), and PTENP1 (Phosphatase And Tensin Homolog 
Pseudogene 1) (Ge et al., 2017).  
Mechanistic investigations of SNPs associated with lncRNAs have 
suggested that the risk variants may, in some cases, affect regulatory DNA 
sequences, thereby resulting in altered lncRNA expression. For example, the 
PCAT1-linked risk variant rs7463708 was found to increase the activity of a distal 
enhancer, resulting in increased PCAT1 expression (Guo et al., 2016), whereas the 
PCAT19-linked SNP rs11672691 was proposed to perturb transcription factor 
binding sites, resulting in the increased expression of a pro-metastatic PCAT19 
isoform (Gao et al., 2018; Hua et al., 2018). Finally, a high-risk neuroblastoma 
associated SNP rs693940 on chromosome 6p22 was found to contribute to 
differential CpG methylation and decreased expression of NBAT-1 
(Neuroblastoma Associated Transcript-1, also known as CASC14), a lncRNA with 
tumor suppressor properties (Pandey et al., 2014). Apart from these intriguing 
examples, however, the majority of lncRNA-associated SNPs lack experimental 
support that would robustly link the cancer-susceptibility variants with 
deregulation of lncRNA levels or function, and have thus had limited impact on the 
identification and characterization of functional lncRNAs in cancer.  
 
LncRNAs differentially expressed in cancer  
Global gene expression analyses of normal and cancer samples have also led 
to the identification of numerous differentially expressed lncRNAs hypothesized 
to contribute to disease development. Some of the initial analyses revealed 
frequent upregulation of lncRNAs, such as the imprinted lncRNA H19 in Wilms’ 
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tumors and lung cancer (Hibi et al., 1996; Kondo et al., 1995; Rainier et al., 1993), 
the prostate cancer-specific lncRNA PCGEM1 (Prostate Cancer Gene Expression 
Marker 1) (Srikantan et al., 2000), the lung metastasis-promoting lncRNA 
MALAT1 (Ji et al., 2003) and the hepatocellular carcinoma overexpressed lncRNA 
HULC (Panzitt et al., 2007).  
The differential expression of some of these lncRNAs has been associated 
with clinical outcomes. For example, altered H19 expression correlates with poor 
clinical outcomes across various cancer types including breast cancer, non-small 
cell lung cancer and acute myeloid leukemia (Shima et al., 2018; Zhang et al., 
2018b; Zhou et al., 2017). On the other hand, increased expression of PCGEM1 in 
normal prostate tissue is a prostate cancer risk factor (Petrovics et al., 2004; 
Srikantan et al., 2000). At the same time, a large body of literature has cemented 
the strong correlation between high MALAT1 expression levels and poor patient 
prognosis across over 20 cancer types (Amodio et al., 2018; Zhang et al., 2015). 
Finally, high expression of HULC is associated with poor overall survival and 
distant metastases (Chen et al., 2017).  
Notably, integrated analysis of gene expression and methylation datasets 
has also led to the identification of differentially expressed lncRNAs arising from 
cancer-associated epigenetic changes, including AFAP1-AS1 (AFAP1 Antisense 
RNA 1) and EPIC1 (Epigenetically Induced LncRNA1), both identified as 
hypomethylated and overexpressed in Barrett's esophagus and esophageal 
adenocarcinoma, and breast cancer, respectively (Wang et al., 2018; Wu et al., 
2013).  
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Gene expression profiling in cohorts of cancer patients have further fueled 
the discovery of lncRNAs associated with specific cancer types. Transcriptome 
sequencing across a cohort of prostate cancer patients identified PCAT-1 amongst 
121 unannotated prostate cancer-associated ncRNA (noncoding RNA) transcripts 
(PCATs) (Prensner et al., 2011). Similarly, comprehensive lncRNA profiling in 
colorectal carcinoma led to the identification of CCAT1 (Kim et al., 2014b; Nissan 
et al., 2012), CCAT2 (Ling et al., 2013) and other CCAT family members (Kim et 
al., 2015b), whereas the lncRNA GAPLINC (Gastric Adenocarcinoma Predictive 
Long Intergenic Noncoding RNA) stood out as aberrantly overexpressed in gastric 
tumors (Hu et al., 2014b). A different set of analyses led to the identification of 
stage-specific lncRNAs, such as the lncRNA CRNDE (Colorectal Neoplasia 
Differentially Expressed) (Graham et al., 2011), a marker of early stages of 
colorectal cancer development, although the protein-coding capacity of CRDNE 
remains an open question (Szafron et al., 2015). Transcriptome profiling of breast 
cancer subtypes, on the other hand, highlighted sets of lncRNAs which are either 
differentially expressed in tumor samples compared to normal tissues or uniquely 
enriched in specific stages or subtypes of breast cancer. Examples include MALAT1 
(Arun et al., 2016; Jadaliha et al., 2016), HOTAIR (Gupta et al., 2010), and BCAR4 
(Breast Cancer Anti- Estrogen Resistance 4) (Meijer et al., 2006; Xing et al., 2014). 
In parallel, mouse models of cancer were recently employed for the identification 
of 30 murine MaTARs (Mammary Tumor Associated RNAs), many of which were 
found to have human counterparts (hMaTARs) with potential clinical significance 
determined based on differential expression and correlation with cancer subtype 
and/or hormone receptor status (Diermeier et al., 2016). Interestingly, many of 
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these examples of cancer-specific lncRNAs were later found to show differential 
expression across multiple cancer types, hinting at universal roles in cancer 
pathogenesis. 
 
LncRNAs in cancer pathways  
In addition to profiling tumor samples, many researchers have undertaken 
diverse functional approaches to identify novel lncRNAs, including dissecting 
tumor suppressive and pro-oncogenic transcriptional networks, analyzing various 
cancer-related cellular states and processes, and performing genome-wide 
functional screens.  
Analysis of the p53 (also known as Trp53) transcriptional network, in 
particular, has revealed a wealth of lncRNAs with potential tumor suppressor 
functions. By comparing gene expression profiles and p53 binding patterns in the 
absence and in the presence of genotoxic or oncogenic stress, known to activate the 
p53 pathway, as well as in p53-proficient and -deficient cells, researchers have 
identified multiple direct lncRNA targets of p53. These included lincRNA-p21 
(Huarte et al., 2010); PANDAR (Promoter Of CDKN1A Antisense DNA Damage 
Activated RNA, also known as PANDA) (Hung et al., 2011); p53BERs (p53-Bound 
Enhancer Regions) (Melo et al., 2013); Pint (P53 Induced Transcript) (Marin-Bejar 
et al., 2013); LED (LncRNA Activator of Enhancer Domains) (Leveille et al., 2015); 
PR-lncRNAs (p53-Regulated lncRNAs) (Sanchez et al., 2014; Younger et al., 2015); 
DINO (Damage Induced Noncoding) (Schmitt et al., 2016); lncPRESS1 (LncRNA 
P53 Regulated And ESC Associated 1) (Jain et al., 2016); NEAT1 (Nuclear Enriched 
Abundant Transcript 1) (Adriaens et al., 2016; Blume et al., 2015; Mello et al., 
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2017); PURPL (P53 Upregulated Regulator Of P53 Levels) (Li et al., 2017); PINCR 
(P53-Induced Noncoding RNA) (Chaudhary et al., 2017); GUARDIN (Hu et al., 
2018); and an isoform of Pvt1, Pvt1b (Olivero et al., 2020). Functional 
characterizations have suggested that many of these lncRNAs contribute to p53 
tumor suppressor activities.  
Other lncRNAs have been identified downstream of oncogenic signaling 
networks, giving insight into their potential functions. For example, Orilnc1 
(Oncogenic RAS-Induced lncRNA 1) was identified as a target of oncogenic RAS 
signaling with a proposed role in promoting cell growth (Zhang et al., 2017). 
LncRNA-OIS1 (Oncogene- Induced Senescence 1) was found to modulate 
senescence induced by activation of oncogenic RAS (Li et al., 2018), whereas 
BANCR (BRAF-Activated Non-Protein Coding RNA) was identified as a transcript 
induced upon expression of oncogenic BRAFV600E (Flockhart et al., 2012). 
Analogously, investigation of estrogen receptor (ER) signaling targets identified 33 
ER agitation-related (ERAR) lncRNAs and suggested potential roles in ER-positive 
breast cancer (Wu et al., 2016). A similar study was performed to examine lncRNAs 
regulated by androgen receptor (AR) signaling, which identified ARLNC1 (AR-
Regulated Long Noncoding RNA 1) as both a downstream target and upstream 
effector of AR signaling during prostate cancer progression (Zhang et al., 2018c). 
MYC-regulated lncRNAs have also been identified, including a set of MYCLos 
(MYC-regulated lncRNAs) (Kim et al., 2015b); LAST (LncRNA-Assisted 
Stabilization of Transcripts) (Cao et al., 2017); DANCR (Differentiation 
Antagonizing Non-Protein Coding RNA) (Lu et al., 2018), and SNHG15 (Small 
Nucleolar RNA Host Gene 15) (Jiang et al., 2018).  
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Alterations of cancer hallmarks that enable tumorigenesis have also been 
linked to the functions of specific lncRNAs (reviewed in (Gutschner and 
Diederichs, 2012)). Examples include lncRNA gadd7 (growth-arrested DNA 
damage-inducible gene 7) with a proposed role in suppressing cell cycle 
progression (Liu et al., 2012), SPRY4-IT1 (SPRY4 Intronic Transcript 1) with a 
proposed role in inhibiting apoptosis in melanoma (Khaitan et al., 2011), and 
SALNR (Senescence-Associated lncRNA), proposed to regulate senescence (Wu et 
al., 2015). 
Finally, genome-wide functional screens for lncRNAs involved in 
promoting or inhibiting specific cellular outcomes important in cancer have aimed 
to identify candidates for further study. A CRISPR/Cas9-based genome editing 
approach used a paired guide RNA (gRNA) strategy to target for deletion a set of 
700 human lncRNAs, identifying 51 lncRNAs able to regulate cancer cell growth 
(Zhu et al., 2016). Alternatively, CRISPRi (CRISPR inactivation) and CRISPRa 
(CRISPR activation) screens, involving a nuclease-dead Cas9 to tether 
transcriptional repressors or activators to lncRNA loci have provided effective 
epigenetic loss-of-function and gain-of-function approaches to query on a genome-
wide level the role of lncRNAs in processes such as cellular proliferation or 
therapeutic resistance (Bester et al., 2018; Joung et al., 2017; Liu et al., 2017; Liu 
et al., 2020).  
 
Functional characterization of lncRNAs in cancer 
Common approaches and limitations  
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For the hundred or so lncRNAs identified in the approaches described 
above, the pressing question has become how to accurately distinguish functional 
lncRNAs from lncRNAs that are subject to passenger genetic and epigenetic 
alterations in cancer. RNA interference (RNAi)-mediated downregulation of 
lncRNAs has been a common approach for functional characterization. In parallel, 
antisense oligonucleotides (ASOs) have provided a convenient and efficient loss-
of-function alternative. While RNAi is most effective for lncRNAs exported to the 
cytoplasm, ASOs lend broader efficacy by triggering RNase H-mediated co-
transcriptional RNA cleavage and degradation, in some cases accompanied by 
transcriptional repression (Lai et al., 2020; Lee and Mendell, 2020). Frequently, 
RNAi and ASO approaches have been performed in parallel with exogenous 
lncRNA overexpression. Regrettably, few studies have complemented RNAi or 
ASO loss-of-function experiments with knockdown-resistant lncRNA rescue 
mutants, missing an important opportunity to both demonstrate specificity and 
establish a system to investigate the sequence basis for lncRNA function. CRISPR-
based epigenetic inhibition (CRISPRi) and activation (CRISPRa) have also been 
employed as successful loss-of-function and gain-of-function approaches, 
respectively.  
Genetically engineered mouse models (GEMMs) of lncRNAs and CRISPR-
based editing of lncRNA loci in cell lines have also brought important insights. In 
contrast to protein-coding genes, where genetic approaches aim to perturb the 
open reading frame (ORF) and therefore, the functional output of the transcript, 
methods to target lncRNAs have been, by necessity, more diverse and creative 
(reviewed in (Bassett et al., 2014)). Some loss-of-function studies have undertaken 
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deletion of the entire gene body, the promoter region, or narrower functional 
regions, while others have employed introduction of a premature polyadenylation 
signal (PAS) or polyadenylation cassette (STOP) to terminate transcription. 
Conversely, gain-of-function studies in animal models have involved the 
introduction of a transgenic lncRNA sequence or amplification of an entire lncRNA 
locus.  
Strikingly, for many lncRNAs, observed phenotypes have varied with the 
use of alternative approaches. For example, initial RNAi knockdown of the p53-
regulated lncRNA, lincRNA-p21, suggested that it acts globally to modulate the 
expression of multiple p53 target genes, whereas subsequent genetic deletion of its 
promoter in the mouse revealed a more restricted role in promoting the expression 
of the neighboring p21/CDKN1a gene (Dimitrova et al., 2014; Huarte et al., 2010). 
Further investigation involving a locus deletion genetic approach, however, raised 
doubts about whether the lncRNA plays any functional role at all (Groff et al., 
2016). The metastasis-promoting lncRNA HOTAIR has provided additional 
examples of the complexity in developing lncRNA models. While ectopic 
expression of HOTAIR in breast cancer cells induced global gene expression 
changes and increased metastases in a xenograft mouse model, supporting an 
oncogenic function (Gupta et al., 2010), loss-of-function models, including RNAi-
mediated knockdown, a 4 Kb gene body deletion, and a 140 Kb locus deletion have 
led to significant discrepancies (Amandio et al., 2016; Li et al., 2013; Rinn et al., 
2007; Schorderet and Duboule, 2011). The differences between alternative models 
have highlighted the need to use multiple independent and complementary 
approaches to investigate the functional roles of lncRNAs in cancer biology.  
 32 
Multi-pronged approaches to lncRNA characterization  
In this section, we focus on a small set of lncRNAs for which work from 
multiple groups or involving an array of in vitro and in vivo approaches has 
revealed exciting functional insights and provided starting points for further 
exploration of their contributions to tumor development.  
 
MALAT1 
MALAT1 remains one of the most studied cancer-associated lncRNAs, with 
proposed roles in influencing nuclear speckles (Hutchinson et al., 2007), pre-
mRNA splicing (Tripathi et al., 2010), and epigenetically regulating gene 
transcription (West et al., 2014). While initial studies pointed to a pro-metastatic 
function (Ji et al., 2003), further characterization resulted in discrepancies (Figure 
2). Three different loss-of-function GEMMs, including an insertion of a LacZ 
reporter and polyadenylation cassette 69 nucleotides downstream of the Malat1 
transcription start site, a 3 Kb deletion of the 5’ end and promoter region of Malat1, 
and a conditional deletion of 7 Kb encompassing the entire Malat1 gene body, 
revealed that Malat1 is dispensable for organismal development and viability 
(Eissmann et al., 2012; Nakagawa et al., 2012; Zhang et al., 2012a). Strikingly, none 
of the mouse models showed effects on global gene expression, nuclear speckle 
formation, or alternative pre-mRNA splicing. This opposed previous findings 
using RNAi to downregulate MALAT1 levels in cancer cell lines in vitro (Tripathi 
et al., 2010; West et al., 2014), perhaps suggesting a cancer-specific function. 
Furthermore, different in vivo models have yielded conflicting results about the 
function of MALAT1 in cancer. On the one hand, crossing the promoter deletion 
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model (Zhang et al., 2012a) to the MMTV-PyMT (mouse mammary tumor virus-
polyomavirus middle T antigen) mouse model of breast cancer resulted in reduced 
metastases to the lung, without affecting primary tumor burden, an effect largely 
recapitulated by ASO-depletion of Malat1 in vivo (Arun et al., 2016). This pro-
metastatic function was also observed in a mouse xenograft model of lung cancer 
where MALAT1 knockout human lung tumor cells formed fewer tumor nodules 
(Gutschner et al., 2013). In this model, targeting MALAT1 with ASOs after tumor 
implantation prevented metastasis formation, pointing to MALAT1 as a viable 
therapeutic target (Gutschner et al., 2013). On the other hand, crossing the Malat1 
premature termination model (Nakagawa et al., 2012) to the MMTV-PyMT breast 
cancer model led to a significant increase in the number and area of metastatic 
nodules in the lungs (Kim et al., 2018). This surprising tumor suppressive effect 
could be rescued with a Malat1 transgene expressed from the Rosa26 locus (Kim 
et al., 2018). A similar effect was observed in vitro in human breast cancer cells, 
with expression of MALAT1 from an exogenous construct rescuing the increased 
metastatic ability conferred by MALAT1 knockout in clonal cell populations (Kim 
et al., 2018). The debate surrounding the precise contribution of MALAT1 to cancer 
development is ongoing. It is unclear whether the phenotypic differences arising 
from MALAT1 loss might be due to differences in experimental setup, such as 
mouse strain or knockout approach, or reflect the complex biology of MALAT1. 
Altogether, investigations of MALAT1 using in vitro and in vivo approaches have 
highlighted the biological and technical complexities associated with studying the 
functional roles of lncRNAs in cancer (Arun and Spector, 2019; Sun and Ma, 2019).  
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Figure 2. Identification and functional characterization of MALAT1. MALAT1 was 
identified as upregulated in metastatic (M) LUAD (lung adenocarcinoma) compared to non- 
metastatic (NM) tissue. Functional characterization of MALAT1 has utilized various loss-of-
function (LOF) and gain-of-function (GOF) models including polyadenylation cassette insertion 
(Malat1STOP, (Nakagawa et al., 2012)), promoter deletion (Malat1 D3, (Zhang et al., 2012a)), and 
locus deletion (Malat1 D7, (Eissmann et al., 2012)) genetically engineered mouse models (GEMMs), 
as well as transcript degradation with RNAi and ASO, and transgenic overexpression. Crossing 
Malat1  D3 or Malat1STOP GEMMs to the MMTV-PyMT BC (breast cancer) mouse model has 
resulted in either oncogenic (red box, (Arun et al., 2016)) or tumor suppressor (green box, (Kim et 







Similarly to MALAT1, several studies have examined the role of NEAT1 
during cancer development, leading to opposing views (Figure 3). Initial studies 
suggested that NEAT1 levels were elevated in a variety of human cancers relative 
to normal tissues and correlated with worse prognosis, suggesting a pro-oncogenic 
role for NEAT1 ((Chakravarty et al., 2014) and reviewed in (Yang et al., 2017)). 
This conclusion was supported by a study of Neat1 knockout mice subjected to 
chemical induction of skin squamous cell carcinoma with the carcinogen DMBA 
and the pro- inflammatory agent TPA (Adriaens et al., 2016; Nassar et al., 2015). 
While Neat1-deficient animals displayed no obvious phenotypes in the absence of 
stress (Nakagawa et al., 2011), loss of Neat1 conferred resistance to chemically-
induced squamous cell carcinoma (Adriaens et al., 2016). Interestingly, studies 
have also suggested that NEAT1 may be a target of the p53 pathway and, therefore, 
may have tumor suppressive activities in some contexts (Blume et al., 2015; 
Idogawa et al., 2017). Indeed, tumor suppressive functions of Neat1 were unveiled 
in primary mouse embryonic fibroblasts (MEFs), where Neat1 knockout led to 
increased colony formation in an E1A; HrasG12V transformation experiment, as 
well as in an autochthonous mouse model of pancreatic cancer, where Neat1 
deficiency increased the occurrence of premalignant lesions, known as pancreatic 
intraepithelial neoplasias (PanINs) (Mello et al., 2017). Interestingly, Malat1 and 
Neat1 are neighboring genes and studies have suggested that genomic deletion of 
either lncRNA may impact the epigenetic organization and transcriptional profiles 
of the entire locus, raising questions about the specificity of each approach 
(Nakagawa et al., 2012).  
 36 
 
Figure 3. Identification and functional characterization of NEAT1. NEAT1 was initially 
identified as being upregulated in prostate cancer (PCa) compared to normal (N) tissue, suggesting 
a potential oncogenic function (top, red box). Later, it was also identified as a p53 target with p53 
binding to a conserved p53 Response Element (p53RE) in the NEAT1 promoter, as well as a 
paraspeckle component induced by cellular stress, suggesting a potential tumor suppressor 
function (top, green box). Functional characterization of NEAT1 has utilized various loss-of-
function (LOF) and gain-of-function (GOF) models including a polyadenylation cassette insertion 
genetically engineered mouse model (GEMM) (Nakagawa et al., 2011), transcript degradation with 
RNAi or ASO, and exogenous overexpression. The Neat1STOP GEMM has been shown to either 
decrease (Adriaens et al., 2016) or increase (Mello et al., 2017) tumor growth following chemical 
induction of SCC (squamous cell carcinoma) or when crossed to a PDAC (pancreatic ductal 
adenocarcinoma) GEMM, respectively, suggesting either oncogenic (bottom, red box) or tumor 





As one of the lncRNAs strongly associated with advanced disease and poor 
patient prognosis, PVT1 has been the subject of extensive investigation (Figure 4). 
In keeping with the finding that PVT1 is frequently co- amplified with the MYC 
proto-oncogene, Myc-Pvt1 co-amplification in a mouse model of breast cancer was 
found to be more tumorigenic than Myc amplification alone (Tseng et al., 2014). 
This study suggested that PVT1 acts in trans to promote MYC protein stability, 
based on evidence that a 300 Kb genomic deletion of the PVT1 locus in a human 
colorectal carcinoma cell line resulted in decreased MYC protein levels (Tseng et 
al., 2014). However, later studies found evidence for MYC enhancers within the 
region of deletion, raising questions about the role of the PVT1 locus and its 
associated RNA in MYC regulation (Fulco et al., 2016). Subsequent studies 
confirmed the presence of DNA regulatory elements in the locus but challenged the 
understanding of PVT1 as a strictly pro-oncogenic lncRNA (Cho et al., 2018; Porter 
et al., 2017). On the one hand, deletion of a ~600 bp region containing a p53 
binding site and mapping to the 5’ end of PVT1 led to defects in p53-mediated MYC 
repression, although the contribution of PVT1 to the p53 response was unclear 
(Porter et al., 2017). On the other hand, CRISPRi-based inhibition of PVT1 in 
breast cancer cell lines revealed a role for the PVT1 promoter as a DNA tumor 
suppressor boundary element that limits MYC promoter accessibility to enhancers 
within the PVT1 gene body, resulting in restricted MYC expression (Cho et al., 
2018). In this setting, the PVT1 RNA appeared to be dispensable (Cho et al., 2018). 
In contrast, our group identified a stress-induced, p53- dependent isoform of Pvt1, 
Pvt1b, which is both necessary and sufficient to repress Myc transcription (Olivero 
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et al., 2020). These findings were recapitulated in vitro using a genetic loss-of-
function approach to mutate the p53 binding site required for Pvt1b expression 
(Olivero et al., 2020). Importantly, mutagenesis of the Pvt1-associated p53 binding 
site at the time of tumor initiation in an autochthonous mouse model of lung 
cancer led to larger tumors and indicated a key role for Pvt1b in restraining tumor 
growth downstream of p53 (Olivero et al., 2020). In the future, it would be 
interesting to deconvolve the oncogenic and tumor suppressive elements in the 
PVT1 locus and to differentiate between DNA elements and RNA isoforms with 

















Figure 4. Identification and functional characterization of PVT1. PVT1 was identified in 
murine lymphomas following the observation of translocations, viral insertions, and amplifications 
involving the Pvt1 locus. Functional characterization of PVT1 has utilized various loss-of- function 
(LOF) and gain-of-function (GOF) models including amplification genetically engineered mouse 
models (GEMMs) (Myc/Pvt1AMP, MycAMP, (Tseng et al., 2014)), locus deletion (PVT1 ), tumor-
specific mutagenesis of the Pvt1-associated p53 Response Element (p53RE) (p53RE, (Olivero et al., 
2020)), transcript degradation with RNAi and ASO, and CRISPR-mediated epigenetic activation 
and inhibition (CRISPRa/i). The increased tumor growth observed in a Myc/Pvt1 co-amplification 
GEMM (Myc/Pvt1AMP) compared to Myc amplification alone (MycAMP) when crossed to the 
MMTV-Neu BC (breast cancer) GEMM suggests an oncogenic function for Pvt1 (red box, (Tseng et 
al., 2014)). However, the increased tumor growth in Pvt1-associated p53RE mutagenized lung 
tumors following Cre-mediated tumor initiation in a Kras-driven lung adenocarcinoma (LUAD) 





With a critical role in X chromosome inactivation and dosage compensation 
that has been investigated for decades (reviewed in (Brockdorff et al., 2020; 
Sahakyan et al., 2018)), the potential role of XIST (X Inactive Specific Transcript) 
in tumorigenesis has intrigued researchers. Historically, it has been observed that 
altered chromosome copy numbers and inappropriate dosage compensation are 
frequently associated with human cancer. Notably, men with Klinefelter syndrome 
characterized by an extra X chromosome have an increased risk of many 
malignancies including breast cancer and non-Hodgkin lymphoma (Swerdlow et 
al., 2005), and loss of X chromosome inactivation has been observed in breast 
cancer cell lines (Sirchia et al., 2005) and testicular germ cell tumors (Kawakami 
et al., 2003). In support of these correlative observations, a conditional Xist 
deletion model in mouse blood cell lineages led to aggressive myeloproliferative 
neoplasm and myelodysplastic syndrome with complete penetrance, likely as the 
result of widespread gene expression changes (Yildirim et al., 2013). The tumor 
suppressive role of XIST was recapitulated in RNAi and overexpression studies in 
breast cancer cell lines as well as by crossing the Xist knockout to the MMTV-PyMT 
mouse model of breast cancer (Xing et al., 2018). Further studies should determine 
the prevalence of XIST and X inactivation perturbations in human cancer and 
investigate the possibility of targeting this pathway as a therapeutic strategy.  
 
ANRIL  
High ANRIL expression in tumor tissues has been linked to aggressive 
pathological features and poor overall survival (reviewed in (Kong et al., 2018)). 
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In initial studies, targeted deletion of a 70 Kb region in the Anril locus, which 
harbors multiple cancer and coronary artery disease associated SNPs, led to viable 
progeny but showed increased mortality during development and as adults (Visel 
et al., 2010). Primary cultures of smooth muscle cells, isolated from mutant mice, 
exhibited excessive proliferation and diminished senescence, cellular phenotypes 
consistent both with accelerated coronary disease pathogenesis and increased 
cancer risk. Mechanistic investigation revealed that the effects were mediated in 
cis through the reduced expression of Cdkn2a and Cdkn2b and led to the 
conclusion that the risk region contained key regulatory elements. Subsequent 
investigation using exogenous overexpression of ANRIL in primary human 
fibroblasts suggested that the lncRNA may be responsible for CDKN2A/2B 
repression through the locus-specific recruitment of the repressive PRC1 complex 
(Yap et al., 2010). Unfortunately, little progress has been made over the past 
decade in determining whether ANRIL transcription or transcript accumulation is 
required for its cis-regulatory function, in part due to the limited conservation of 
ANRIL sequence and exonic structure between human and mouse.  
 
Promising lncRNA candidates warranting further investigation  
In this section we examine exciting, albeit limited, initial studies of lncRNAs 
with putative cancer functions, the validation of which could benefit from the 






To investigate the role of SAMMSON as a lineage addiction oncogene in 
melanoma, researchers employed ASO-mediated knockdown and exogenous 
overexpression as loss-of-function and gain-of-function tools (Leucci et al., 2016). 
They observed that SAMMSON amplification and increased expression led to 
altered mitochondrial metabolism and homeostasis. In turn, this caused increased 
melanoma cell viability and clonogenic potential and resulted in sensitization of 
melanoma cells to MAPK targeting therapeutics in vitro and in patient-derived 
xenograft (PDX) models in vivo. Further mechanistic studies clarified the role of 
SAMMSON in balancing mitochondrial translation rates (Vendramin et al., 2018). 
The generation of genetic models of SAMMSON may reveal further insights into 
its role in melanoma development.  
 
NKILA 
NKILA (NF-κB interacting long noncoding RNA) was identified as both a 
target and negative modulator of the NF-κB signaling pathway, with low NKILA 
levels observed in metastatic breast cancer cell lines and correlated with decreased 
disease-free survival in a cohort of breast cancer patients (Liu et al., 2015). 
Mechanistically, a series of deletion mutants demonstrated that NKILA interacts 
directly and stably with the NF-κB:IκB complex in the cytoplasm to prevent IκB 
phosphorylation and suppress activation of the NF-κB pathway, suggesting a 
tumor suppressive role for NKILA in limiting inflammatory processes in cancer 
(Liu et al., 2015). A different study from the same group showed that RNAi 
downregulation of NKILA in cytotoxic T cells (CTLs) led to increased tumor 
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infiltration and reduced tumor volume in a breast cancer PDX mouse model, 
implicating NKILA as a potential target in the field of cancer immunotherapy 
(Huang et al., 2018a).  
 
LncGata6 
LncGata6 (LncRNA GATA6) was identified as a divergent transcript 
expressed from the promoter of Gata6, which is specifically enriched in a subset of 
intestinal stem cells (Zhu et al., 2018). Deletion of exons 2-4 of lncGata6 in the 
mouse did not affect Gata6 levels but resulted in decreased intestinal regeneration 
due to decreased proliferative capacity of intestinal stem cells (Zhu et al., 2018). 
Consistent with the key role of stem cells in intestinal tumorigenesis, genetic and 
ASO-mediated depletion of lncGata6/lncGATA6 were found to impair tumor 
growth in the APCmin mouse model of intestinal adenoma and in a PDX model 
(Zhu et al., 2018). Future studies should focus on elucidating the mechanism by 
which lncGATA6 is upregulated in colorectal cancer and on determining the extent 
to which it contributes to aberrant Wnt signaling, a known colorectal cancer driver.  
 
DINO 
The p53 target lncRNA DINO binds to and stabilizes p53 in a positive 
feedback loop, enhancing the activation of p53 target genes (Schmitt et al., 2016). 
Importantly, RNAi knockdown of DINO in human fibroblasts and a deletion of the 
Dino promoter in MEFs led to impaired cell cycle arrest following genotoxic stress 
(Schmitt et al., 2016). Interestingly, ectopic expression of DINO in HPV-positive 
cervical cancer cells, which suppress p53 stabilization and express DINO at low 
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levels, led to reactivation of dormant p53, resulting in sensitization of the cancer 
cells to chemotherapeutic agents and vulnerability to metabolic stress (Sharma 
and Munger, 2020). To date, however, evidence that DINO acts as a tumor 
suppressor in human cancer is limited.  
 
LINC-PINT 
Like DINO, linc-Pint was also identified as a p53 target (Marin-Bejar et al., 
2013). A knockout mouse generated by replacing the linc-Pint locus with a LacZ 
reporter cassette yielded smaller pups, suggesting a role for linc-Pint in early 
development (Sauvageau et al., 2013). Characterization of LINC-PINT function in 
cancer suggested a role in limiting cell invasion, with LINC-PINT overexpression 
leading to decreased liver metastases in a mouse model (Marin-Bejar et al., 2017). 
In a transwell migration and invasion assay, invasiveness increased following 
treatment with LINC-PINT -targeting ASOs or following CRISPR-mediated 
deletion of a highly conserved LINC-PINT sequence element (Marin-Bejar et al., 
2017). Analysis of the previously generated linc-Pint knockout mouse (Sauvageau 
et al., 2013) in a cancer background could help support these results. However, the 
potential role of the LINC-PINT RNA may be confounded by the identification of 
a peptide with a function in suppressing cell proliferation encoded by a circular 
form of LINC-PINT (Zhang et al., 2018a).  
 
THOR  
While examples of alternative organismal models for lncRNA function in 
cancer are limited, in part due to low evolutionary conservation of lncRNAs, 
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investigation of the highly conserved lncRNA THOR (Testis-associated Highly 
conserved Oncogenic long noncoding RNA) in human and zebrafish cancer models 
has implicated this lncRNA in promoting melanoma development (Figure 5) 
(Hosono et al., 2017). THOR expression is normally restricted to the testis, but has 
been found aberrantly overexpressed in multiple cancer types, including lung 
adenocarcinoma, lung squamous carcinoma, and melanoma (Hosono et al., 2017). 
Knockdown of THOR via RNAi and ASOs in lung adenocarcinoma and melanoma 
cell lines led to decreased proliferation and reduced colony formation (Hosono et 
al., 2017). These findings were corroborated in two independently derived lung 
adenocarcinoma cell lines harboring approximately 3 Kb CRISPR-mediated 
deletions within the THOR gene body. Conversely, THOR overexpression gave the 
opposite phenotype, leading to increased proliferative capacity and anchorage- 
independent growth. Importantly, ectopic expression of human THOR in zebrafish 
cooperated with oncogenic NRAS and p53 loss to promote melanoma 
development, whereas knockout of THOR in zebrafish embryos delayed mutant 
NRAS-induced melanoma formation (Hosono et al., 2017). Further studies may 
reveal the potential of using THOR expression as a biomarker or targeting THOR 









Figure 5. Identification and functional characterization of THOR. THOR was identified 
as a testis-specific ultra-conserved lncRNA aberrantly expressed in cancer tissues (Hosono et al., 
2017). Hosono and colleagues generated several in vitro and in vivo loss-of-function (LOF) and 
gain-of-function (GOF) models to functionally characterize THOR. LOF models included transcript 
degradation with RNAi and ASO, and THOR partial locus deletion (THOR-/-) in both human cells 
injected in severe combined immunodeficiency disease (SCID) mice and in a genetically engineered 
zebrafish model (THOR-/-) embryonically injected with NRAS to induce melanoma. GOF models 
included THOR overexpression (OE) in vitro and OE of human THOR (hTHOR) in p53-deficient 
zebrafish (p53-/-) embryonically injected with NRAS to induce melanoma. Overexpression of 
THOR plays an oncogenic role (red box) in cancer by binding to IGF2BP1 and increasing the 






Identification of lncRNAs that are genetically or epigenetically perturbed in 
cancer has risen sharply over the past decade. The precipitous increase in the 
number of cancer-associated lncRNAs has been accompanied by a growing 
excitement that many lncRNAs may act as novel drivers of cancer development. 
Yet, lagging understanding of how lncRNAs function in physiologic and pathologic 
contexts has limited our insights into the roles of lncRNAs in tumorigenesis. The 
current literature points to many lncRNAs acting as both oncogenes and tumor 
suppressors. While these seemingly contradictory findings may stem from 
differences in experimental models, they may also be reflective of complex and 
context-dependent lncRNA biology, analogous to the dual oncogenic and tumor 
suppressor roles played by cancer-associated protein-coding genes (Shen et al., 
2018). Future studies should prioritize the identification and validation of true 
dual functions from technical inconsistencies.  
LncRNAs make attractive drug targets, particularly in diseases where 
protein candidates are not amenable to pharmacological inhibition (Dang et al., 
2017). Both siRNA- and ASO-mediated lncRNA degradation as well as locked 
nucleic acid (LNA)-mediated interference with lncRNA function have emerged as 
clinic-ready approaches (Arun et al., 2018; Lieberman, 2018). The successful 
deployment of these approaches in cancer, however, is predicated upon robust 
functional characterization. In the future, it would be essential to develop in vitro 
and in vivo models that closely recapitulate the recurrent genetic or epigenetic 
changes of lncRNAs observed in human cancer. In parallel, experiments that 
uncover the functional elements of perturbed lncRNA loci will inform whether 
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motives or structural features of the lncRNA molecules, the act of their 
transcription, or underlying DNA elements mediate their roles in disease 
development. These questions will be best answered through the integration of 
diverse and complementary approaches and by corroboration from multiple 
independent studies.  
 
 
The p53 and Myc duet in cancer 
Transcription networks coordinate the expression of a variety of genes in 
response to cellular inputs. As such, transcription factors and their downstream 
gene expression programs are frequently deregulated in cancer, with many the 
target of alterations that promote tumor growth (reviewed in (Bradner et al., 
2017)). Two significant transcription networks in cancer are regulated by the p53 
tumor suppressor and the Myc proto-oncogene, respectively. As a consequence of 
their central roles in controlling cellular growth and survival, albeit activated by 
very different cellular impulses, both networks are often subject to pro-
tumorigenic genetic and epigenetic modifications (Dang, 2012; Kastenhuber and 
Lowe, 2017). 
The human TP53 gene, which encodes the p53 tumor suppressor protein, is 
mutated in as many as 50% of all human cancers, with p53 loss often predictive of 
advanced tumor grade and poor overall survival (Kandoth et al., 2013; Olivier et 
al., 2010). Germline TP53 mutations, the defining characteristic of Li Fraumeni 
Syndrome, dramatically increase the risk of developing a range of tumor types 
(Olivier et al., 2010). Similarly, mice with germline loss of one or both copies of 
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p53 (Trp53-/- or Trp53+/-) are prone to spontaneous tumorigenesis, with 
complete p53 loss often resulting in neoplasm development within the first year of 
life (Donehower et al., 1992; Jacks et al., 1994). Apart from mutations which inhibit 
p53 directly, mutations that disturb critical p53 effector genes are also common, 
and can be equally as disruptive to p53 network function. For example, transgenic 
mice that overexpress Mdm2 (Mouse double minute 2), a negative regulator of p53, 
and mice lacking Arf (Alternate reading frame of Cdkn2a), a positive regulator of 
p53, are both similarly prone to spontaneous tumorigenesis (Jones et al., 1998; 
Kamijo et al., 1999). 
On the other hand, cancer-driving mutations affecting the Myc network are 
often characterized not by alterations to Myc coding sequences, but by alterations 
that increase Myc expression or activity. Upregulation of MYC in avian leukosis 
virus (ALV)-induced lymphomas via retroviral insertion upstream of the MYC 
promoter is well-documented (Hayward et al., 1981; Payne et al., 1982). 
Furthermore, an analysis of somatic copy number alterations (SCNAs) in human 
cancer revealed MYC alterations as one of the most prominent (Beroukhim et al., 
2010). The MYC locus often participates in chromosomal rearrangements, and is 
a frequent translocation partner of the immunoglobulin heavy chain locus (Taub 
et al., 1982), a fusion that increases MYC expression and is modeled in the Eµ–
Myc mouse model of B-cell lymphoma (Adams et al., 1985). Focal genomic 
amplifications of the MYC locus in the form of homogeneously staining regions 
and double minutes are also common (Alitalo et al., 1983; Collins and Groudine, 
1982). Notably, several studies have illustrated MYC oncogene addiction, with 
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suppression of MYC sufficient to cause tumor regression (reviewed in (Dang, 
2012)), suggesting its importance for viability in MYC-driven cancers. 
The observation that loss-of-function and gain-of-function mutations in 
TP53 and MYC, respectively, have such pervasive effects on cancer pathology 
points to critical roles for these transcription networks in maintaining normal 
cellular growth and homeostasis. 
 
The p53 tumor suppressor pathway 
Under normal conditions, p53 is constitutively produced and degraded, 
enabling rapid action to be taken against cellular assaults (Kastenhuber and Lowe, 
2017). In response to a variety of cellular stressors, such as doxorubicin-induced 
DNA damage or the expression of an activated oncogene, p53 is stabilized via 
repression of MDM2 activity and p53 post-translational modifications, thus 
enabling its tetrameric binding to canonical p53 response elements (p53REs) and 
the induction of the p53 transcriptional program (Figure 6) (Beckerman and 
Prives, 2010; Kastenhuber and Lowe, 2017). The ability of p53 to bind specific DNA 
sequences is critical to its function. Genes directly induced by p53 share the 
presence of a conserved p53RE, usually in their promoter or first intron 
(Beckerman and Prives, 2010), composed of two 10 bp motifs separated by a 
stretch of nucleotides between 10-13 bp in length (el-Deiry et al., 1992).  There is 
some evidence of gene repression downstream of p53 (Allen et al., 2014), but its 
contribution to the p53 response remains unclear. Significantly, p53 stabilization 
strongly correlates with reduced MYC levels, suggesting that p53 may actively 
suppress positive regulators of the cell cycle rather than simply promoting the 
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expression of negative regulators of cell growth (Ho et al., 2005; Porter et al., 
2017). 
Through the activation of its transcription program, p53 drives a variety of 
cellular outcomes, the most prominent of which are transient cell cycle arrest 
(Brugarolas et al., 1995), senescence (Ferbeyre et al., 2002), and apoptosis (Lowe 
et al., 1994). Moreover, several studies have suggested that canonical p53 
responses and full p53 transcriptional activation may be dispensable for tumor 
suppression, suggesting that some non-canonical p53-driven responses may play 
equally important roles in cellular homeostasis (Jiang et al., 2011; Li et al., 2012).  
The targets of p53 are diverse and include coding and noncoding genes with 
functions in a range of cellular processes such as cell cycle regulation,  
pluripotency, metabolism, and inflammation (reviewed in (Kastenhuber and 
Lowe, 2017)). Notably, the characterization of numerous lncRNA targets of p53 in 
recent years suggests the growing importance of this class of noncoding transcripts 
in the p53 response to stress (as discussed previously in this chapter). What 
dictates selection of a particular cellular outcome in response to p53 activation is 
unclear, although evidence suggests it may depend on cell type and stressor 
(Attardi et al., 2004; Paris et al., 2008). Despite these gaps in knowledge, it is clear 
that p53 is critical in preventing the outgrowth of aberrantly proliferating cell 







Figure 6. The p53 tumor suppressor pathway. The tumor suppressor protein p53 is a 
transcription factor that is stabilized by cellular stress (i.e. DNA damage, oncogene activation, 
hypoxia, etc) and binds p53 Response Elements (p53REs) to upregulate various coding and 
noncoding target genes. The induction of the p53 transcription program drives cellular outcomes 












The proto-oncogenic Myc network 
Myc responds to pro-growth stimuli by orchestrating the induction of cell 
cycle genes to promote cell division. It does so most commonly through 
heterodimerization with its partner Max (Myc-associated factor X) and 
cooperative binding to E-box (CACGTG) sequences in the promoters of target 
genes (Amati et al., 1993; Blackwell et al., 1990). While Myc half-life is short, Max 
is more stable, pointing to both Myc expression and protein synthesis as rate 
limiting steps in cellular proliferation (Amati et al., 1993). 
Researchers have long sought to define a universal set of Myc target genes, 
but precise characterization of the Myc transcription network has remained 
elusive. Analysis of serum-stimulated fibroblasts revealed nearly 300 genes 
induced in a Myc-dependent manner (Perna et al., 2012), consistent with an 
understanding of Myc as driving a selective gene expression program (Sabo et al., 
2014; Walz et al., 2014). However, several studies have advocated a less 
discriminatory role for Myc function, suggesting that Myc acts not necessarily as a 
sequence-specific transcription factor, but as a global amplifier of genes expressed 
from open chromatin (Lin et al., 2012; Rahl et al., 2010). These differing 
viewpoints stem, in part, from normalization tactics used in RNA-sequencing 
experiments to identify Myc target genes. Specifically, there has been 
disagreement over how to contend with the proposed ability of Myc to increase 
global transcription as a potential confounding factor in standard normalization 
practices. Some have argued that normalization based on cell equivalents 
overcomes biases introduced by Myc-induced surges in total RNA content, but in 
practice accuracy may require multiple analyses (Kress et al., 2015). Of note, Myc 
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roles in gene repression have also been suggested, such as its proposed function in 
influencing the cellular response to DNA damage by downregulating the CDK 
inhibitor p21 to promote apoptosis, perhaps indicating feedback between the p53 
and Myc transcription programs (Seoane et al., 2002). 
 Ambiguities concerning Myc regulation and function in cancer also persist. 
Expressed from the 8q24 locus, MYC is impacted by a range of cis-acting DNA 
elements (Fulco et al., 2016). An abundance of lncRNAs in the MYC locus have also 
been identified, with some proposed to have cancer-specific functions in MYC 
regulation (Ling et al., 2013; Xiang et al., 2014). How these lncRNAs and other 
enhancer and repressor elements adjacent to the MYC locus drive MYC expression 
in different cancer types is still an open question. While elevated Myc levels are 
known to promote aberrant cell growth under circumstances favorable to 
tumorigenesis, its dysregulation has also been associated with an increased 
propensity for cells to undergo programmed cell death (Zindy et al., 1998). 
Interestingly, some have speculated about a Myc expression threshold cells cannot 
surpass without triggering apoptosis (Murphy et al., 2008). This has been 
proposed as especially critical in early cancer development when cells retain 
functional tumor suppressor pathways, suggesting that lower levels of Myc 
dysregulation may be optimal for initial cancer cell survival. 
 
 
Project framework: p53, Myc, and the missing lncRNA 
This chapter links together disparate elements of lncRNA biology and 
cancer biology in broad strokes. A key question raised at the intersection of these 
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fields is whether, and to what extent, lncRNA aberrations in cancer can constitute 
true drivers of tumorigenesis. There is abundant evidence for genetic and 
epigenetic alterations of lncRNAs in cancer and their presence in pathways 
essential to cancer growth and development is well-documented. However, 
ultimately only a small fraction of cancer-related lncRNAs have been shown to 
have significant, and functionally consistent, physiological impacts when they are 
manipulated in vivo (discussed in detail previously in this chapter). As such, the 
functional impacts of individual lncRNAs, and indeed lncRNAs as a class, on 
cancer pathogenesis are incompletely understood. 
An additional, and ultimately related, question highlighted here concerns 
the elusive threads connecting the p53 and Myc transcription networks. Given the 
significant, albeit often contradictory, influences of the tumor suppressor p53 and 
the proto-oncogene Myc on cell growth, and by extension, cancer development, 
one might expect a need for cells to coordinate their activities in order to avoid the 
transmission of opposing cellular impulses (Figure 7). As alluded to previously, 
p53 activation results in repression of Myc as a mechanism for temporarily 
curtailing cellular proliferation in stressed cells (discussed more in Chapter 2). 
This phenomenon has long been of interest to cancer biologists, but remained 
poorly understood despite decades spent studying Myc regulation. We find that 
this cellular fail-safe is primarily facilitated by the lncRNA isoform Pvt1b, the 
subject of this work. Considering the heterogeneity of lncRNAs in form and 
function, they make apt candidates for enacting specific local regulation 
downstream of broadly active transcription factors. However, the lncRNA field has 
been plagued by challenges in ascertaining lncRNA functional roles, particularly 
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under tumorigenic conditions; many controversies center on lncRNAs with both 
ascribed pro- and anti- oncogenic capabilities rooted in evidence from conflicting 
model systems. 
Here I describe Pvt1b as an emissary connecting two extensive gene 
expression programs, a potential archetype for lncRNA function, which may exist 
in other cellular processes and pathways. Incorporating lessons in experimental 
design derived from lncRNA literature and guided by an understanding of the roles 
of p53 and Myc in cancer, I employ a range of orthogonal approaches to assess the 
function and biological significance of Pvt1b under physiologic and tumorigenic 
conditions. I first identify and characterize Pvt1b, presenting evidence for its role 
in repressing Myc transcription downstream of p53 activation (see Chapter 2). I 
further investigate the functional elements of the Pvt1b transcript (see Chapter 
3) and pursue a potential mechanism of action involving Pvt1b-guided  histone 
deacetylation at the Myc promoter (see Chapter 4). Finally, I provide a 
foundation for future dissection of Pvt1 function in vivo through my role in 
generating three genetically engineered Pvt1 mouse models, the incisive 
combination of which should help illuminate features of the Pvt1 locus required 
for its activities (see Chapter 5). Rationales for specific experiments are discussed 








Figure 7. The p53 and Myc transcription networks in cancer. In response to mitogenic 
stimuli, MYC (red) dimerizes with its partner MAX (yellow) to upregulate target genes that promote 
cellular proliferation. In contrast, p53 (green) responds to cellular stress, binding as a tetramer to 
induce genes that suppress cellular growth. In cancer, MYC is frequently the target of gain-of-
function (GOF) mutations, while p53 is frequently the target of loss-of-function (LOF) mutations. 
MYC levels have been observed to decrease following p53 activation, and various mechanisms, both 














p53 activates the long noncoding RNA Pvt1b to inhibit Myc and 
suppress tumorigenesis 
 
The work described in this chapter has been published as follows: Olivero, C.E., 
Martinez-Terroba, E., Zimmer, J., Liao, C., Tesfaye, E., Hooshdaran, N., 
Schofield, J.A., Bendor, J., Fang, D., Simon, M.D., et al. (2020). p53 Activates the 
Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis. Mol Cell 
77, 761-774 e768. Co-author contributions that have also been included in this 
thesis are specified in figure legends and/or text.  
 
Introduction  
The p53 (also known as TP53) network is a central tumor suppressive 
mechanism in mammalian cells that is inactivated in the vast majority of human 
cancers (Vousden and Prives, 2009). In response to cellular stress induced by DNA 
damage or oncogenic signaling, p53 transcriptionally activates target genes to limit 
cellular proliferation or to permanently eliminate damaged cells (Vousden and 
Prives, 2009). Transcriptional activation by p53 relies on its binding to conserved 
p53 response elements (p53REs) in the promoters of target genes (Levine and 
Oren, 2009). p53 has also been implicated in the repression of cell cycle regulators 
(Engeland, 2018). One of the prominent targets of p53 repression is the 
Myelocytomasis (Myc) oncogene (Ho et al., 2005; Levy et al., 1993; Sachdeva et al., 
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2009), a global transcriptional amplifier that responds to mitogenic signals to 
promote cellular proliferation (Lin et al., 2012). Multiple models for how p53 
negatively affects Myc levels have been proposed, including p53 binding to the Myc 
promoter to suppress histone acetylation, binding to a distal regulatory element to 
alter nucleosome positioning in the Myc promoter, or activating repressive Myc-
targeting microRNAs (Ho et al., 2005; Porter et al., 2017; Sachdeva et al., 2009). 
However, the mechanism of p53-mediated Myc downregulation and its 
contribution to tumor suppression in vivo have remained unclear. 
Long noncoding RNAs (lncRNAs) can modulate gene expression locally by 
accumulating near their sites of transcription (Kopp and Mendell, 2018). In dosage 
compensation, Xist and other lncRNAs expressed from the X-chromosome 
specifically repress genes across the entire X-chromosome through the 
recruitment of epigenetic regulators (Lee, 2012). Other cis-regulatory lncRNAs act 
in a more limited, locus-specific manner, such as the p53 target lincRNA-p21 
proposed to promote the levels of its neighbor p21 (also known as Cdkn1a) by 
recruiting activating factors (Dimitrova et al., 2014). While studies of locus-specific 
cis-regulatory lncRNAs have revealed important roles in diverse biological 
processes (Dimitrova et al., 2014; Elling et al., 2018; Kotzin et al., 2016), 
characterization of the RNA molecule is often confounded by potential functional 
roles of DNA regulatory sequences in the lncRNA locus (Bassett et al., 2014; 
Engreitz et al., 2016; Groff et al., 2016). Defining the RNA-mediated regulation 
provides important opportunities for RNA-based therapeutics that can alter 
hardwired molecular interactions to change cellular responses. 
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Plasmacytoma variant 1 (Pvt1), a lncRNA expressed 50 Kb downstream of 
Myc, is altered in a large fraction of human cancers. Frequent translocations and 
viral integrations in the Pvt1 locus in lymphomas suggest important roles for Pvt1 
in cancer progression (Cory et al., 1985; Graham and Adams, 1986; Graham et al., 
1985). In addition, co-amplification of Myc and Pvt1 across multiple cancer types 
correlates with poor cancer patient prognosis, suggesting cooperation between the 
two genes during tumorigenesis (Cui et al., 2016; Tseng and Bagchi, 2015; Zeng et 
al., 2017). This pro-oncogenic cooperation between Myc and Pvt1 was recently 
confounded by the identification of a p53-binding site in the Pvt1 locus and by the 
description of the Pvt1 promoter as a transcriptional repressor of Myc (Cho et al., 
2018; Porter et al., 2017). These studies suggested undefined roles for Pvt1 in 
cancer progression and a potential crosstalk between the tumor suppressor p53 
pathway and the oncogenic Myc network.  
In this study, I characterized Pvt1b, a p53-induced isoform of the lncRNA 
Pvt1, and determined its contribution to Myc regulation and the p53 response to 
stress. I show that production of the Pvt1b RNA downstream of p53 represses Myc 
transcription and suppresses cellular proliferation during stress and in the early 
stages of tumorigenesis. The model presented here illuminates a role for the 
lncRNA isoform Pvt1b as a locus-specific transcriptional regulator that serves to 






p53 suppresses Myc under conditions of genotoxic and oncogenic 
stress  
To gain insight into the mechanism by which p53 causes suppression of 
Myc, I used multiple independent approaches to model the p53-dependent 
response to stress. To model the cellular response to genotoxic stress, I utilized 
wild-type (WT) mouse embryonic fibroblasts (MEFs) treated with the genotoxic 
agent Doxorubicin (Doxo) (Figure 8A). I observed that activation of the p53 
transcriptional program following Doxo treatment for 24 hours resulted in 3-fold 
induction of the p53 target p21 and a concomitant reduction in Myc RNA and 
protein levels by 34±6% (p=0.008, Figure 8B) and 44±15% (p=0.0051, Figure 8C), 
respectively, consistent with previous findings (Ho et al., 2005; Porter et al., 2017). 
I also found that p53 activation by oncogenic stress, modeled by Tamoxifen (Tam)-
CreER-dependent restoration of endogenous p53 expression in a murine lung 
adenocarcinoma cell line (K-rasLA2-G12D/+; p53LSL/LSL; Rosa26-CreERT2+, KPR) 
(Figure 8D) (Feldser et al., 2010), similarly led to a 70-fold activation of p21, a 
34±7% repression of Myc RNA (p=0.0020, Figure 8E) and a 37±10% decrease in 
Myc protein (p=0.0028, Figure 8F). Myc repression by 39±5% was also observed 
in intestinal epithelium cells isolated from mice exposed to 6 Grays (Gy) of whole-
body irradiation, which leads to a well-characterized p53-mediated response to 
genotoxic stress in vivo (p=0.0007, Figures 8G and 8H) (Clarke et al., 1994). 
Altogether, these results suggested that Myc repression is a general event 
downstream of p53 transcriptional activation. 
In an effort to elucidate the mechanism by which p53 activation results in 
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Myc repression, Nadya Dimitrova examined whether p53 associates with the Myc 
locus. She observed that both in Doxo-treated MEFs and Tam-treated KPR cells, 
stress-dependent Myc repression was accompanied by binding of p53 to a distal 
p53RE, located 50 Kb downstream of Myc, which has previously been implicated 
in limiting Myc expression (Figure 8I)(Porter et al., 2017).  
Consistent with p53 dependency, the changes in Myc RNA and protein 
levels were present in p53-proficient, but not p53-deficient MEFs (Figures 8J and 
8K). Additionally, the decrease in Myc RNA levels was detectable as early as 4 
hours following p53 activation and was coincident with the decrease in Myc protein 
levels, suggesting direct transcriptional modulation by p53 (Figures 8L and 8M). 
Inhibition of protein translation with Cycloheximide (Chx) revealed that Myc 
protein stability was not significantly affected by the presence of stress, suggesting 
that the decrease in Myc levels was not primarily due to post-translational 













Figure 8. p53 suppresses Myc in response to genotoxic and oncogenic stress. (A) 
Schematic of the model system for studying p53-mediated response to genotoxic stress in WT MEFs 
untreated or treated with Doxo for 24 h. Activation of p53 by passaging or by genotoxic stress is 
represented by light and dark red nuclei, respectively. (B) p21 and Myc RNA levels in cells from 
(A). Data show mean ± SEM (n=4, biological replicates),  *p<0.05, **p<0.01, paired t test. (C) Left 
Representative image and quantification of Myc protein levels from cells in (A). Hsp90 as a loading 
 64 
control. Right Bargraph of Myc protein levels showing mean±SEM (n=5, biological replicates), 
**p<0.01, paired t test. (D) Schematic of the model system for studying p53-mediated response to 
oncogenic stress in KPR cells untreated or treated with Tam for 24 h. Activation of p53 by oncogenic 
stress is represented by red nucleus. (E) p21 and Myc RNA levels in cells from (D). Data show mean 
± SEM (n=6, biological replicates), ***p<0.001, paired t test. (F) Left Representative image and 
quantification of Myc protein levels from cells in (D). Hsp90 as a loading control. Right Bargraph 
of Myc protein levels showing mean±SEM (n=5, biological replicates), **p<0.01, paired t test. (G) 
Schematic of the model system for studying p53-mediated response in vivo in intestinal epithelial 
cells isolated from WT mice at 6 h post 6 Gy whole-body irradiation. Samples provided by Nadya 
Dimitrova. (H) p21 and Myc RNA levels from mice in (G). Data show mean ± SEM (n=3, biological 
replicates) **p<0.01, ***p<0.001, unpaired t test. (I) Enrichment of p53 binding at the Pvt1-
associated p53RE by ChIP-qPCR in Left Doxo-treated MEFs and Right Tam-treated KPR cells. Data 
show mean ± SEM (MEFs: n=4; KPR: n=3, biological replicates) *p<0.05, **p<0.01, paired t test. 
P53 ChIP performed by Nadya Dimitrova. (J) Myc RNA levels in p53-deficient or p53-proficient 
MEFs, untreated or treated with Doxo for 24 h. Data show mean ± SEM (n=3, biological replicates), 
ns = not significant, *p<0.05, paired t test. (K) Left Representative image and quantification of 
Myc protein levels from cells in (J). Hsp90 as a loading control. Right Bargraph of Myc protein 
levels showing mean ± SEM (n=3, biological replicates), ns = not significant, *p<0.05, paired t test. 
(L) Myc RNA levels in WT MEFs, untreated or treated with Doxo for the indicated times. Data 
show mean ± SEM (n=4, biological replicates), ***p<0.001, paired t test. (M) Left Representative 
image and quantification of Myc protein levels from cells in (L). Hsp90 as a loading control. Right 
Bargraph of Myc protein levels showing mean ± SEM (n=4, biological replicates), **p<0.01, 
***p<0.001, paired t test. (N) Left Representative image and quantification of Myc protein levels 
following treatment with cycloheximide (Chx) for indicated times in WT MEFs, untreated or treated 
with Doxo for 8 h. Right Myc protein half-life (n=3, biological replicates), ns = not significant, 
paired t test. 
 
Contributions from N. Dimitrova in (G) and (I) are described above. 
 
 
Myc repression correlates with activation of a p53-dependent Pvt1 
isoform, Pvt1b 
I was intrigued that the distal p53RE was located within the gene body of 
the lncRNA Pvt1 (Figure 9A), which has previously been implicated as a p53 target 
(Barsotti et al., 2012). Considering lncRNAs can act in cis to regulate the 
transcription of neighboring genes, I examined whether Pvt1 played a role in 
restricting Myc expression during stress. I noted significant stress-dependent 
induction of an isoform of Pvt1, termed Pvt1b, initiated at a transcription start site 
located immediately downstream of the p53RE. I observed a 3.1±0.2-fold 
induction of Pvt1b in Doxo-treated MEFs (Figure 9B) and a 38±6-fold induction 
of Pvt1b in Tam-treated KPR cells (Figure 9C). Pvt1a, an isoform of Pvt1 initiated 
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at exon 1a, was induced to a lesser extent in Doxo-treated MEFs (Figure 9B) and 
was not significantly induced by Tam in KPR cells (Figure 9C). Copy number 
calculations suggested that Pvt1b was induced from 20 to 210 copes per cell, while 
Pvt1a was expressed at 300-400 copies per cell (Figure 10A). Notably, activation 
of Pvt1b was coincident with Myc repression and occurred as early as 4 hours 
following Doxo treatment in MEFs (Figure 10B) or 6 hours following Tam 
treatment in KPR cells (Figure 10C), consistent with direct transcriptional 
regulation by p53. Similarly, Doxo-treated human fibroblasts exhibited a 2-fold 
decrease in MYC levels and an 8-fold increase of human PVT1B (Figure 10D). 
These findings indicated that the downregulation of Myc and the activation of a 
p53-dependent, stress-specific Pvt1 variant are conserved between mouse and 
human.  
To further characterize the transcripts produced from the Pvt1 locus, I 
performed RT-PCR with forward primers located in either exon 1a or 1b and a 
reverse primer in exon 5. I found evidence for extensive alternative splicing and 
confirmed that variants containing exon 1b were induced by p53, while exon 1a-
containing variants were constitutively expressed (Figures 9D and 9E). Despite the 
splicing heterogeneity, sequencing of nascent RNA revealed that stress-induced 
Pvt1b differed from constitutively expressed Pvt1a solely by the use of exon 1b 
versus exon 1a, and exhibited comparable splicing patterns to downstream exons 
(Figure 9F). I concluded that p53 activation during genotoxic and oncogenic stress 
initiated transcription in the Pvt1 locus from exon 1b, leading to the production of 
the p53-dependent isoform, Pvt1b, while Pvt1a represented a largely constitutively 
expressed isoform.  
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Figure 9. p53-dependent induction of the Pvt1 isoform, Pvt1b. (A) Schematic of the 
mouse Myc-Pvt1 locus, highlighting exons 1a and 1b of Pvt1 and the location of the p53RE (green 
*). (B, C) Isoform-specific and total Pvt1 RNA levels detected with primers located in indicated 
exons in (B) WT MEFs and (C) KPR cells, treated as indicated. Data show mean ± SEM (n=3, 
biological replicates), *p<0.05, **p<0.01, ***p<0.001, paired t test. (D, E) RT-PCR detection of 
Pvt1a isoforms (a, blue), amplified with primers from exon 1a to exon 5, and Pvt1b isoforms (b, 
orange), amplified with primers from exon 1b to exon 5, in RNA isolated from (D) MEFs and (E) 
KPR cells, ladder (L). (F) Genome browser tracks and Sashimi plots from TimeLapse-seq data in 
KPR cells, treated as indicated. Average number of splice junctions from 2 biological replicates from 
exon 1a to exon 2 (blue) and from exon 1b to exon 2 (orange) are indicated. Processing of samples 
for TimeLapse-seq and data analysis performed by Jeremy Schofield and Josh Zimmer. 
 
Contributions from J. Schofield and J. Zimmer in (F) are described above. 
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Figure 10. p53 activates the lncRNA isoform Pvt1b. (A) Copy number calculations of Pvt1a, 
Pvt1b, and Myc by qRT-PCR analysis of KPR cells untreated or 24 h post-treatment with Tam. (B, 
C) qRT-PCR analysis of Pvt1b levels in (B) MEFs treated with Doxo for the indicated times and (C) 
KPR cells treated with Tam for the indicated times. The observed induction of Pvt1b as early as 4-
6 hours post stress suggests direct transcriptional activation by p53. (D) Top Schematic of the 
human PVT1 locus, highlighting exon 1a (blue), exon 1b (orange), the conserved p53RE (green star) 
and showing the location of qPCR primers (red arrows), Bottom qRT-PCR analysis of relative 
PVT1A, PVT1B, and MYC RNA levels in normal human fibroblasts untreated or treated with Doxo 
for 24 h. Data show the mean ± SEM of 3 technical replicates from a representative example of two 
biological replicates. Human fibroblast samples provided by Nadya Dimitrova. 
 





Stress-induced Myc repression occurs in the absence of promoter-
enhancer contact reorganization 
Previous work had shown that CRISPR-mediated transcriptional regulation 
of the Pvt1 promoter in p53-deficient cancer cells causes reorganization of the 
chromatin architecture in the locus and impacts the access of Myc to downstream 
enhancers (Cho et al., 2018). To test whether the stress-responsive, p53-dependent 
induction of Pvt1b was associated with changes of these chromatin contacts, I 
performed Chromosome Conformation Capture (3C) in MEFs and KPR cells. 
Using an anchor in the Myc promoter, I confirmed that the Myc promoter accessed 
multiple upstream and downstream enhancers, including previously described 
Pvt1 intragenic enhancers (Figures 11A and 11B) (Cho et al., 2018). However, I did 
not detect significant changes in the chromatin looping between the Myc promoter 
and Myc-associated enhancers during the p53-mediated stress response (Figures 
11A and 11B). These results argue against a model where p53-dependent activation 











Figure 11. p53 activation does not substantially alter chromatin architecture of the 
Myc-Pvt1 locus. (A-B) 3C analysis of BamHI-digested DNA from (A) WT MEFs, untreated or 
treated for 24 h with Doxo and (B) KPR cells, untreated or treated for 24 h with Tam. Interaction 
frequency with an anchor in the Myc promoter (A1, green arrow) is plotted relative to genomic 
location. A unidirectional forward primer strategy was used to probe chromatin interactions within 
the Myc- Pvt1 locus and primers were designed to query previously described enhancer regions 
interacting with the Myc promoter (Cho et al., Cell 2018), published H3K4me1 peaks (Meyer et al., 
JBC 2016), and control regions. Top Interaction frequency plots depicting the strongest 
interactions between the Myc promoter and upstream and downstream enhancers. Note that the 
chromatin architecture is largely unchanged by the presence of stress. Bottom Interaction 
frequency plot depicting weaker interactions between the Myc promoter and upstream and 
downstream enhancers. Note the change of scale and that the three strongest peaks, depicted in the 
Top panels, are excluded in the Bottom panels to allow visualization of smaller peaks. Note that 
there is a pre-existing chromatin looping interaction between the Myc and Pvt1 promoters, which 
exhibits a mild increase following Doxo treatment in (A) WT MEFs but is not significantly changed 
in (B) Tam-treated compared to untreated KPR cells. Data represent (A) n=3 biological replicates 





Accumulation of Pvt1b in the chromatin surrounding the Pvt1-Myc 
locus 
To gain insight into the potential regulatory function of Pvt1b, I performed 
single-molecule RNA Fluorescence in situ Hybridization (smRNA-FISH), which 
allows visualization of individual RNA molecules by utilizing multiple 
fluorescently-labeled probes per transcript. I designed four independent probesets 
to detect Pvt1 transcripts. Pvt1a- and Pvt1b-specific probesets (named Pvt1a 
(ex.1a) and Pvt1b (ex.1b)) were designed against the first exon of each isoform. 
While isoform-specific, the two probesets were not expected to detect single RNA 
molecules due to the low number of probes per transcript. The probeset Pvt1 
(ex.1a-10) was designed to detect both full-length Pvt1a and full-length Pvt1b at 
single-molecule resolution, while the Pvt1 (introns) probeset was specific to 
unspliced Pvt1 molecules. Finally, I designed a probeset to detect Myc intronic 
regions (Myc (intron)) and mark the site of Myc transcription. I observed that 
Pvt1a and Pvt1b exhibited a primarily 2- or 4-dot nuclear pattern in Etoposide 
(Etop)-treated MEFs, reflective of G1 or S/G2 stages of the cell cycle, respectively 
(Figures 12A and 13A). Pvt1a and Pvt1b formed larger clouds in Tam-treated KPR 
cells (Figures 12B and 13B), which have amplified the locus, as shown by DNA 
Fluorescence in situ Hybridization (DNA-FISH) (Figure 13C). By co-staining either 
Pvt1a or Pvt1b with total Pvt1, I concluded that both isoforms exhibited an 
identical localization pattern (Figures 12A, 12B, 13A and 13B). Notably, Pvt1a- and 
Pvt1b-containing foci co-localized with signals specific to the introns of nascent 
Myc (Figures 12C and 12D) as well as with nascent Pvt1 transcripts (Figures 12E 
and 12F). These results led me to conclude that, following transcription, Pvt1a and 
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Pvt1b are retained on the chromatin surrounding the Pvt1-Myc locus. Subcellular 
fractionation analysis confirmed enrichment of both Pvt1 variants in the 























Figure 12. Accumulation of Pvt1 isoforms in the chromatin surrounding the Pvt1-Myc 
locus. (A-F) smRNA-FISH with indicated probes in (A, C, E) WT MEFs, untreated or treated with 
Etop for 24 h and in (B, D, F) KPR cells untreated or treated with Tam for 24 h. DNA, DAPI. Note: 
Pvt1b is detectable in untreated, p53-proficient MEFs likely due to activation of the p53 pathway 
by passaging in primary cells but is undetectable in untreated, p53-deficient KPR cells. (G) Pvt1a 
and Pvt1b RNA levels in Doxo-treated WT MEFs following subcellular fractionation (representative 
from n=2 biological replicates). Rn7s1 and Kcnq1ot1 used as controls for the cytoplasmic and 
chromatin fractions, respectively. Subcellular fractionation and analysis performed by Ephrath 
Tesfaye. 
 





Figure 13. Co-localization of Pvt1a and total Pvt1 by smRNA-FISH. (A-B) smRNA-FISH 
with probes designed against indicated regions in (A) WT MEFs, untreated or treated with Etop for 
24 h and in (B) KPR cells untreated or treated with Tam for 24 h. The following probesets are 
shown: Pvt1a (ex.1a, red) detecting Pvt1a isoform with 11 probes spanning exon 1a and Pvt1 (ex.1a-
10, green) detecting total Pvt1 with 48 probes spanning exons 1a-10. Note: The Pvt1a probeset does 
not detect at the single molecule level. (C) DNA-FISH with probes generated using a Bacterial 
Artificial Chromosome (BAC) of the Myc locus (Myc BAC, red) or a control region in chromosome 
6 (Chr 6 BAC, green) in untreated WT MEFs and KPR cells, highlighting increased copy number of 
the Myc locus in KPR cells. DNA-FISH performed by Dorthy Fang. 
Contributions from D. Fang in (C) are described above. 
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Pvt1b RNA represses Myc levels in cis 
Based on the stress-dependent expression of Pvt1b and its local chromatin 
accumulation, I hypothesized that Pvt1b could be involved in Myc repression 
through an RNA-dependent mechanism. To directly test this hypothesis, I 
designed three independent antisense oligonucleotides (ASOs) specific to exon 1b 
(Figure 14A). I used a non-targeting ASO (CON) as a negative control. As ASOs 
lead to co-transcriptional RNA cleavage and degradation, ASO1, 2, and 3 
significantly downregulated both Pvt1a and Pvt1b (Figure 14B).  
Next, I examined how Pvt1-targeting ASOs affected Myc expression levels. 
In untreated MEFs, Myc RNA and protein levels were not significantly altered in 
ASO compared to CON samples, indicating that knockdown of Pvt1 isoforms did 
not affect Myc regulation in the absence of stress, consistent with previous findings 
(Figures 14C, 14D and 15A) (Cho et al., 2018). As expected, upon treatment with 
Doxo, CON MEFs experienced a significant decrease in Myc RNA (Figure 14C) and 
protein levels (Figures 14D and 15A). On the other hand, I found that Pvt1-
targeting ASOs completely rescued stress-induced downregulation of Myc RNA 
and protein (Figures 14C, 14D and 15A). These findings revealed that 
transcriptional activation of Pvt1b by p53 is required for Myc repression during 
stress. As a control, the absence of Myc downregulation was not due to altered 
association of p53 with the Pvt1b-associated p53RE (Figure 15B).  
To test the sufficiency of Pvt1b in suppressing Myc, Elena Martínez-Terroba 
employed the CRISPR-SAM (Synergistic Activation Mediator) system to activate 
the expression of endogenous Pvt1b in p53-deficient cells (Dahlman et al., 2015). 
CRISPR-SAM combines nuclease-proficient Cas9 with 15-nucleotide ʻdead RNAsʼ 
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(dRNAs), which are competent for Cas9 recruitment but do not support Cas9 
nuclease activity. In CRISPR-SAM, the dRNA scaffold is extended by two MS2 
binding loops (dRNA-MS2), which serve to recruit the MS2-binding protein (MBP) 
fused to the transcriptional activator domains of p65 and HSF1, allowing CRISPR 
activation (CRISPRa) of target genes (Dahlman et al., 2015). Martínez-Terroba 
designed A1 and A2 dRNA-MS2 targeting the promoters of Pvt1a and Pvt1b, 
respectively (Figure 14E). Compared to a non-targeting control (C), CRISPRa using 
A1 led to 1.6-fold induction of Pvt1a, without altering Pvt1b levels, while A2 
resulted in a 20-fold activation of Pvt1b with no significant induction of Pvt1a 
(Figure 14F). Next, she examined the effect of activation of endogenous Pvt1a and 
Pvt1b on Myc levels. In support of the model, she found that CRISPRa of Pvt1b, 
but not Pvt1a, was sufficient to significantly repress Myc RNA in p53-deficient cells 
compared to control dRNA-expressing cells (p=0.023, Figure 14G). Activation of 
Pvt1b did not further downregulate Myc levels following p53 restoration, 
indicating that Pvt1b acted downstream of p53 (Figure 14G). On the other hand, 
activation of Pvt1b was not sufficient to suppress Myc protein levels, opening the 
possibility for Pvt1b-independent input at the post-transcriptional level (Figures 
15C and 14H).  
To distinguish between activity in cis versus in trans, I tested whether 
exogenous overexpression of Pvt1a and Pvt1b by transfection of cDNA constructs 
containing exons 1a-10  (1a) or 1b-10 (1b) affected Myc expression (Figure 14I). I 
observed a 6.5-fold overexpression of Pvt1a as well as a 23-fold overexpression of 
Pvt1b, which were comparable to CRISPRa-induced overexpression (Figure 14J). 
However, I found that exogenously delivered Pvt1a or Pvt1b did not significantly 
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affect Myc RNA or protein levels, arguing against an effect in trans (Figures 14K, 
14L and 15D). Altogether, these data supported a previously unappreciated role for 























Figure 14. Production of Pvt1b RNA suppresses Myc expression in cis. (A) Schematic 
of ASO design. * denotes p53RE. (B) Isoform-specific and total Pvt1 RNA levels in WT MEFs 
transfected with indicated control (CON) or Pvt1-targeting ASOs and harvested 24 h post Doxo 
treatment. Data are normalized to CON and show mean ± SEM (n=3, biological replicates). (C) 
Myc RNA levels in cells from (B), untreated or treated with Doxo for 24 h. Data are normalized to 
CON-Doxo and show mean ± SEM (n=3, biological replicates), ***p<0.001, ns = not significant, 
paired t test. (D) Quantification of Myc protein levels in cells from (B). Data are normalized to 
CON-Doxo and show mean ± SEM (n=3, biological replicates), *p<0.05, ns = not significant, paired 
t test. (E) Schematic of CRISPRa dRNA design. * denotes p53RE. CRISPRa cell lines generated by 
Elena Martínez-Terroba. (F) Pvt1a and Pvt1b RNA levels following Pvt1a (A1) or Pvt1b (A2) 
transcriptional activation in KPR cells, untreated or treated with Tam for 24 hours. Data are 
normalized to control dRNA (C) and show mean ± SEM (n=5, biological replicates), ns = not 
significant, *p<0.05, paired t test. Data collection and analysis performed by Elena Martínez-
Terroba. (G) Myc RNA levels from experiment in (F). Data collection and analysis performed by 
Elena Martínez-Terroba. (H) Quantification of Myc protein levels in cells from (F). Data show 
mean ± SEM (n=3, biological replicates), ns = not significant, paired t test. Protein samples 
provided by Elena Martínez-Terroba. (I) Schematic of Pvt1a and Pvt1b overexpression constructs. 
(J) Isoform-specific and total Pvt1 RNA levels in WT MEFs transiently overexpressing full length 
Pvt1a (1a) or Pvt1b (1b). Data are normalized to empty vector (EV) and show mean ± SEM (n=3, 
biological replicates), ns = not significant, paired t-test. (K) Myc RNA levels from experiment in 
(J). (L) Quantification of Myc protein levels in cells from (J). Data show mean ± SEM (n=3, 
biological replicates), ns = not significant, paired t test. 
 








Figure 15. Effects of Pvt1b manipulation in cis and in trans on Myc protein levels. (A) 
Representative immunoblot analysis of Myc protein levels in whole-cell extracts isolated from ASO 
knockdown experiments in Fig. 4D. Hsp90 as a loading control. (B) ChIP-qPCR analysis showing 
the enrichment of p53 binding at p53RE relative to input in CON- and ASO1- treated WT MEFs 
following 8 h Doxo treatment. Data represented mean ± - SEM of biological replicates, ns = not 
significant, paired t-test. P53 ChIP performed by Nadya Dimitrova. (C) Representative 
immunoblot analysis of Myc protein levels in whole-cell extracts isolated from CRISPRa 
experiments in Fig. 4H. Hsp90 as a loading control. Protein samples provided by Elena Martínez-
Terroba. (D) Representative immunoblot analysis of Myc protein levels in whole-cell extracts 
isolated from exogenous overexpression experiments in Fig. 4L. Hsp90 as a loading control.  






Genetic inhibition of Pvt1b reverses stress-induced Myc 
downregulation 
To investigate the functional contribution of Pvt1b to the p53 tumor 
suppressor pathway, I developed a genetic approach to specifically inhibit Pvt1b 
expression by mutating the p53RE required for its expression. I targeted Cas9 to 
the Pvt1b p53RE by designing a guide RNA (DRE) adjacent to the GGG protospacer 
adjacent motif (PAM) site located in the central region of the p53 consensus 
binding motif (Figure 16A). A non-targeting gRNA (Con) was used as a negative 
control. I generated control (Con) and mutant (DRE) KPR population, MEF 
population, and KPR clonal cell lines, which contain numerous or clone-specific 
CRISPR/Cas9-induced mutations of the Pvt1b-associated p53RE. I confirmed 
mutagenesis of the p53RE by Sanger sequencing (Figures 16A, 17A and 17B) and 
ChIP showed that DRE mutagenesis reduced p53 binding by 15-fold (Figure 16B). 
Importantly, by qRT-PCR, Pvt1b levels were significantly suppressed in DRE cells 
compared to controls (Figures 16C, 17C, 17D and 17G), and, by smRNA-FISH, I 
observed loss of Pvt1b-specific signal in Tam-treated DRE KPR cells compared to 
Tam-treated controls (Figures 16D and 16E). These observations led to the 
conclusion that mutagenesis of the Pvt1b-associated p53RE leads to efficient 
abrogation of stress-dependent Pvt1b activation.  
Next, I queried whether DRE mutagenesis led to isoform-specific inhibition. 
By qRT-PCR and smRNA-FISH, I found that Pvt1a RNA levels and localization 
pattern were not significantly altered in DRE KPR population and clonal cell lines 
compared to controls, indicating that mutation of the p53RE led to specific 
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inhibition of Pvt1b in KPR cells (Figures 16C, 16D, 17C and 17D). On the other 
hand, mutagenesis of the p53RE in MEFs led to a significant reduction of Pvt1a 
(Figure 17G), consistent with our findings that Pvt1a expression has a p53-
dependent component in this cell type (Figure 9B). 
Finally, I examined by qRT-PCR and immunoblotting the effects of the DRE 
mutation and the resulting loss of Pvt1b expression on Myc levels during the 
cellular response to stress. In Con KPR population, KPR clonal, and MEF lines, 
exposure to oncogenic or genotoxic stress led to the expected significant decrease 
in Myc RNA (Figures 16F, 17E, 17F and 17H) and protein levels (Figures 16G, 16H, 
17I and 17J). In contrast, exposure to stress in DRE KPR population, KPR clonal, 
and MEF lines did not lead to a significant decrease in Myc RNA levels compared 
to unstressed cells, consistent with the ASO data (Figures 16F, 17E, 17F and 17H). 
These results provided an independent, genetic confirmation that Pvt1b regulates 
Myc RNA levels downstream of p53. 
Interestingly, while Myc protein levels were significantly elevated in DRE 
KPR+Tam and DRE MEF+Doxo lines compared to Con KPR+Tam and Con 
MEF+Doxo lines, respectively, the rescue was not complete (Figures 16G, 16H, 17I 
and 17J), consistent with the possibility of Pvt1b-independent regulatory input at 
the post-transcriptional level (Figure 14H). 
Of note, mutagenesis of the Pvt1b-associated p53RE did not impact the 
long-range chromatin interactions in the locus, consistent with chromatin 




Figure 16. Genetic inhibition of Pvt1b leads to increased Myc levels. (A) Top Schematic 
of p53RE mutagenesis, indicating the PAM site (red box) and Cas9 cleavage site (red arrow). 
Bottom Mutant alleles, determined by Sanger sequencing. (B) ChIP-qPCR analysis of p53 
enrichment at Pvt1b-associated p53RE in indicated cells and treatments. Data show mean ± SEM 
(n=3, biological replicates) *p<0.05, paired t test. P53 ChIP performed by Nadya Dimitrova. (C) 
Pvt1a and Pvt1b RNA levels in indicated cells and treatments. Data show mean ± SEM (n=3, 
biological replicates), **p<0.01, ns = not significant, paired t test. (D, E) smRNA-FISH of Pvt1b 
(ex.1b, red) co-localized with (D) total Pvt1 (ex1a-10, green) or (E) nascent Myc (intron, green) in 
indicated cells and treatments. DNA, DAPI. (F) Myc RNA levels in indicated cells and treatments. 
Data show mean ± SEM (n=3, biological replicates), *p<0.05, ***p<0.001, ns = not significant, 
paired t test. (G) Representative image and quantification of Myc protein levels in indicated cells 
and treatments. Hsp90 as a loading control. (H) Quantification of Myc protein levels from 
experiments in (G). Data show mean ± SEM (n=6, biological replicates), *p<0.05, ***p<0.001, 
paired t test.  
 









Figure 17. Genetic inhibition of Pvt1b rescues stress-dependent Myc repression in 
KPR clonal and MEF cell lines. (A-F) Analysis of (A, C, E) clone D and (B, D, F) clone E, 
isolated from KPR cells infected with a gRNA targeting the Pvt1b p53RE (ΔRE). As a control, KPR 
clones expressing Con gRNA were analyzed. (A, B) Sanger sequencing of the region containing the 
Pvt1b-associated p53RE. (C, D) qRT-PCR analysis of relative Pvt1a and Pvt1b RNA levels in 
indicated samples. (E, F) qRT-PCR of the ratio (+Tam/-Tam) of Myc expression in indicated 
clones. Bars show the mean ± SEM of n=3 biological replicates, ***p<0.001, paired t-test. (G-J) 
 84 
Analysis of MEF population cell lines, infected with a gRNA targeting the Pvt1b p53RE (ΔRE) or a 
non-targeting control (Con) and harvested untreated or 8-24 h post Doxo treatment. (G) qRT-PCR 
analysis of relative Pvt1a and Pvt1b RNA levels in indicated samples. Data represent mean ± SEM 
of n=3 biological replicates, **p<0.01, ***p<0.001, paired t- test. (H) qRT-PCR analysis of relative 
Myc RNA levels in indicated samples. Data represented as mean±SEM of n=3 biological replicates, 
ns = not significant, ***p<0.001, paired t- test. (I) Immunoblot analysis of Myc protein levels in 
whole-cell extracts from indicated cells. Hsp90 as a loading control. (J) Quantification of Myc 
protein levels from cells in (I). Data represent mean ± SEM of n=7 biological replicates, *p<0.05, 




















Figure 18. Effects of genetic inhibition of Pvt1b on the chromatin architecture of the 
Myc-Pvt1 locus and Myc transcription. (A) 3C analysis in KPR cells, infected with Pvt1b 
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p53RE-targeting (ΔRE) or Control (Con) gRNAs and treated for 24 h with Tam. Interaction 
frequency relative to an anchor in the Myc promoter (A1, green arrow) is plotted from three 
technical replicates from a representative experiment of two biological replicates, as described in 
Figure S2. (B) MA plots from TT-TimeLapse-seq data depicting log2 fold change in nascent RNA 
(n >11,000 for each condition) in (A) untreated or (B) Tam-treated KPR cells. Myc and total Pvt1 
are indicated (purple dots). Processing of samples for TT-TimeLapse-seq and data analysis 
performed by Jeremy Schofield, Josh Zimmer and Matt Simon. 
 
Contributions from J. Schofield, J. Zimmer, and M. Simon in (B) are described above. 
 
Pvt1b suppresses Myc transcriptional activity and cellular 
proliferation in vitro 
By analyzing the effects of the DRE mutation on gene expression in total 
RNA from untreated and Doxo-treated DRE and Con MEFs in collaboration with 
Nima Hooshdaran and Jesse Zamudio, I confirmed that Myc is a target of Pvt1b 
regulation in response to stress (Figure 19A). Next, to test whether Pvt1b acted at 
the transcriptional or post-transcriptional level, my collaborators Josh Zimmer, 
Jeremy Schofield and Matt Simon sequenced nascent RNA from untreated and 
Tam-treated DRE and Con KPR cells (Schofield et al., 2018). They found that 
nascent Myc transcripts were significantly upregulated in DRE+Tam compared to 
Con+Tam KPR cells, indicative of transcriptional regulation (Figures 19B and 
19C). These data revealed that Pvt1b production promotes transcriptional 
suppression of Myc. 
Next, Hooshdaran and Zamudio queried how the changes in Myc RNA 
levels affected the Myc transcriptional program by examining the consequence of 
Pvt1b loss on a curated set of 196 Myc target genes (Gene Set Enrichment Analysis, 
HALLMARK_MYC_TARGETS_V1 (Liberzon et al., 2015)). They plotted the 
cumulative frequency distribution of the fold change of Myc target genes in DRE 
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cells relative to Con cells in the presence of stress (logFC [DRE/Con+stress]). 
Compared to a randomly generated set of control genes expressed at comparable 
levels, they found a significant increase in the levels of Myc targets in MEFs and 
KPR cells (Figures 19D and 19E). They concluded that Myc derepression by DRE 
mutagenesis leads to a small but significant increase in the transcriptional activity 
of Myc.  
Considering Myc target genes include factors that promote cellular growth, 
I compared the proliferation of mutant cells compared to controls. It has 
previously been shown that Tam-mediated p53 restoration in KPR cells leads to a 
permanent cell cycle arrest, called senescence (Feldser et al., 2010). While loss of 
Pvt1b expression did not overcome senescence, it led to a significant increase in 
cellular proliferation and colony formation compared to control cells (Figures 19F 
and 19G). As a control, the DRE mutation did not impact Myc levels and 
proliferation in p53-deficient cells, ruling out off target effects (Figures 18B and 
19F). These data suggested that Pvt1b mediates specific aspects of p53 function to 









Figure 19. Pvt1b suppresses Myc transcription and proliferative function. (A, B) 
Butterfly plot depicting the fold change (logFC) in gene expression of indicated samples relative to 
statistical significance (-log10(p-value), MEF: n=3; KPR: n=2, biological replicates). Gene 
expression profiling was performed by (A) RNAseq of polyA-selected RNA isolated from Con or 
ΔRE gRNA-expressing MEFs, untreated or treated with Doxo for 24 hours or (B) TimeLapse-seq of 
ribosomal cDNA-depleted s4U-labeled RNA isolated from Con or ΔRE gRNA-expressing KPR cells, 
untreated or treated with Tam for 16 hours. Total Pvt1 (blue) and Myc (red) are labeled. Library 
preparation performed by Nadya Dimitrova. Data analysis performed by Nima Hooshdaran and 
Jesse Zamudio. (C) Top Genome browser tracks depicting the Myc-Pvt1 locus and Bottom Detail 
of the Myc locus from TT-TimeLapse-seq. Processing of samples for TT-TimeLapse-seq and data 
analysis performed by Jeremy Schofield, Josh Zimmer and Matt Simon. (D, E) Cumulative 
frequency distribution plot of differential expression for a set of curated Myc target genes and a 
matched set of control genes from analyses in (A, B). Library preparation performed by Nadya 
Dimitrova. Data analysis performed by Nima Hooshdaran and Jesse Zamudio. (F) Population 
doublings in Con or ΔRE gRNA-expressing KPR cells, untreated or treated with Tam over indicated 
timecourse. Data show mean ± SEM (n=3, biological replicates), **p<0.01, unpaired t test. (G) 
Representative images of colony formation assay of Tam-treated KPR cells, infected with Con or 
ΔRE gRNAs. Numbers show mean ± SEM (n=3, biological replicates), **p<0.01, unpaired t test. 
 
Contributions from N. Hooshdaran and J. Zamudio in (A), (B), (D) and (E), and from J. Schofield, 
J. Zimmer, and M. Simon in (C) are described above. 
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Tumor-specific inhibition of Pvt1b promotes tumor growth in vivo 
Inactivation of p53 in the K-rasLSL-G12D/+(K) autochthonous mouse model of 
lung cancer has been shown to increase tumor burden and promote tumor 
progression from benign to aggressive disease (DuPage et al., 2009; Jackson et al., 
2005; Jackson et al., 2001). To elucidate whether Pvt1b mediated some aspects of 
p53 function, Nadya Dimitrova and Clara Liao performed tumor-specific 
mutagenesis of the Pvt1b-associated p53RE (Figure 20A). Dimitrova built a 
bifunctional lentiviral construct (U6-gRNA PGK-Cre, UGPC) for co-expression of 
the DRE gRNA (UGPC-DRE) and Cre recombinase, required for Cas9 targeting and 
tumor initiation, respectively (DuPage et al., 2009). Expression of Cas9 in a tumor-
specific manner was achieved by crossing the K model to Rosa26-Cas9LSL (C) mice 
to generate KC animals (Platt et al., 2014). As a negative control, they used a non-
targeting control (UGPC-Con). As a positive control, they used a previously 
described gRNA that targets the open reading frame of p53 (UGPC-p53KO) (Xue 
et al., 2014). Sanger sequencing confirmed successful mutagenesis of the Pvt1b-
associated p53RE in UGPC-DRE-infected animals (Figure 20B).  
They next examined hematoxylin and eosin (H&E) sections of lungs from 
mice infected with UGPC-Con, -p53KO and -DRE virus and sacrificed at 16 weeks 
post tumor initiation. In the K model, progression of atypical adenomatous 
hyperplasia (AAH, grade 1) and lung adenoma (grade 2) to adenocarcinoma (grade 
3) and invasive adenocarcinoma (grade 4) is promoted by loss of p53 function 
(Jackson et al., 2005). Indeed, histopathological analysis revealed that all of the 
tumors (53/53 tumors) in UGPC-Con-infected animals manifested grade 1 features 
(Figures 20C and 20D). In contrast, 70% of UGPC-p53KO-expressing tumors 
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(39/56 tumors) were marked by atypical nuclei, desmoplasia, and transition to a 
poorly differentiated phenotype and were classified as grade 2 or 3 (Figures 20C 
and 20D) (DuPage et al., 2009). Based on these data, they estimated that a large 
portion of the tumors underwent successful CRISPR/Cas9 editing in vivo. Editing 
of the Pvt1b-associated p53RE resulted in tumors with histopathological features 
comparable to controls and only 3% of tumors (2/67 tumors) in UGPC-DRE-
infected animals were classified grade 2 or 3, suggesting that tumor progression 
was not accelerated by Pvt1b inhibition (Figures 20C and 20D). They concluded 
that Pvt1b does not likely mediate the ability of p53 to restrain tumor progression 
from benign hyperplasia to advanced disease.  
On the other hand, quantification of the tumor area relative to the total lung 
area revealed that the tumor burden in UGPC-DRE-infected animals (21±4%) was 
significantly increased compared to the burden of control mice (12±2%) 
(p=0.0040, Figure 20E). Notably, the tumor burden in p53RE-edited mice was 
comparable to the tumor burden in UGPC-p53KO-infected mice (26±3%) (Figure 
20E). These findings suggested that Pvt1b mediated in large part the growth-
restrictive functions downstream of p53, particularly during the pre-malignant 
stages of the disease. As a control for potential off-target effects of Cas9 expression 
and CRISPR editing, Ephrath Tesfaye used two independent sgRNAs (sg1 and sg2) 
to target the p53RE in intron 1 of an unrelated lncRNA, Gm26542, for which we 
had evidence for direct p53 regulation (Figures 21A, 21B and 21C). In contrast to 
Pvt1b, inhibition of Gm26542 did not affect proliferation in Tam-treated KPR cells 
in vitro (Figure 21D) and did not significantly alter the tumor burden in KC mice 
in vivo (Figure 21E).  
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The increase in tumor burden in UGPC-DRE-infected animals compared to 
UGPC-Con mice was not due to decreased apoptosis as there was no evidence for 
Cleaved Caspase 3 (CC3) immunohistochemistry (IHC) staining in lung sections. 
Instead, the increase in tumor burden could be attributed to enhanced 
proliferation, as manifested by the significantly greater number of phosphorylated 
histone H3 (pHH3)-positive mitotic cells in Pvt1b-deficient tumors from UGPC-
DRE-infected animals compared to tumors from UGPC-Con-infected mice 
(p=0.0026, Figures 20F and 20G).  
Finally, to investigate whether Pvt1b acted downstream or independent of 
p53, Dimitrova and Liao performed an epistasis experiment. They generated 
cohorts of either KC or K-rasLSL-G12D/+; p53FL/FL; Rosa26-Cas9LSL/LSL (KPC) 
animals, which have genetically engineered Cre-inducible loss-of-function alleles 
of p53. They analyzed tumor burden at 12 weeks post tumor initiation with UGPC-
Con or -DRE virus. Consistent with their findings above, they observed a significant 
increase in the tumor burden of UGPC-DRE-infected mice compared to UGPC-
Con-infected KC animals (p=0.0035, Figure 20H). In contrast, they found that the 
tumor burden was not significantly different between UGPC-DRE and UGPC-Con-
infected KPC animals (Figure 20H). Moreover, there was no statistically significant 
difference between the tumor burden of KC mice infected with UGPC-DRE and 
KPC mice infected with UGPC-Con (Figure 20H). Altogether, these results 
revealed that Pvt1b and p53 enhance the expansion of pre-malignant tumors 




Figure 20. Tumor-specific editing in a lung cancer model reveals a role for Pvt1b in 
suppressing tumor growth, but not progression. (A) Schematic of tumor-specific gene 
editing in KC and KPC lung cancer mouse models. (B) Mutant ΔRE alleles, determined by Sanger 
sequencing of bulk DNA isolated from tumor-bearing lungs. (C) H&E staining of lung sections of 
KC mice infected with indicated gRNAs and analyzed at 16 weeks post tumor initiation (pti). Scale 
bars as indicated. (D) Quantification of tumor grade in mice described in (C). The number of 
tumors analyzed from n=5 mice is indicated for each group. (E) Quantification of tumor burden in 
mice described in (C). Dots represent individual animals and bargraph shows mean ± SEM (n=7 
mice), ***p<0.001, **p<0.01, ns = not significant, unpaired t test. (F) Representative images of 
immunohistochemistry for the mitotic marker pHH3 in lung sections from (C). Scale bars as 
indicated. (G) Quantification of images in (F). Data show mean ± SEM of n=13-15 tumors from 
n=5 mice, **p<0.01, Mann-Whitney test. (H) Quantification of tumor burden in KC and KPC mice 
infected with indicated gRNAs and analyzed at 12 weeks pti. Dots represent individual animals and 
bargraph shows mean ± SEM (KC: n=6 mice, KPC: n=3 mice), *p<0.05, ns=not significant, 
unpaired t-test. All in vivo experiments and data analysis performed by Nadya Dimitrova and Clara 
Liao.   
 




Figure 21. Mutagenesis of Gm26542-associated p53RE does not affect proliferation 
in vitro, tumor growth in vivo. (A) Schematic of the mouse Gm26542 lncRNA locus depicting 
the sequence of the p53RE located in intron 1, and the PAM sites (PAM #1 and PAM #2) utilized by 
guide RNAs sg1 and sg2, respectively. Schematic provided by Ephrath Tesfaye. (B) Sanger 
sequencing of the region containing the Gm26542-associated p53RE in KPR cells infected with sg1 
or sg2. Data collection and analysis performed by Ephrath Tesfaye. (C) qRT-PCR analysis of 
relative RNA levels of the Gm26542 lncRNA in Con-, sg1- and sg2- infected KPR cell populations 
showing the p53-dependent induction of Gm26542 at 24 hours post Tam treatment and the 
abrogation of this induction by p53RE mutagenesis. Data collection and analysis performed by 
Ephrath Tesfaye. (D) Growth analysis showing population doublings in Con, sg1, or sg2 gRNA-
expressing KPR cells, untreated or treated with Tam. Data show mean ± SEM of n=3 biological 
replicates, ns= not significant, unpaired t-test. Cell lines provided by Ephrath Tesfaye. (E) 
Quantification of tumor burden as tumor area relative to total lung area in KC mice infected with 
indicated gRNAs and analyzed at 16 weeks post tumor initiation (pti) as described in Fig. 20. Data 
show tumor burden of individual mice and mean±SD, ns = not significant, unpaired t-test. In vivo 
experiments and data analysis performed by Nadya Dimitrova. 
 





This study provides new mechanistic insights into the function of the 
lncRNA Pvt1 in the context of the p53 tumor suppressor pathway. I identify a 
conserved isoform of Pvt1, Pvt1b, which is directly activated by p53 in response to 
genotoxic and oncogenic stress. My data reveal that production of Pvt1b functions 
as a p53-dependent mechanism that is wired into the Myc-Pvt1 locus to directly 
and swiftly down-regulate Myc transcription during stress (Figure 22). This 
appears to be the primary mechanism underlying stress-induced Myc reduction at 
the transcriptional level, although these data are also consistent with Pvt1b-
independent regulation at the post-transcriptional level. 
Functionally, I observed that Pvt1b activation leads to restricted Myc levels 
and transcriptional activity and suppressed cellular proliferation. Furthermore, 
use of an autochthonous mouse model of lung cancer demonstrated that Pvt1b acts 
downstream of p53 during the early stages of cancer development to limit tumor 
growth. Strikingly, in this respect, epistasis analysis suggested that Pvt1b acts as 
the primary mediator of p53. On the other hand, I found that Pvt1b is not involved 
in other aspects of p53 function, such as promoting senescence or limiting tumor 
progression to advanced disease. Altogether, these analyses define the specific 
contributions of Pvt1b downstream of p53, pointing to growth limiting and tumor 
suppressive functions of Pvt1b in the context of cancer. These conclusions contrast 
the common classification of Pvt1 as an oncogene, which is based on extensive 
correlative evidence linking Pvt1 aberrations with increased invasive capacities of 
cancer cells and poor patient survival (Guan et al., 2007; Guo et al., 2018; Kong et 
al., 2015; Riquelme et al., 2014; Tseng et al., 2014; Zeng et al., 2017; Zhang et al., 
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2019; Zhao et al., 2018; Zheng et al., 2016; Zhu et al., 2017). On the other hand, 
these data are consistent with recent reports of tumor suppressive elements in the 
Pvt1 locus (Barsotti et al., 2012; Cho et al., 2018; Porter et al., 2017).  
My findings shed light on a subset of genomic aberrations reported across a 
variety of malignancies, which represent translocations between the first exon of 
Pvt1a fused to various 3’ gene partners (Iwakawa et al., 2013; Kim et al., 2014a; 
Nagoshi et al., 2012; Northcott et al., 2012). Such rearrangements would be 
expected to separate the Myc locus from Pvt1b, providing cells with a proliferative 
advantage due to the inability of p53 to suppress Myc levels during early stages of 
tumor development. On the other hand, the proposed tumor suppressive role of 
Pvt1b is at odds with the common amplification of the Pvt1 locus in cancer (Guan 
et al., 2007; Riquelme et al., 2014). I propose that amplification of other elements, 
such as the Pvt1a transcript or Pvt1-associated Myc enhancers may be the drivers 
of oncogenic activities in this setting, as proposed by others (Cho et al., 2018; Tseng 
et al., 2014). Alternatively, these alterations might be occurring following p53 
inactivation, which would preclude Pvt1b expression. 
Mechanistically, I provide direct evidence for a role of Pvt1b RNA 
production in Myc regulation. Antisense-mediated depletion experiments reveal 
that Pvt1b is required for stress-induced Myc inhibition, whereas epigenetic 
activation from the endogenous locus shows that Pvt1b is sufficient to repress Myc 
in the absence of stress or a functional p53 pathway. While ASO-based knockdown 
and CRISPR-guided epigenetic experiments cannot formally differentiate between 
the mature Pvt1b molecules or the production of nascent Pvt1b transcripts as the 
mediator of Myc repression, these data support an RNA-based mechanism. 
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This conclusion differs from the recent finding that the Pvt1a promoter 
suppresses Myc levels in an RNA-independent manner (Cho et al., 2018). The 
discrepancy can potentially be explained by the previous focus on the constitutive 
Pvt1 isoform, by the use of p53-deficient cell lines, or by the use of ineffective ASOs 
(Cho et al., 2018). Alternatively, I propose that the two tumor suppressive activities 
in the Pvt1 locus, one p53- and RNA-dependent and the other p53- and RNA-
independent, may co-exist and operate in distinct cellular contexts. My findings 
also do not contradict studies that have implicated Pvt1a or circular Pvt1 isoforms 
as oncogenes via diverse mechanisms, such as oncoprotein stabilization or 
competition for miRNA binding (Tseng et al., 2014; Xu et al., 2017; Zhao et al., 
2018). Indeed, the complexity of the Pvt1 locus highlights the need for further 
rigorous dissection of the various alternative start site- and splice-variants.  
It is important to note that Pvt1b mediates a repressive event downstream 
of p53, which is a well-characterized transcriptional activator. Considered in the 
context of the previously characterized p53-dependent cis-regulatory lincRNA-p21 
(Dimitrova et al., 2014), it appears that transcription factors use lncRNAs to either 
enhance their inherent activity or to allow reverse regulation within local circuits. 
LncRNAs which accumulate at their sites of transcription, such as Pvt1b, are poised 
to act as modulators of gene expression in a locus-specific manner. Indeed, Pvt1b 
activation leads to Myc repression within four hours of exposure to genotoxic 
stress, which is comparable to the kinetics of activation of p53 target genes. I 
propose that production and/or chromatin accumulation of p53-induced Pvt1b 
transcripts act in cis during the cellular response to stress to rapidly influence the 
transcriptional environment at the Myc promoter. Thus, locus-specific 
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transcriptional regulation by lncRNAs may provide additional tools within a 
transcriptional program that allow dynamic and swift responses to cellular 
challenges. As the mechanisms of more p53-dependent lncRNAs are revealed, we 
can gain new insight into how regulatory RNAs contribute to the cellular responses 
to stress mediated by p53. Although future work will determine the functional 
elements of Pvt1b transcripts, the widespread importance of this regulatory circuit 
in normal and transformed cells in vitro and in vivo suggests the possibility of 












Figure 22. LncRNA Pvt1b mediates crosstalk between the Myc and p53 
transcriptional networks. Top Under conditions of cellular stress, p53 (green) directly activates 
lncRNA Pvt1b (orange) to indirectly repress Myc (red), inhibiting cellular proliferation and tumor 
growth. Bottom p53-mediated induction of Pvt1b following cellular stress leads to local repression 






Investigating the functional elements of the Pvt1b transcript 
 
Introduction 
The elements of lncRNAs required to perform specific functions can 
comprise a range of characteristics encoded in the transcripts themselves, 
including sequence and/or structural motifs (see Chapter 1). The sequence of a 
lncRNA may enable its association with specific RNA binding proteins (RBPs) or 
may fold into unique hairpins or more complex structures that otherwise confer 
function (reviewed in (Zampetaki et al., 2018)). Given that Pvt1b differs from 
Pvt1a primarily based on whether transcript initiation is from exon 1b or exon 1a, 
respectively, I reasoned that the function of Pvt1b may depend explicitly on the 
exon 1b sequence or any structures therein. In this chapter, I investigate the 
importance of Pvt1 exon 1b for p53-dependent Myc repression by attempting to 
either alter Pvt1b-specific sequences or disrupt their production. In doing so, I 
provide insight into the potential mechanism by which Pvt1b downregulates Myc 
under conditions of cellular stress. 
 
Results 
Investigating the function of the Pvt1 exon 1b sequence in p53-
dependent Myc repression 
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To determine if Pvt1 exon 1b harbors any sequence and/or structural motifs 
required for Pvt1b function, I developed a genetic approach to test the functionality 
of regions within exon 1b whose disruption could rescue p53-induced Myc 
repression. To accomplish this, I employed a strategy to generate numerous 
CRISPR/Cas9-induced mutations throughout the 191 bp exon 1b sequence (Figure 
23A). After analyzing available PAM sites, I selected 11 high specificity guide RNAs, 
excluding those with low specificity scores (Concordet and Haeussler, 2018) and 
those targeting similar areas of the exon 1b sequence (Figure 23B). I generated 11 
mutant (gALT1-11) KPR population and PR MEF population cell lines (refer to 
Chapter 2, Figure 8 for descriptions of KPR and PR MEF cell lines), each of which 
contain heterogeneous mutations in the guide RNA-specific region targeted by 
Cas9 (Figure 23B). A guide RNA targeting dTomato (gTOM) was used as a negative 
control, while the guide RNA targeting the Pvt1b-associated p53RE (gRE, see 
Chapter 2, Figure 16) was used as a positive control due to its previously 
documented ability to rescue stress-induced Myc downregulation (see Chapter 2, 
Figure 16). I confirmed mutagenesis by each guide RNA (gALT1-11) by Sanger 
sequencing and Tracking of Indels by DEcomposition (TIDE) analysis (Brinkman 
et al., 2014), observing estimated mutagenesis efficiencies ranging from 37.2 – 
94.4% (Figure 23C). Importantly, by qRT-PCR, Pvt1b levels were significantly 
suppressed in gRE cells compared to controls (Figures 23C and 23E), consistent 
with previous results (see Chapter 2, Figure 16). These observations led us to 
conclude that I had successfully mutagenized sequences in Pvt1 exon 1b. 
 Infection with gALT1-11 resulted in fluctuations in Pvt1b expression levels 
in both KPR and PR MEF cell lines, variations which appeared guide RNA-
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independent, with some guide RNAs yielding differing Pvt1b levels depending on 
cell line (Figures 23C and 23E). Considering that the qRT-PCR Pvt1b forward 
primer overlaps the exon 1b regions targeted by gALT8 and gALT9, I anticipated 
Pvt1b levels in these cell lines might be unusually low, although any 
underestimation of Pvt1b expression appeared to be minimal (Figures 23C and 
23E). Importantly, any reductions in Pvt1b expression resulting from infection 
with gALT1-11 did not approach the extent of Pvt1b inhibition observed following 
infection with gRE (Figures 23C and 23E). 
Finally, I used qRT-PCR to assess whether mutations within the Pvt1 exon 
1b sequence had any effect on Myc levels during the cellular response to stress. In 
negative control KPR population and PR MEF population cell lines infected with 
gTOM, exposure to oncogenic or genotoxic stress led to an expected decrease in 
Myc RNA (Figures 23D and 23F). Importantly, positive control KPR population 
and PR MEF population cell lines infected with gRE experienced a rescue in stress-
dependent Myc downregulation (Figures 23D and 23F), consistent with previous 
findings (see Chapter 2, Figure 16). Next, I found that exposure to stress in 
gALT1-11 KPR population and PR MEF population cell lines did not result in any 
notable increases in Myc levels approaching the rescue observed in gRE cell lines. 
Taken together, these results suggested mutagenesis of sequences throughout Pvt1 





Figure 23. Probing the role of the Pvt1 ex1b sequence in p53-dependent Myc 
repression. (A) Schematic of the 5’ end of the Pvt1 locus showing transcript initiation sites for 
Pvt1a (blue) and Pvt1b (orange) at exon 1a and exon 1b, respectively. Guide RNAs to mutate the 
exon 1b sequence (gALT1-11) shown in red, with red 5’ ends of Pvt1b transcripts indicating 
mutagenesis. Location of Pvt1b-associated p53RE indicated by green asterisk. (B) Left, Pvt1 exon 
1b sequence, with PAM sites (red) utilized by guide RNAs gALT1-11 indicated sequentially. Right, 
percent mutagenesis efficiency yielded by each guide RNA (gRNA) as estimated by Tracking of 
Indels by DEcomposition (TIDE) analysis in KPR cells as described in (Brinkman et al., 2014). N/A 
= data not available. (C) Pvt1b RNA levels in KPR cells infected with indicated guide RNAs, 
untreated or treated with tamoxifen (TAM) for 24 h. Data show mean ± SEM (n=3, technical 
replicates, confirmed in independent biological replicates). (D) Myc RNA levels in same cells as 
(C). Data are normalized to untreated within each cell line and show mean ± SEM (n=2, biological 
replicates). (E) Pvt1b RNA levels in PR MEFs infected with indicated guide RNAs, untreated or 
treated with tamoxifen (TAM) for 48 h and doxorubicin (DOXO) for 24 h. Data show mean ± SEM 
(n=3, technical replicates, confirmed in independent biological replicates). (F) Myc RNA levels in 
the same cells as (E). Data are normalized to untreated within each cell line and show mean ± SEM 






Investigating the function of spliced Pvt1b in p53-dependent Myc 
repression 
 To determine if the spliced Pvt1b transcript is required for p53-dependent 
Myc repression, I developed a genetic approach to abrogate splicing between Pvt1 
exon 1b and its downstream exon 2 and thereby decrease processing of nascent 
Pvt1b transcripts. I designed a guide RNA (gdeltaSS) to target Cas9 close to the 3’ 
end of Pvt1 exon 1b (Figure 24A) with the goal of mutagenizing the AG|GU 
sequence spanning the exon|intron junction, which comprises a key sequence 
element of the splice donor site (Mount, 1982). I generated KPR population and 
PR MEF population cell lines (refer to Chapter 2, Figure 8 for descriptions of KPR 
and PR MEF cell lines) containing numerous mutations at the 3’ end of Pvt1 exon 
1b. As above, a guide RNA targeting dTomato (gTOM) was used as a negative 
control, while the guide RNA targeting the Pvt1b-associated p53RE (gRE, see 
Chapter 2, Figure 16) was used as a positive control due to its previously 
documented ability to rescue stress-induced Myc downregulation. I confirmed 
mutagenesis of the exon|intron junction by Sanger sequencing and Tracking of 
Indels by DEcomposition (TIDE) analysis (Brinkman et al., 2014) in KPR cells and 
PR MEFs, observing 92.8% and 90.5% estimated efficiencies, respectively (Figure 
24B and Figure 24C). However, I observed low frequencies of deletions larger than 
5 nucleotides (Figure 24B and Figure 24C), and given the location of the Cas9 cut 
site 4-5 nucleotides away from the exon|intron junction, it is possible that a low 
percentage of mutations directly affected the AG|GU splice site. 
 To determine the efficacy of this approach in inhibiting the production of 
spliced Pvt1b, I analyzed the expression of Pvt1 transcripts in gdeltaSS-infected 
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population cell lines. While exon 1b 3’ end mutagenesis did not affect Pvt1a 
expression, it resulted in a significant 34% decrease in spliced Pvt1b in tamoxifen-
treated KPR cells relative to control (Figure 24D) and a similar, albeit 
nonsignificant, decrease in spliced Pvt1b in PR MEFs treated with tamoxifen and 
doxorubicin (Figure 24F). Importantly, infection with gRE inhibited Pvt1b 
expression in both KPR cells (Figure 24D) and PR MEFs (Figure 24F), consistent 
with previous results (see Chapter 2, Figure 16). To determine if the observed 
reduction in spliced Pvt1b was due to abrogated splicing and not simply decreased 
expression, I analyzed nascent Pvt1b RNA levels using a qRT-PCR primer set 
spanning the Pvt1 exon 1b|intron junction. Concurrent with a decrease in spliced 
Pvt1b, gdeltaSS-infected KPR and PR MEF cells exhibited increases in nascent 
Pvt1b compared to controls, suggesting a defect in pre-mRNA processing (Figures 
24D and 24F). Collectively, these data suggested partial inhibition of the splicing 
event linking Pvt1 exon 1b and exon 2. 
 To assess whether the processing of nascent Pvt1b into spliced Pvt1b, and 
the resulting Pvt1 ex 1b – exon 2 sequence is required for stress-dependent Myc 
repression, I analyzed Myc RNA levels in response to oncogenic or genotoxic 
stress. In negative control KPR population and PR MEF population cell lines 
infected with gTOM, exposure to oncogenic or genotoxic stress led to an expected 
decrease in Myc RNA (Figures 24E and 24G). Importantly, positive control KPR 
population and PR MEF population cell lines infected with gRE experienced a 
rescue in stress-dependent Myc downregulation (Figures 24E and 24G), consistent 
with previous findings (see Chapter 2, Figure 16). However, mutagenesis of the 
3’ end of exon 1b did not increase Myc levels following cellular stress to the extent 
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observed in gRE-infected cells (Figures 24E and 24G). Given that Pvt1b-associated 
p53RE mutagenesis resulted in near total loss of Pvt1b expression and yielded a  
~30% rescue of Myc levels, I would expect to observe a fraction of that rescue in 
Myc expression with a loss of spliced Pvt1b reaching only as high as 34% in 
gdeltaSS cells (Figures 24D and 24F). As such, these data and the importance of 
spliced Pvt1b in p53-dependent Myc repression are largely inconclusive, but could 















Figure 24. Probing the role of spliced Pvt1b in p53-dependent Myc repression. (A) 
Schematic of the 5’ end of the Pvt1b transcript, indicating splicing between exon 1b and exon 2 and 
its disruption due to CRISPR-induced mutagenesis of the splice site at the 3’ end of exon 1b. Region 
targeted by guide RNA (gdeltaSS) shown in red. (B, C) Mutagenesis efficiency of gdeltaSS 
estimated by Tracking of Indels by DEcomposition (TIDE) analysis in KPR cells (B) and PR MEFs 
(C) as described in (Brinkman et al., 2014). (D) Pvt1a, spliced Pvt1b, and nascent Pvt1b RNA levels 
in KPR cells infected with indicated guide RNAs, untreated or treated with tamoxifen (TAM) for 24 
h. Data show mean ± SEM (n=3, biological replicates); ns = not significant; **p < 0.01, ***p < 0.001 
and ****p < 0.0001, unpaired t test. (E) Myc RNA levels from cells in (D). Data show mean ± SEM 
(n=3, biological replicates); ns = not significant; ***p < 0.001, unpaired t test. (F) Pvt1a, spliced 
Pvt1b, and nascent Pvt1b RNA levels in PR MEFs infected with indicated guide RNAs, untreated or 
treated with tamoxifen (TAM) for 48 h and doxorubicin (DOXO) for 24 h. Data show mean ± SEM 
(n=3, biological replicates); ns = not significant; **p < 0.01, unpaired t test. (G) Myc RNA levels 












 The research presented in this chapter attempts to address whether Pvt1b 
sequence and/or structural specificity is necessary for its stress-dependent 
function in repressing Myc expression. Neither mutagenesis of sequences 
throughout Pvt1 exon 1b, nor abrogation of Pvt1b splicing was sufficient to rescue 
p53-induced Myc downregulation to the extent observed following Pvt1b 
inhibition via mutagenesis of the p53 binding site required for its expression. 
While the experiments outlined in this chapter were ultimately unsuccessful in 
identifying discrete elements of the Pvt1b transcript required for its function, these 
data do not conclusively disprove the existence of such sequence and/or structural 
motifs.  
 The analysis of cell populations with mutation heterogeneity, while useful 
in rapidly assessing the broad importance of numerous sequence elements at once, 
may not be sensitive enough to pinpoint essential sequences. There are several 
possible outcomes of such cell population-based mutagenesis experiments that 
may muddle our interpretation: (1) mutagenesis efficiency is not high enough or, 
depending on the types of indels produced by a particular guide RNA, yields 
mutations that preserve rather than disrupt critical motifs, (2) the guide RNAs 
chosen do not target close enough to key sequences to effectively alter them, and 
(3) any useful mutations that might inhibit RNA function in isolation are easily 
obscured by other, less impactful, mutations. In short, it is possible that these 
approaches are not precise enough to yield interpretable results. For example, the 
decrease in spliced Pvt1b observed in gdeltaSS KPR and PR cell lines is 
significantly less than the decrease in Pvt1b levels following p53RE mutagenesis 
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and may not have been sufficient to rescue Myc levels. Therefore, it is possible a 
more robust abrogation of splicing would nullify Myc repression and recapitulate 
the results observed with Pvt1b transcriptional inhibition. One method for 
overcoming some of these pitfalls involves the isolation of clonal cell lines and 
comprehensive analysis of individual mutations. This approach can be fruitful but 
may result in clone-specific behaviors unrelated to the mutation in question. 
 Choosing the appropriate cell model in which to perform such cell 
population-based mutagenesis experiments poses an additional challenge. KPR 
cells, while a robust model for p53-dependent Myc repression under conditions of 
oncogenic stress, harbor multiple copies of the Myc-Pvt1 locus in the form of 
extrachromosomal DNA circles (see Chapter 2, Figure 13). This leads to a 
landscape of numerous distinct Cas9-induced Pvt1 mutations existing in a single 
cell, the effects of which on the expression of individual Myc alleles may vary and 
produce an average that does not reflect complex heterogeneity between loci. 
However, my experiments in PR MEFs, which do not exhibit the same extensive 
Myc-Pvt1 amplifications, support and provide an independent confirmation of our 
data in KPR cells. In summary, while this set of genetic queries did not successfully 
discover a sequence-based and/or structural mechanism for Pvt1b function, they 
do not preclude the existence of such a mechanism and alternative approaches are 





Investigating the mechanism of Pvt1b-mediated Myc repression 
 
Introduction 
 Previous studies have investigated the role of histone deacetylases (HDACs) 
in p53-dependent Myc repression (Harms and Chen, 2007; Ho et al., 2005). 
Notably, Ho et al. observed decreased histone H4 acetylation marks at the Myc 
promoter following p53 activation and further posited a mechanism for p53-
induced Myc downregulation involving mSin3a, a corepressor that associates with 
HDAC1 (Ho et al., 2005). However, the function of HDACs in regulating Myc 
expression is unclear, with different studies investigating the effect of HDAC 
inhibitors on Myc levels reporting conflicting results (Majumdar et al., 2012; 
Sasakawa et al., 2003; Xu et al., 2005; Yu et al., 2020). 
 The function of lncRNAs in gene regulation via epigenetic modification is 
well-documented (reviewed in (Statello et al., 2020)). A significant example of an 
HDAC-dependent mechanism of lncRNA-mediated gene regulation is the function 
of XIST in cis-repression of the X-chromosome via SHARP/HDAC3 (McHugh et 
al., 2015). One of a family of transcriptional repressors, SHARP (also known as 
Spen) interacts with SMRT (Ariyoshi and Schwabe, 2003), a component of the 
nuclear corepressor complex with a known role in HDAC3-mediated chromatin 
deacetylation (You et al., 2013). A direct interaction between XIST and SHARP is 
required to recruit SMRT and HDAC3, enabling transcriptional silencing of the X-
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chromosome via histone deacetylation and RNA Pol II exclusion (Chu et al., 2015; 
McHugh et al., 2015; Moindrot et al., 2015; Monfort et al., 2015). Recent evidence 
from the Guttman (unpublished) and Chang (Carter et al., 2020) labs notes an 
association between SHARP/Spen and exon 2 of human and mouse Pvt1. In 
preliminary RAP-MS experiments performed by Giuseppe Militello in our lab, we 
also detected evidence for SHARP/Spen binding the Pvt1 RNA in KPR cells (data 
not shown). This may suggest a mechanism of cis-repression by Pvt1b similar to 
that employed by XIST during X-chromosome inactivation (XCI), involving 
histone deacetylation via HDAC3 recruited by SHARP/Spen (McHugh et al., 2015). 
In this chapter, I present preliminary evidence supporting a role for Pvt1b in stress-
dependent Myc repression via histone deacetylation at the Myc promoter. 
 
Results 
Histone deacetylation may be required for stress-dependent Myc 
repression 
 To confirm previous findings (Ho et al., 2005) and determine whether 
histone acetylation marks at the Myc promoter change in response to cellular 
stress, I performed H3K27ac ChIP in KPR cells following treatment with or without 
tamoxifen. Concurrent with a decrease in Myc expression, I observed 
commensurate decreases in H3K27ac marks upstream of the Myc transcriptional 
start site following exposure to oncogenic stress (Figure 25A). To gain insight into 
whether Pvt1b is required for histone deacetylation at the Myc promoter following 
p53 activation, I performed H3K27ac ChIP in KPR cells infected with gRE to 
mutagenize the Pvt1b-associated p53RE and inhibit Pvt1b expression (see 
 111 
Chapter 2). In contrast to the results observed in wildtype cells (Figure 25A), 
H3K27ac marks did not decrease in response to oncogenic stress in cells in which 
Pvt1b expression was inhibited (Figure 25B). These results, while preliminary and 









Figure 25. Histone deacetylation may be required for stress-dependent Myc 
repression. (A) Left, Myc RNA levels in KPR cells, untreated or treated with tamoxifen (TAM) 
for 24 h. Right, ChIP-qPCR analysis of H3K27ac enrichment at the Myc promoter in the same cells. 
Data show mean ± SEM (n=3, technical replicates of one biological replicate); ns = not significant; 
*p < 0.05, paired t test. (B) ChIP-qPCR analysis of H3K27ac enrichment at the Myc promoter in 
KPR cells infected with a guide RNA targeting the Pvt1b-associated p53RE (gRE), untreated or 
treated with tamoxifen (TAM) for 24 h. Data show mean ± SEM (n=3, technical replicates of one 
biological replicate); ns = not significant; paired t test.  (C,D) qRT-PCR of the ratio (+stress/-
stress) of Pvt1b and Myc expression levels in KPR cells (C) and PR MEFs (D) treated with or without 
the HDAC3 inhibitor RGFP966 for 6 h (C) or 4 h (D). KPR cells were treated with 24 h tamoxifen 
(C) and PR MEFs were treated with 48 h tamoxifen and 24 h doxorubicin (D) to induce cellular 
stress. Data in (C) show mean ± SEM (n=3, technical replicates of one biological replicate); *p < 
0.05, paired t test. Data in (D) show mean ± SEM (n=3, biological replicates); ns = not significant; 
paired t test. NT = no treatment. (E,F) qRT-PCR of the ratio (+stress/-stress) of Pvt1b and Myc 
expression levels in KPR cells (E) and PR MEFs (F) treated with or without the pan-HDAC 
inhibitors TSA or SAHA for 4 h. Treatment with cellular stress and fold induction of Pvt1b 
performed as in (C,D). Data show mean ± SEM (n=3, biological replicates); ns = not significant; *p 
< 0.05, paired t test. NT = no treatment.  Data collection and analysis performed by Giuseppe 
Militello. 
 
Contributions from G. Militello in (E) and (F) are described above. 
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Histone deacetylase inhibition rescues stress-dependent Myc 
repression 
 To query whether HDACs play a role in p53-dependent Myc repression 
more directly, I sought to determine whether the inhibition of one or more HDACs 
could rescue stress-induced Myc downregulation. Given the importance of HDAC3 
in XIST-mediated XCI, we treated KPR cells and PR MEFs with the HDAC3 
inhibitor RGFP966 in the presence and absence of stress. HDACs, including 
HDAC3, have a well-documented role in repressing the p53 pathway (Ito et al., 
2002; Monte et al., 2006; Narita et al., 2010), and treatment with RGFP966 caused 
a minor decrease in Pvt1b compared to untreated controls (Figures 25C and 25D). 
While Myc levels decreased in response to both oncogenic and genotoxic stress in 
control samples, we observed a partial, albeit nonsignificant, rescue of Myc levels 
with HDAC3 inhibition (Figures 25C and 25D). These results indicated that 
HDAC3 may play a role in p53-induced Myc repression, but do not completely 
explain the observed decreases in Myc expression. 
 To determine whether additional HDACs might be important for Myc 
downregulation under conditions of cellular stress, Giuseppe Militello performed 
experiments utilizing pan-HDAC inhibitors trichostatin A (TSA) and 
suberoylanilide hydroxamic acid (SAHA), which inhibit class I and class II HDACs, 
including HDAC3 (Xu et al., 2007). While SAHA did not have significant effects on 
Pvt1b expression relative to controls, TSA treatment caused robust downregulation 
of Pvt1b, perhaps indicating systemic effects on the p53 network (Figures 25E and 
25F). While Myc RNA levels displayed an expected decrease in the presence of 
stress, he observed a significant increase in Myc RNA in KPR cells treated with 
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either TSA or SAHA, amounting to a near-full rescue of Myc expression (Figure 
25E). Similarly, he observed robust, albeit nonsignificant, increases in Myc 
expression in stressed PR MEFs following treatment with pan-HDAC inhibitors 
(Figure 25F). Taken together, these data point to an HDAC-dependent mechanism 
for Pvt1b-mediated Myc repression. 
 
Discussion 
 The results presented in this chapter comprise a broad investigation of the 
hypothesis that Pvt1b represses Myc transcription by facilitating histone 
deacetylation at the Myc promoter in response to cellular stress. These preliminary 
data thus far point to a mechanism of p53-dependent Myc repression via histone 
deacetylation, which may require Pvt1b expression. That H3K27ac marks did not 
decrease at the Myc promoter in cells in which Pvt1b expression was inhibited, in 
contrast to wildtype cells, suggests the specific importance of Pvt1b in histone 
deacetylation. Significantly, preliminary findings from an epistasis experiment 
involving HDAC inhibition in cells lacking Pvt1b implicate HDACs as functioning 
in the same pathway as Pvt1b (data not shown), providing further support for 
Pvt1b modulating Myc expression via HDACs. However, additional mechanistic 
studies are needed to establish the link between Pvt1b, HDACs, and Myc 
repression more definitively. While HDAC3 inhibition prompted a partial rescue 
of Myc downregulation under conditions of oncogenic or genotoxic stress, the 
more prominent Myc rescue observed following pan-HDAC inhibition suggests the 
potential involvement of additional HDACs. In the future, it will be necessary to 
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determine which class I/II HDACs inhibited by TSA and SAHA are responsible for 
the stress-dependent decrease in Myc expression.  
 While my results certainly point to a role for histone deacetylation in stress-
specific Myc regulation, any potential involvement of SHARP/Spen in keeping 
with the mechanism of XIST-mediated XCI still needs to be investigated (Chu et 
al., 2015; McHugh et al., 2015; Moindrot et al., 2015; Monfort et al., 2015). I have 
designed a strategy for generating a CRISPR-mediated Spen knockout model, 
which will be useful for assessing any requirement for SHARP/Spen in p53-
dependent Myc regulation. Thoroughly validating any putative interaction 
between Pvt1b and Spen (Carter et al., 2020) via RNA immunoprecipitation (RIP) 
or crosslinking and immunoprecipitation (CLIP) studies will also be important for 
elucidating the mechanism of Pvt1b-mediated Myc repression. LncRNAs often 
engage epigenetic regulators to elicit repression (reviewed in (Statello et al., 
2020)), and the data presented here currently support this paradigm. Future work 
in our lab will focus on both further defining the functional elements of the Pvt1b 








Generation of Pvt1 genetically engineered mouse models 
 
Introduction 
 Historically, the study of lncRNAs in cancer has benefitted from the use of 
GEMMs to probe lncRNA function in vivo (see Chapter 1). Perturbation of 
lncRNA function via genetic or epigenetic modifications to the endogenous locus 
can help overcome many issues with the study of lncRNAs in in vitro model 
systems (see Chapter 1) and can solidify our understanding of lncRNA function 
at the organismal level. Considering the power of in vivo models in resolving 
lncRNA function(s), I sought to deploy a suite of molecular tools that would enable 
elucidation of the function(s) of Pvt1 isoforms under both physiologic and 
tumorigenic conditions. 
 First, I took advantage of a well-characterized synthetic polyadenylation 
signal (PAS) to elicit premature transcription termination (Levitt et al., 1989), a 
robust genetic tool that has been used previously to clarify mechanisms of local 
gene regulation enacted by lncRNAs (Engreitz et al., 2016). The short 49 bp 
sequence, when transcribed as part of the Pvt1 locus, should cause efficient 3’ 
cleavage and polyadenylation of nascent Pvt1 transcripts (Figure 26A) (Levitt et 
al., 1989). In addition to stimulating 3’ end-processing machinery via transcription 
of a A(A/U)UAAA hexamer followed by a GU-rich tract 30 bp downstream 
(Millevoi and Vagner, 2010), PAS insertion may also suppress Pvt1 transcription 
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initiation due to the tight connection between the splicing and transcriptional 
processes (Engreitz et al., 2016). 
I chose to insert the synthetic PAS within Pvt1 exon 1b, just downstream of 
the Pvt1b transcription start site (TSS), in order to abrogate production of the full 
length Pvt1b transcript (Pvt1b-PAS, Figures 26A and 26C). Due to the efficiency 
with which polyadenylation occurs and the location of Pvt1 exon 1b downstream 
from exon 1a, I expected that a PAS insertion within exon 1b would also abrogate 
the production of nascent Pvt1a transcripts, effectively acting as a LOF model for 
both Pvt1a and Pvt1b. Therefore, to distinguish between any potentially divergent 
functions ascribed to Pvt1a and Pvt1b isoforms, I designed a separate LOF model 
specific to Pvt1a (Pvt1a-PAS) by inserting a PAS into Pvt1 exon 1a, just 
downstream of the Pvt1a TSS (Figures 26A and 26C). This model should result in 
specific abrogation of Pvt1a transcription, without negatively affecting Pvt1b, thus 
providing both a control for any experiments using the Pvt1b-PAS model and an 
important tool for elucidating Pvt1a function independent of Pvt1b. 
 To complement the Pvt1a-PAS and Pvt1b-PAS GEMMs, I designed an 
additional Pvt1 GEMM using a novel ribozyme-based tool developed in our lab to 
elicit co-transcriptional cleavage and subsequent transcript degradation (Winkler 
et al., in preparation). This strategy relies on the 74 bp-length self-cleaving 
ribozyme Twister, initially identified and characterized by the Breaker lab at Yale 
(Figure 26B) (Roth et al., 2014). In in vitro studies, Twister undergoes efficient 
self-cleavage under simulated physiologic conditions, approaching rates as high as 
~1000 min-1  (Roth et al., 2014). Twister’s small size and ability to rapidly self-
cleave via site-specific phosphodiester scission (Jimenez et al., 2015) make it an 
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ideal candidate for a lncRNA LOF tool. Previous studies have demonstrated 
success using ribozymes to inhibit ncRNA accumulation in yeast and mouse cells 
(Camblong et al., 2009; Tuck and Buhler, 2021; Tuck et al., 2018) and unpublished 
results from our lab indicate that Twister robustly destabilizes transcript 
aggregation in vivo when inserted into the LincRNA-p21 locus (Winkler et al., in 
preparation). 
I chose to insert the Twister sequence into Pvt1 exon 1b in order to abrogate 
accumulation of both Pvt1a and Pvt1b transcripts, similar to the Pvt1b-PAS model 
(Pvt1b-TWI, Figure 26C). Inserting Twister into the same location as the PAS in 
the Pvt1b-PAS model enables direct comparison between the effects of premature 
polyadenylation and Twister-mediated transcript cleavage on neighboring Myc 
expression. While PAS-mediated transcript cleavage and polyadenylation leaves a 
downstream nascent cleavage product with a terminal 5’ phosphate group, a ready 
substrate for degradation by the 5’ end surveillance factor XRN2 (West et al., 
2004), the downstream fragment resulting from Twister self-cleavage instead 
possesses a 5’ hydroxyl group (Roth et al., 2014), which is unlikely to engage 
XRN2-mediated transcriptional termination (Doamekpor et al., 2020; Jinek et al., 
2011; Mathy et al., 2007; West et al., 2004). Indeed, unpublished results from our 
lab suggest that Twister-mediated RNA cleavage enables some level of 
transcription to proceed through the locus (Winkler et al., in preparation), in 
contrast to the rapid drop-off in transcription resulting from PAS insertion, usually 
within 2 Kb (Core et al., 2008). Considering that local gene regulation by lncRNAs 
may depend on the RNA transcript or the process of transcription through the 
locus alone (Engreitz et al., 2016), the Pvt1b-TWI model will provide further 
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insight into the elements of the Pvt1 transcript required for its function(s). 
Whether the Pvt1b-PAS and Pvt1b-TWI models successfully abrogate both Pvt1a 
and Pvt1b levels will need to be empirically determined, as the increased distance 
between either the polyadenylation sequence or the Twister ribozyme and the 
Pvt1a TSS may result in reduced efficiency of these LOF tools (Engreitz et al., 2016; 
Tuck and Buhler, 2021; Tuck et al., 2018). 
 In this chapter, I describe the successful generation of the Pvt1a-PAS, 
Pvt1b-PAS and Pvt1b-TWI alleles in the mouse and provide evidence for their 
germline transmission. These GEMMs set the stage for further extensive 
characterization of the contributions of Pvt1a and Pvt1b isoforms to organismal 










Figure 26. Schematic of Pvt1 GEMMs. (A) Illustration of premature RNA cleavage and 
polyadenylation induced by insertion of a 49 bp synthetic polyadenylation signal (PAS) into an 
endogenous gene. Inhibitory line indicates transcriptional suppression. (B) Illustration of co-
transcriptional RNA degradation induced by insertion of the 74 bp self-cleaving Twister ribozyme 
(TWI) into an endogenous gene. Inhibitory line indicates transcriptional suppression. The 
structure of the Twister ribozyme is shown (adapted from Roth et al. 2014). (C) Top, schematic of 
the Myc-Pvt1 locus. Bottom, schematics of the Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI alleles, as 
present in their associated genetically engineered mouse models (GEMMs). 
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Results 
Design and generation of in vivo Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI 
alleles 
 Pvt1a-PAS, Pvt1b-PAS and Pvt1-TWI mice were generated in collaboration 
with Adam Williams and Rick Maser at the Jackson Laboratory for Genomic 
Medicine (JAX). We chose candidate guide RNAs based on predicted specificity 
scores (Concordet and Haeussler, 2018) and the criteria that Cas9 cleavage and 
subsequent insertion of either PAS or TWI occur <100 bp from Pvt1a and Pvt1b 
TSSs to increase the likelihood of efficient premature transcript termination or co-
transcriptional transcript degradation, respectively. The final two guide RNAs, one 
targeting Pvt1 exon 1a (gEx1a) and one targeting Pvt1 exon 1b (gEx1b), were 
selected based on cleavage efficiency estimates from in vitro analyses performed 
at JAX (Figure 27A; data not shown). Homology directed repair (HDR) templates 
were subsequently designed with either the 49 bp PAS or the 74 bp TWI sequence 
inserted at the expected Cas9 cleavage site with appropriate length homology arms 
on either side of the altered DNA. Single-stranded oligo donors (ssODNs) were 
constructed complementary to the non-target strand to increase repair efficiency 
(Richardson et al., 2016). 
Briefly, mouse embryos were electroporated with guide RNA:Cas9 
ribonucleoprotein (RNP) complexes and the appropriate homology directed repair 
(HDR) templates to generate Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI alleles. These 
embryos were surgically implanted into pseudo-pregnant mice and we received the 
resulting litters from JAX including at least five potential founder mice for each 
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allele with successful knock-ins based on initial genotyping performed by JAX 

























Figure 27. Pvt1-PAS, Pvt1b-PAS, and Pvt1b-TWI genotyping. (A) Schematic of the mouse 
Pvt1 locus highlighting in vivo CRISPR/Cas9 editing strategy, including guide RNAs used to edit 
Pvt1 exon 1a (gEx1a) and exon 1b (gEx1B), respectively. Red lines indicate location of genotyping 
primers. (B-D) Gel images of genotyping results from potential (B) Pvt1a-PAS, (C) Pvt1b-PAS, and 
(D) Pvt1b-TWI founder mice. Allele combinations of each mouse indicated. PAS = Polyadenylation 
sequence; TWI = Twister ribozyme; KI = Knock-in; WT = Wildtype. Genotyping performed by 
Nadya Dimitrova. (E) Gel images of genotyping results from F1 mice, generated by backcrossing 
Pvt1 mutant (mut) founder mice to wildtype (wt) mice to produce heterozygotes. Genotyping 
results from F1 heterozygous mice with germline transmission of Pvt1a-PAS, Pvt1b-PAS, and 
Pvt1b-TWI alleles are shown. PAS = Polyadenylation sequence; TWI = Twister ribozyme; WT = 
Wildtype. Matings and genotyping performed by Nadya Dimitrova. 
 









Germline transmission of Pvt1a-PAS, Pvt1b-PAS, and Pvt1b-TWI 
alleles 
 As founder mice are subject to mosaicism, it is necessary to deconvolve the 
altered Pvt1 alleles and establish germline transmission of successful knock-ins. 
First, the presence of Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI alleles in potential 
founder mice was confirmed by genotyping of DNA extracted from mouse tail 
clippings (Figures 27A-D). In multiple independent founders, increases in band 
size compared to wildtype mice were observed, indicating varying degrees of 
successful PAS and TWI knock-ins (Figures 27B-D). All five potential Pvt1a-PAS 
founders appeared homozygous for PAS knock-in, six potential Pvt1b-PAS 
founders appeared heterozygous for PAS knock-in, and analysis of potential Pvt1b-
TWI founders revealed one homozygous and four heterozygous for TWI knock-in 
(Figures 27B-D). 
 To establish germline transmission, founder mice were crossed to wildtype 
C57BL/6J mice. Heterozygous mice constitute generation F1 (filial 1) and are 
poised to be utilized in future experiments, as they, unlike the founder mice, do not 
suffer from the challenges associated with mosaicism. Crossing two F1 
heterozygous mice together will produce a litter of wildtype mice and mice 
heterozygous or homozygous for the altered allele, enabling further analyses. 
Therefore, the establishment of germline transmission for all Pvt1a-PAS, Pvt1b-
PAS, and Pvt1b-TWI alleles and production of F1 mice heterozygous for these 





In summary, this chapter describes the design and generation of the Pvt1a-
PAS, Pvt1b-PAS and Pvt1b-TWI mouse models, the combination of which will 
allow us to better understand and define the functional elements of the Pvt1 locus 
and its associated isoforms. Future experiments will focus on characterizing the 
effects of these mutant alleles on both Pvt1 transcription and transcript stability, 
and on neighboring Myc expression. Careful analysis of the efficacy of the PAS and 
TWI alleles in vivo and how they influence local regulation of Myc will allow us to 
more precisely describe how Pvt1b represses Myc transcription, and whether this 
requires Pvt1b RNA production alone, or additionally requires the Pvt1b RNA 
transcript itself. In addition, the inclusion of a Pvt1a-specific mouse model, will 
provide insight into the potentially divergent functions of the Pvt1a and Pvt1b 
isoforms and whether pro- and anti-tumorigenic functions coexist in the same 
locus. 
Importantly, the insertion of either the synthetic polyadenylation signal or 
the Twister ribozyme constitutes the addition of a short (<100 bp) sequence into 
the endogenous Pvt1 locus without requiring the deletion of any DNA elements. 
Previous work has demonstrated the role of DNA elements encoded in the Pvt1 
locus in positively and negatively regulating Myc expression (Cho et al., 2018; 
Fulco et al., 2016), suggesting the importance of minimal disruption to the 
endogenous sequence in Pvt1 GEMM design considerations. Deletion of over 300 
Kb of the Pvt1 locus in vivo resulted in reduced stability of the Myc protein (Tseng 
et al., 2014), but raised questions about the relative functional contributions of the 
Pvt1 RNA itself compared to DNA elements. In comparison, the mouse models 
 126 
described above do not delete, and should largely avoid the disruption of, DNA 
elements, providing an opportunity to assess the role of the Pvt1 RNA and its 
production more directly. 
In addition to helping elucidate molecular mechanism, these three GEMMs 
will improve our understanding of the importance of Pvt1 at the organismal level. 
For example, analysis of developmental timepoints and aging studies will shed 
light on any physiologic effects observed as a result of Pvt1 loss, and may suggest 
new roles in organism growth and homeostasis. While Pvt1 loss alone may not be 
sufficient to predispose animals to spontaneous tumor development, crossing the 
Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI models with established cancer models will 
enable investigation of the importance of Pvt1 in promoting or suppressing various 
cancer types. There is much that we still do not understand about the role of Pvt1b 
as a tumor suppressor, For example, previous work has demonstrated that Pvt1b 
loss increases oncogenic K-ras-driven tumor growth (see Chapter 2, Figure 19). 
However, it is unknown whether Pvt1b loss in combination with loss of another 
tumor suppressor gene may constitute a second “hit” in the “two-hit hypothesis” 
framework of cancer development (Knudson, 2001) and be sufficient to drive 
tumorigenesis. Taken together, these novel GEMMs provide an unprecedented 
opportunity to further our knowledge of Pvt1’s roles in development and disease 




Chapter 6: Summary and Perspectives 
 
Here I have identified and characterized Pvt1b, revealing a bona fide tumor 
suppressor function embedded in the Pvt1 locus and mediated by a stress-specific 
lncRNA isoform. This work substantially contributes to both the fields of cancer 
biology and lncRNA biology by (1) improving our understanding of the regulatory 
feedback between the p53 tumor suppressor and Myc proto-oncogenic networks 
and its physiological impacts on cancer initiation and development, and (2) 
uncovering a novel lncRNA isoform-switching mechanism that enables swift locus-
specific reverse regulation downstream of a transcriptional activator. In employing 
diverse LOF and GOF tools in powerful in vitro and in vivo model systems, I 
provided critical insight into how, and the extent to which, Pvt1b contributes to 
tumor suppression and growth inhibition downstream of p53 activation. 
I found that Pvt1b is rapidly induced by genotoxic and oncogenic stress in a 
p53-dependent manner. The production of the Pvt1b RNA, 50 Kb downstream of 
the Myc locus, is necessary and sufficient to repress Myc transcription in cis, with 
negative functional consequences on Myc transcriptional activity and cellular 
proliferation. Importantly, using a genetic LOF model specific to p53 function, I 
demonstrated that Pvt1b inhibition increases Myc expression, cellular 
proliferation, and tumorigenesis under conditions of cellular stress. These 
observations complicate the long-standing classification of Pvt1 as an oncogenic 
lncRNA, which stems from decades of evidence linking its elevated expression to 
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the increased proliferative and invasive capacities of cancer cells (Cui et al., 2016) 
as well as increased tumor aggressiveness and poor patient survival (Zhu et al., 
2017). In stark contrast to this body of literature, I have unearthed a novel tumor 
suppressor function for this lncRNA gene, previously hidden in the vast expanse of 
the complex pro-oncogenic Pvt1 locus. My work does not contradict the wealth of 
evidence implicating Pvt1 as an oncogenic lncRNA, which dates back to its 
discovery nearly 40 years ago (Cory et al., 1985; Graham et al., 1985). Instead, we 
can now propose a more nuanced and holistic model for Pvt1 function that 
incorporates both tumor suppressive and oncogenic activities as mediated by 
different elements of the Pvt1 locus and its associated RNAs. 
The study of cancer-associated genetic and epigenetic alterations and their 
frequencies has implicated both coding and noncoding genes as potential drivers 
of tumorigenesis (see Chapter 1). As such, the identification of recurrent genetic 
rearrangements involving the lncRNA Pvt1 locus provided strong impetus for the 
study of Pvt1 in the context of cancer (Cory et al., 1985; Graham and Adams, 1986; 
Graham et al., 1985; Shtivelman et al., 1989). In keeping with co-amplifications of 
the Myc-Pvt1 locus observed in tumors (Riquelme et al., 2014), co-gain of Myc and 
Pvt1 was found to advance cancer progression in a mouse model of breast cancer 
(Tseng et al., 2014). Importantly, gain of either Myc or Pvt1 alone had more limited 
effects on tumor growth, suggesting a pro-oncogenic synergy between these two 
loci, perhaps deriving from a role for the Pvt1 RNA in promoting Myc protein 
stability (Tseng et al., 2014). Several additional molecular mechanisms have been 
proposed to describe the tumor-promoting function of Pvt1, including its function 
as a miRNA sponge (Panda et al., 2017; Zhao et al., 2018), its role in epigenetically 
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repressing tumor suppressor genes via association with chromatin modifying 
complexes (Kong et al., 2015), and its ability to stabilize oncoproteins (Xu et al., 
2017). Distinct from these proposed oncogenic functions, my work and the work of 
others demonstrates a function for the Pvt1 locus in restricting Myc expression to 
limit tumorigenesis, either through DNA elements (Cho et al., 2018; Fulco et al., 
2016) or through stress-induced production of the Pvt1b RNA, as shown here. The 
discovery of both activating and repressive DNA elements in the Pvt1 locus that 
regulate Myc expression calls into question previous assumptions about Pvt1 
function (Fulco et al., 2016), suggesting a more nuanced picture of Pvt1 regulatory 
roles.  
The tumor suppressive function of Pvt1 may have operated under the radar 
of cancer biologists due to the frequent inactivation of the p53 network in tumor 
development. In such cases where Pvt1b is inhibited due to genetic alterations in 
the Pvt1 locus or the removal of upstream activating signals, the oncogenic 
activities of Pvt1 would be expected to predominate. This may explain the 
acquisition of extrachromosomal DNA (ecDNA) circles harboring Myc-Pvt1 co-
amplifications in p53-deficient KPR cells, as well as the recent observation of a 
Myc-Pvt1 ecDNA genomic rearrangement in a human colon cancer cell line, which 
fused exon 1 of Pvt1 to exons 2 and 3 of Myc, disrupting normal cis-regulatory 
circuits in the locus (Hung et al., 2020). Interestingly, genomic alterations in the 
region surrounding the Pvt1 p53RE are common. Several studies have documented 
translocations specifically involving the first exon of Pvt1 fused to a number of 3’ 
gene partners across a variety of malignancies (Iwakawa et al., 2013; Nagoshi et 
al., 2012; Northcott et al., 2012), and various somatic mutations encompassing the 
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Pvt1 promoter (Cho et al., 2018). In p53-proficient tumors, such genetic 
aberrations might be expected to either separate the Myc locus from Pvt1b, likely 
rendering Pvt1b incapable of repressing Myc in trans, or potentially destroy the 
p53RE required for Pvt1b expression, thus providing cells with a proliferative 
advantage. Future studies of Pvt1 in cancer should therefore consider whether 
observed Pvt1-associated tumor-promoting effects derive from the activation of its 
oncogenic features, the disruption of its tumor suppressive features, or some 
combination thereof. 
Pvt1 functional studies have largely been performed in cancer backgrounds. 
However, surprisingly little knowledge has been amassed concerning the function 
of Pvt1 under physiological conditions, with the biological relevance of some 
proposed regulatory activities of Pvt1 unclear due to their inherent cancer-
specificity (Cho et al., 2018). Here I have provided insight into this mystery by 
demonstrating that Pvt1b is a target of the p53 gene expression program, and is 
therefore linked to normal cellular homeostasis and the cellular response to stress. 
Researchers long puzzled over the molecular mechanism(s) underpinning the 
negative regulatory feedback observed between the p53 and Myc pathways, and 
whether p53 activation played a direct or indirect role in Myc repression. Several 
models to explain this phenomenon have been proposed, including histone de-
acetylation at the Myc promoter via direct p53 binding (Ho et al., 2005), p53 
induction of Myc-targeting miRNAs (Christoffersen et al., 2010; Sachdeva et al., 
2009), and p53 binding to a distal repressor element in the Pvt1 locus to reduce 
Myc levels (Porter et al., 2017). Pvt1 has been previously identified as a p53 target 
gene in several studies (Allen et al., 2014; Barsotti et al., 2012), but the role of Pvt1 
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within the p53 transcriptional program, if any, was virtually unexplored. 
Expanding on these findings, I provided evidence that induction of Pvt1b by p53 is 
the primary mediator of p53-dependent Myc repression using two distinct LOF 
systems. Therefore, Pvt1b joins a class of p53-regulated lncRNAs responsible for 
executing important growth-inhibitory functions within the p53-coordinated 
tumor suppressor response (Dimitrova et al., 2014; Hung et al., 2011; Schmitt et 
al., 2016). While p53 has been previously implicated in the indirect repression of 
cell cycle genes through the p53-DREAM (p53–p21–DREAM–E2F/CHR) pathway 
(reviewed in (Engeland, 2018)), to my knowledge Pvt1b is the first example of a 
p53-regulated lncRNA enacting local repression of a growth-promoting gene. 
Indeed, work from our lab has found that cis-acting lncRNA targets of p53 often 
engage in positive co-regulatory relationships with neighboring loci, while Pvt1b is 
currently the only known outlier in this trend (Tesfaye et al., In review). Taken 
together, I propose a model whereby p53 induces Pvt1b to dampen proliferative 
signaling during potential cancer-initiating events. As such, Pvt1b acts at the 
intersection between two pervasive transcription networks, providing a crucial 
avenue of communication that allows cells to prioritize tumor suppression over 
continued growth under conditions of stress. 
While I describe a stress-specific role for Pvt1b in restricting Myc 
expression, the molecular mechanism underlying this regulatory relationship is 
still a matter of open investigation. Both the localization of Pvt1b near its TSS and 
the negative effect of Pvt1b induction on neighboring Myc transcription clearly 
establish a cis-regulatory model for Pvt1b function. Moreover, the effects of ASO-
mediated depletion or endogenous activation of Pvt1b point to a role for the Pvt1b 
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RNA in Myc repression, as opposed to DNA elements in the locus. Importantly, 
p53 is not explicitly required for this effect, as upregulation of Pvt1b alone is 
sufficient to drive Myc downregulation. ASO-mediated depletion of Pvt1b reduced 
Myc levels, suggesting a role for the RNA molecule itself; however, we cannot 
formally exclude a role for the act of Pvt1b transcription in mediating Myc 
repression, especially in light of recent evidence that ASOs can cause premature 
transcription termination (Lee and Mendell, 2020). Indeed, my Pvt1 exon 1b-
targeting ASOs act near the Pvt1b TSS, rendering it impossible to distinguish 
between the effects mediated by the Pvt1b RNA or its production. However, my 
findings concerning the role of HDACs in Myc repression via p53-dependent 
deacetylation of the Myc promoter, and the potential requirement for Pvt1b in this 
process, while preliminary, strongly suggest a function for the lncRNA molecule. 
Modulation of epigenetic marks is a common mode by which lncRNAs regulate 
gene expression, especially in cis (see Chapter 1). Therefore, we may envision 
Pvt1b as acting in a similar manner to lncRNA Morrbid, regulating a neighboring 
gene via association with chromatin modifying complexes to influence critical cell 
survival decisions (Kotzin et al., 2016). Notably, the additional evidence that Pvt1b 
binds SHARP (Carter et al., 2020), a transcriptional repressor known to function 
in Xist-mediated histone deacetylation of the X-chromosome (McHugh et al., 
2015) and predicted to have Xist-like repressive activity via computational analysis 
(Kirk et al., 2018), may implicate Pvt1b as engaging in a similar mechanism of 
action to Xist. Future work will explore this possibility. 
Our inability to identify sequences in Pvt1 exon 1b required for p53-
dependent Myc repression does not preclude a role for the RNA molecule, or 
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indeed the existence of sequence-specific function. My attempts to mutate critical 
Pvt1b sequence and/or structural motifs may not have been efficient or pervasive 
enough to produce effects at the population level. On the other hand, the ~200 bp 
stretch of nucleotides unique to the Pvt1b isoform may be dispensable to its 
function. The existence of RNA sequence-independent lncRNA mechanisms has 
been insinuated by the nonspecific interactions between RNAs and PRC2 
(Davidovich et al., 2013). Indeed, some proteins can engage in dynamic and 
promiscuous RNA interactions in the absence of a true RNA-binding domain due 
to intrinsically disordered regions (IDRs) (Protter et al., 2018). The structural 
disorder of IDRs also favors liquid-liquid phase separation (LLPS), and IDR-
containing proteins have been shown to interact with lncRNAs in the formation of 
nuclear and cytoplasmic condensates (Garcia-Jove Navarro et al., 2019; Yamazaki 
et al., 2018). As such, Pvt1b may associate with IDR-containing proteins or other 
RBPs to repress Myc in a sequence-independent manner, although this possibility 
requires further investigation. 
Critically, Nadya Dimitrova and Clara Liao demonstrated a role for Pvt1b in 
restricting tumor growth at the organismal level using an autochthonous mouse 
model of lung cancer. In the KC mouse, tumorigenesis is driven by oncogenic K-
ras and is exquisitely sensitive to p53 loss. Tumor-specific Pvt1b ablation in this 
background had profound consequences, producing tumors that were larger than 
their Pvt1b-expressing counterparts and increasing tumor burden almost to the 
extent observed with p53 loss. Epistasis analysis and the absence of increases in 
tumor grade in Pvt1b-deficient tumors revealed a highly specific and powerful role 
for Pvt1b downstream of p53 activation in curtailing tumor growth. In this way, 
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Pvt1b acts as a critical barrier to the ability of cancer cells to proliferate unchecked, 
joining the ranks of a select number of cancer-associated lncRNAs with 
documented roles in tumorigenesis in vivo (Gupta et al., 2010; Gutschner et al., 
2013; Mello et al., 2017). While this LOF model does not allow for differentiation 
between the effects of DNA elements in the Pvt1 locus and the Pvt1b RNA, the 
Pvt1a-PAS, Pvt1b-PAS, and Pvt1b-TWI mouse models, generated in the course of 
this work, should distinguish the functional elements of Pvt1 transcripts with a 
higher degree of sensitivity. 
An exciting implication from this work is the significant influence cis-acting 
lncRNAs can exert over cellular activities via highly specific local gene regulation. 
Pvt1b represses one transcription factor downstream of another transcription 
factor, thus acting as a mediator between two gene expression networks to rapidly 
fine-tune cellular outputs in response to a specific cellular input. To my knowledge, 
Pvt1b is the first example of a lncRNA acting in this manner, although cis-
regulation of transcription factors by lncRNAs may be far more commonplace (Liu 
et al., 2018). The closest example I could find of a similar lncRNA mechanism is 
that of NANCI (Nkx2.1-Associated Noncoding Intergenic RNA). NANCI is induced 
downstream of Wnt (Wingless/Integrated) signaling, upon which it upregulates its 
neighbor NKX2.1 (NK2 Homeobox 1) to influence lung epithelial development 
through the activation of a plethora of NKX2.1 target genes (Herriges et al., 2014). 
Differing only in whether their cis-regulation is activating or repressive, NANCI 
and Pvt1b may represent the founding members of a burgeoning class of cis-acting 
lncRNAs that function at the intersection of transcription programs to influence 
gene expression on a broader scale. Considering the speed with which lncRNAs can 
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be produced relative to proteins, lncRNAs are uniquely poised to swiftly and 
dynamically respond to cellular stimuli. Cis-acting lncRNAs are even more well-
suited for this task because their site of transcription is the same as their site of 
action. In this way, Pvt1b as an expeditious regulatory lever is similar to p53 itself, 
which is constitutively produced and degraded, and therefore always primed for 
rapid activation. Global analyses have revealed many lncRNAs expressed in close 
spatial proximity to genes with roles in transcription regulation including 
transcription factors and chromatin modifiers (Guttman et al., 2009; Ponjavic et 
al., 2009). Such lncRNAs are co-expressed with their neighboring protein-coding 
gene(s) more frequently than expected by chance, suggesting functional regulatory 
relationships (Ponjavic et al., 2009). Taken together, cis-acting lncRNAs may play 
outsized roles in global gene regulation and are apt candidates for transmitting 
rapid feedback between cellular pathways. As such, future studies should pay 
particular attention to lncRNAs adjacent to genes with broad transcription 
regulatory capabilities. 
One compelling discovery from my work is the identification of an isoform-
specific function for Pvt1b. Traditionally, studies have viewed lncRNA loci as 
discrete functional units, with many lncRNA genetic LOF models based on deletion 
of either the entire lncRNA locus, or the promoter, resulting in complete loss of 
lncRNA expression (see Chapter 1). In recent years, our expanding 
understanding of the numerous and interconnected functional elements of lncRNA 
genes has prompted the development of more targeted genetic models that attempt 
to disrupt or enhance specific features of the lncRNA transcript while preserving 
as much of the endogenous locus as possible (see Chapter 1). Increased attention 
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to how lncRNAs produce a particular regulatory output, and whether these 
functions are transcript-dependent or transcript-independent has encouraged the 
use of innovative and thoughtful experimental tools and approaches. That 
transcript-dependent lncRNA mechanisms can involve varied RNA-DNA, RNA-
RNA, and RNA-protein interactions is now well-documented (reviewed in 
(Statello et al., 2020)). While it is understood that the abundance and availability 
of lncRNA interactors may change in different cellular contexts, little attention has 
been paid thus far to how alterations in the lncRNA transcript itself might 
influence function in response to cellular inputs. 
The alternative splicing and processing of lncRNAs presents numerous 
opportunities for the production of transcripts with diverse functions and 
mechanisms of action. The sequence and/or structural motifs in a lncRNA 
transcript often dictate function by specifying the molecular interactions in which 
a lncRNA can engage (reviewed in (Zampetaki et al., 2018)). Therefore, it stands 
to reason that the inclusion or exclusion of defined regions of a lncRNA transcript 
through alternative transcript initiation, processing, or termination events may 
expand, restrict, or otherwise transform a lncRNA’s regulatory repertoire. Multi-
exonic lncRNAs can be spliced in numerous combinations, potentially producing 
transcripts with different functions due to the combination of specific sequence 
motifs, or the generation of rare exon-exon junctions, which may influence the set 
of possible RBPs, or other factors, a lncRNA can bind. Our analysis of splice 
junctions in nascent Pvt1 RNAs revealed abundant transcripts produced from the 
Pvt1 locus, composed of various combinations of exons. Similar diversity in 
spliceoforms has been observed for other lncRNAs (Niemczyk et al., 2013). There 
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are few examples of lncRNA isoforms executing distinct regulatory functions, 
including a SNP-specific function for PCAT19 in prostate cancer (Hua et al., 2018) 
and a role for a long isoform of CCAT1, CCAT1-L, in transcriptional regulation of 
MYC (Xiang et al., 2014). However, Pvt1 is unique in that the tumor suppressor 
function of the stress-induced Pvt1b coexists alongside the varied, and potentially 
oncogenic, activities of the constitutively transcribed Pvt1a. Fortunately, advances 
in the depth and sensitivity of RNA-sequencing technologies may enable more 
robust identification of lncRNA isoforms moving forward, paving the way for an 
improved understanding of lncRNA isoform-dependent activities. 
Finally, this work has important implications for Myc-based therapeutic 
interventions in cancer. Myc-driven cancers can regress upon Myc inhibition 
(Soucek et al., 2002), suggesting its potency as a therapeutic target. However, drug 
development efforts have been challenged by the absence of a targetable binding 
pocket on the surface of Myc (Dang et al., 2017). LncRNA perturbation can provide 
alternative avenues for therapeutic intervention as a way of side-stepping so-called 
‘undruggable’ proteins. This therapeutic perturbation can be accomplished in 
several ways, with the most common and clinic-ready approaches including: 1) 
small interfering RNAs (siRNAs) and ASOs to achieve lncRNA degradation and 2) 
ASOs, often in the form of locked nucleic acids (LNAs), to cause steric disruption 
of lncRNA function by altering splicing, inhibiting specific lncRNA-binding 
partner interactions or causing a change in secondary structure formation (Arun 
et al., 2018). In principle, cis-acting lncRNAs make particularly attractive 
therapeutic targets; with such confined regulatory outputs, their perturbation may 
be less likely to trigger unwanted off-target effects. Theoretically, Pvt1b induction 
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in p53-deficient tumors may provide a way to limit Myc expression at its source. 
However, current clinic-ready technologies target RNAs for degradation and, in 
practice, Myc repression via Pvt1b would instead require its upregulation from the 
endogenous locus. Targeting lncRNA molecules to specific genomic locations in 
vitro has been made possible by CRISPR (Shechner et al., 2015). However, 
deployment of this technology in vivo is unlikely to happen for many years. 
Nonetheless, the prospect of modulating Myc expression in cancer, via Pvt1b or 




















Previous work has often treated Pvt1 as a simple genetic unit, not always 
leaving space for complex regulatory functions that may arise from its 300 Kb of 
genomic information. My distinction between the Pvt1a and Pvt1b isoforms 
provides an avenue to re-evaluate Pvt1 and, by extension, its relationship to Myc, 
in a new light. My findings do not necessarily conflict with the body of literature 
supporting a synergistic relationship between Myc and Pvt1. Rather, they raise the 
possibility that Pvt1a and Pvt1b may have distinct, and perhaps opposing, 
functions, with DNA elements in the Pvt1 locus and Pvt1a cooperating with Myc to 
promote its expression and activity, and Pvt1b acting as a stress-specific molecular 
brake for this process. This multiplicity of function may not be restricted to the 
Pvt1 locus, suggesting that the lncRNA class as a whole should be re-examined for 
alternative functions encoded in lncRNA loci. Our work further highlights the 
potential for cis-acting lncRNAs, when expressed in close proximity to 
transcription factors or other protein-coding genes with widespread influence, to 
exert profound control over cellular operations. Taken together, the results 
presented here implicate Pvt1b as a central node of communication between the 
p53 and Myc transcription networks, which enacts selective gene repression 
downstream of a broad transcriptional activator to limit cell growth and perhaps 
prevent cancer before its onset. Future studies should focus on both identifying the 
element(s) of Pvt1b required for Myc repression, and disentangling the intricacies 
of the Pvt1 locus to illuminate its varied, and perhaps isoform-specific, functions. 
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Chapter 7: Materials and Methods 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mouse strains  
All animal work was conducted in accordance with a protocol approved by 
the Yale University Institutional Animal Care and Use Committee. K-rasLSL-G12D/+
 
(K) and p53FL/FL (P) mice were previously described (Jackson et al., 2005; Jackson 
et al., 2001) and obtained from the laboratory of T. Jacks (MIT). Rosa26-
Cas9LSL/LSL (C) mice were previously described (Platt et al., 2014) and purchased 
from Jackson Laboratories (026556). Wild-type (WT) C57BL/6J mice were 
purchased from Jackson Laboratories (000664). Pvt1a-PAS, Pvt1b-PAS and 
Pvt1b-TWI mice were generated using CRISPR/Cas9-mediated engineering in 
C57BL/6J mice in collaboration with Rick Maser and Adam Williams at the 
Jackson Laboratory for Genomic Medicine. In brief, guide RNA:Cas9 
ribonucleoprotein (RNP) complexes and HDR templates were introduced into 
embryos via electroporation. Mice carrying successful knock-ins were identified by 
PCR-based genotyping and germline transmission was established by 
backcrossing once to WT (C57BL/6J) mice. Guide RNA and HDR template 
sequences can be found in Supplementary Table 1; genotyping primer sequences 
can be found in Supplementary Table 2. 
For irradiation experiments, 4-8 months-old mice were irradiated with 6 Gy 
of whole body irradiation and sacrificed 6 hours post irradiation. For tumor studies, 
3-6 months-old mice were used. Experiments were performed blind to gender and 
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with an equal distribution of males and females in each experimental group. 
 
Cell culture and drug treatments  
WT MEFs were isolated from embryos at E13.5 from timed matings of WT 
C57BL/6J animals. All MEF experiments were performed at passages 2-10. KPR8 
lung adenocarcinoma cell line of the genotype K-rasG12D/+; p53LSL/LSL; Rosa-
CreERT2 was previously established from spontaneously arising primary tumors 
isolated from K-rasLA2-G12D/+; p53LSL/LSL; Rosa-CreERT2 mice, as previously 
described (Feldser et al., 2010). p53-restorable p53LSL/LSL; Rosa-CreERT2 MEFs 
were previously described (Ventura et al., 2007). Genotypes and Tam-mediated 
restoration of p53 expression were validated by genotyping and by qRT-PCR and 
immunoblotting, respectively. Puromycin-sensitive KPR8 (KPR) and p53-
restorable MEF clones were generated by transient transfection with a guide RNA 
targeting the ORF of puromycin to inactivate the puromycin-resistance gene 
expressed from the Stop cassette, cloned downstream of a U6 promoter in a 
BRD004 lentiviral construct (a gift from the Broad Institute, MIT) that co-
expresses spCas9 and GFP. Normal human fetal lung fibroblasts were purchased 
from the NIA Aging Cell Culture Repository (TIG-1, NG06173). Primary MEFs and 
human fibroblasts were maintained in DMEM (Gibco) supplemented with 15% 
FBS (F0926, Sigma-Aldrich), 50 U/ml pen/strep (Gibco), 2 mM L-glutamine 
(Gibco), 0.1 mM non-essential amino acids (Gibco), and 0.055 mM b-
mercaptoethanol (Gibco). Cancer cells and 293 viral packaging cells were cultured 
in DMEM supplemented with 10% FBS, 50 U/ml pen/strep, 2 mM L-glutamine, 
and 0.1 mM non-essential amino acids. All cell cultures were maintained at 37°C 
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in a humidified incubator with 5% CO2. Viral titering was performed in 3TZ cells, 
a derivative of 3T3 cells, expressing a LSL-LacZ transgene (generously provided by 
the laboratory of T. Jacks, MIT).  
To delete the loxP-STOP-loxP (LSL) cassette preventing p53 expression, 
cells were treated with 0.5 µM 4-hydroxytamoxifen (Tam, Cayman Chemical 
Company). To induce DNA damage, cells were treated with 0.5 µM doxorubicin 
(Doxo, Sigma-Aldrich) or 50 µM etoposide (Etop, Millipore Sigma) for smRNA-
FISH studies. To assess protein stability, cells were treated with 50 µg/ml 
cycloheximide (Chx, Sigma-Aldrich) for the indicated times. To inhibit HDAC3, 
cells were treated with 14 µM RGFP966 (MedChem Express). To inhibit all HDACs, 
KPR cells were treated with 50 ng/ml trichostatin A (TSA, Sigma-Aldrich) or 50 
nM suberoylanilide hydroxamic acid (SAHA, Sigma-Aldrich) and p53-restorable 
MEFs were treated with 25 ng/ml TSA or 75 nM SAHA, respectively. 
 
Constructs  
Mutagenesis of p53REs in cultured cells was performed with a gRNA 
targeting the p53RE of Pvt1b (gDRE) or Gm26542 (g1 or g2), cloned downstream 
of a U6 promoter in BRD001 or BRD004 lentiviral constructs (gifts from the Broad 
Institute, MIT) that co-express spCas9 and either an IRES-driven puromycin-
resistance gene or GFP, respectively. Mutagenesis of Pvt1 exon 1b or the Pvt1 exon 
1b splice site in cultured cells was performed with gRNAs targeting across the Pvt1 
exon 1b sequence (gALT1-11) or a gRNA targeting the 3’ end of exon 1b (gdeltaSS), 
respectively, each cloned into the BRD001 lentiviral construct, as previously 
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described. Control gRNA targeting dTomato (Con) was used as a negative control. 
Tumor-specific mutagenesis of p53REs in vivo was performed with gRNAs cloned 
downstream of a U6 promoter in UGPC (U6-gRNA-PGK-Cre) lentiviral vector. 
UGPC-Con targeting dTomato was used as a negative control. UGPC-p53KO 
targeting the ORF of p53 was used as a positive control (Xue et al., 2014). For 
CRISPRa experiments, a lentiviral vector (lenti-SAM-Hygro) was constructed to 
co-express nuclease-proficient spCas9, a U6-driven 15-mer ʻdead RNAʼ (dRNA) 
extended by two MS2 loops (dRNA-MS2) (Dahlman et al., 2015), the 
transcriptional activator domains p65 and HSF1 fused to the MS2-binding protein 
(MBP), and a hygromycin-resistance gene. All sgRNA and dRNA sequences used 
in this study can be found in Supplementary Table 1. 
Lentivirus was produced in 293 cells by co-transfecting the lentiviral 
constructs with pCMV-dR8.2 dvpr (Addgene plasmid #8455) and pCMV-VSV-G 
(Addgene plasmid #8454) viral packaging constructs. Viral containing 
supernatants supplemented with 4 µg/ml polybrene (Millipore Sigma) were used 
to infect WT MEFs and KPR cells by 2-3 consecutive lentiviral infections, delivered 
at 24 hour-intervals. Following infections, cells were selected with 5 µg/ml (KPR) 
or 2 µg/ml (MEFs) puromycin (Sigma-Aldrich) or 800 µg/ml hygromycin (Roche). 
UGPC lentivirus was prepared as above, concentrated by ultracentrifugation, and 
titered by infecting 3TZ cells and determining the number of viral particles based 
on the fraction of LacZ-positive cells as previously described (DuPage et al., 2009). 
Mutagenesis of the Pvt1b and Gm26542 p53REs was confirmed by PCR 
amplification of the region, subsequent cloning into pCR-Blunt II-TOPO® vector 
(Invitrogen) and Sanger sequencing. Mutagenesis of the Pvt1 exon 1b sequence and 
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the Pvt1 exon 1b splice site was confirmed by PCR amplification of the region, 
Sanger sequencing and Tracking of Indels by Decomposition (TIDE) analysis 
(Brinkman et al., 2014). Primers used in mutagenesis efficiency estimates can be 
found in Supplementary Table 2. 
For overexpression experiments, full-length Pvt1a (exon 1a-10) and Pvt1b 
(exon 1b-10) cDNAs were synthesized as gene blocks and cloned into pWZL Hygro 
retroviral vector (Addgene plasmid #18750). 5 µg of empty vector, Pvt1a-, or 
Pvt1b-expressing constructs were transfected into 1-3x106 WT MEFs using the 
Amaxa Mouse/Rat Hepatocyte Nucleofector Kit (Lonza, VPL-1004) and the 
Nucleofector 2b Device (Lonza). Analysis was performed at 48 hours post 
transfection. Information about key plasmids used in this work can be found in 
Supplementary Table 3. 
 
METHOD DETAILS 
RNA isolation and qRT-PCR  
For RNA-seq and qRT-PCR analysis, RNA was isolated with the RNeasy 
Mini Kit (Qiagen) and 0.5-1 µg of total RNA was reverse transcribed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). SYBR Green PCR 
master mix (Kapa Biosystems) was used for quantitative PCR in triplicate reactions 
with primers listed in Supplementary Table 2. Relative RNA expression levels were 






Cells were collected, counted, and lysed in 2×Laemmli buffer (100 mM Tris-
HCl pH6.8, 200 mM DTT, 3% SDS, 20% glycerol) at 0.5-1x104 cells/µl. Samples 
were heated at 95°C for 7 minutes and passed through an insulin syringe. Protein 
from 1x105 cells was separated on 10% SDS-polyacrylamide gels and transferred to 
nitrocellulose membranes (Bio-Rad). After blocking (5% milk, PBST), membranes 
were incubated overnight at 4°C in primary antibody, then 1hr at RT in secondary 
antibody. The following antibodies were used: anti-c-Myc (1:1000, clone Y69, 
ab32072, Abcam), anti-Hsp90 (1:2500, 610419, BD Transduction Laboratories), 
anti-Hsp90 (1:1000, 4877S, Cell Signaling Technology), goat anti-mouse 
secondary antibody (1:50000, 1706516, Bio-Rad), and donkey anti-rabbit 
secondary antibody (1:50000, 711-035-152, Jackson ImmunoResearch). Protein 
bands were visualized using Amersham ECL Prime Western Blotting Detection 
Reagent (GE Healthcare). Quantification of Myc and Hsp90 protein levels was 
performed using the rectangle selection and measure tools in FIJI and Myc levels 
plotted relative to Hsp90 levels and normalized to negative control in relevant 
graphs. For cycloheximide experiments, Myc levels were normalized to negative 
control and half-life of Myc protein was determined using Prism8 software. 
 
Chromatin immunoprecipitation (ChIP)  
Cells were harvested by trypsinization, counted, washed once in PBS and 
crosslinked in 1% methanol-free formaldehyde (Thermo Scientific) diluted in PBS 
for 10 min at RT. The reaction was stopped by adding glycine to a final 
concentration of 100 mM and placing the samples on ice for 5 min. Cells were 
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washed twice in cold PBS and the pellet was frozen and stored at -80°C.  
5-10x106 nuclei were isolated by incubating the thawed cell pellet in Cell 
lysis buffer (20 mM Tris-HCl, pH 8.0, 85 mM KCl, 0.5% NP-40), supplemented 
with protease inhibitors (1 mM PMSF and Mini Complete Protease Inhibitor 
Cocktail Tablet, Roche) on ice for 10 min. After centrifugation, the supernatant was 
removed and the nuclei were resuspended in Nuclei lysis buffer (50 mM Tris-HCl, 
pH 8.0, 10 mM EDTA, 1% SDS supplemented with protease inhibitors) and 
incubated for 10 min on ice. Next, chromatin was sonicated to 300-500 bp 
fragment size in an ice-water slurry for 10 cycles (15” ON, 30” OFF) for p53 ChIP 
and 10-12 cycles (10” ON, 30” OFF) for H3K27ac ChIP using a Bioruptor sonicator 
(Diagenode). Sonicated lysates were centrifuged at 13K rpm for 20 min and diluted 
in ChIP dilution buffer (0.01% SDS, 1.1% Triton- X100, 1.1 mM EDTA, 20 mM Tris-
HCl, pH 8.0, 167 mM NaCl, supplemented with protease inhibitors). Input aliquots 
were saved at this point. The sonicated chromatin was precleared with beads 
(PureProteome Protein G Magnetic Beads, Millipore Sigma) and used to set up 
chromatin immunoprecipitations with a p53 antibody (P53-CM5P-L, Leica), 
H3K27ac antibody (ab4729, Abcam), or control IgG (ab46540, Abcam) and 
incubated overnight at 4°C on a rotator. Beads (PureProteome Protein G Magnetic 
Beads, Millipore Sigma) were blocked overnight in 1% BSA in PBS supplemented 
with 20 µg salmon sperm DNA (Invitrogen) per immunoprecipitation reaction. 
The next day, the blocked beads were added to the immunoprecipitation reactions 
and samples were incubated on the rotator for an additional hour. Beads were 
washed once in each of the following washes for 5 min at 4°C on the rotator: Low 
salt wash (0.1% SDS, 1% Triton-X100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 
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mM NaCl supplemented with protease inhibitors), High salt wash (0.1% SDS, 1% 
Triton-X100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl), LiCl wash 
(0.25 M LiCl, 1% NP-40, 1% Na deoxycholate, 1 mM EDTA, 20 mM Tris-HCl, pH 
8.0), and TE wash (10 mM Tris-HCl, pH 8.0, 1 mM EDTA).  
After completely removing any remaining liquid from the washes, beads 
were resuspended in Elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, pH 
8.0, 1% SDS) and incubated at 65°C for 15 min with frequent vortexing to prevent 
settling. After elution, the beads were pelleted, and the supernatant was 
transferred to a new tube and incubated overnight at 65°C to reverse the 
crosslinking. The next day, samples were treated with RNaseA or 2 hours at 37°C, 
followed by a proteinase K (Roche) treatment for 30 min at 55°C. The DNA was 
purified by phenol-chloroform extraction and EtOH precipitation. The DNA pellet 
was air dried, resuspended in 200 µl H2O and used for quantitative PCR analysis 
(ChIP-qPCR) using primers listed in Supplementary Table 2.  
 
Single-molecule FISH (smRNA-FISH) 
Quasar570 (Q570)- and Quasar670 (Q670)-conjugated Stellaris FISH 
probes are listed in Supplementary Table 1 (Stellaris, LGC Biosciences). smRNA-
FISH was performed according to the manufacturer recommendations. Briefly, 
cells were grown on coverslips and fixed for 10 min in 4% methanol-free 
formaldehyde (Thermo Scientific) at RT, followed by PBS washes. Cells were 
dehydrated overnight at 4°C in 70% EtOH (diluted in DEPC-H2O) and stored in 
70% EtOH for up to a week at 4°C. Coverslips were transferred to a hybridization 
chamber and equilibrated for 5 min in Wash Buffer A (Stellaris, LGC Biosciences) 
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prepared with formamide (Millipore Sigma) according to manufacturer’s 
instructions. Cells were incubated overnight at 30°C with the indicated probes 
diluted 1:50 in Hybridization solution (Stellaris, LGC Biosciences) prepared with 
formamide according to manufacturer’s instructions. The next day, cells were 
washed 2 times for 30 min at 30°C in Wash Buffer A, incubated in Wash Buffer B 
(Stellaris, LGC Biosciences) for 5 min at RT, and mounted in antifade reagent 
(Vectashield Mounting medium with DAPI, Vector Laboratories). The following 
probesets were used: Pvt1b (ex.1b) detecting Pvt1b isoform with 10 probes 
spanning exon 1b, labeled with Q670 and false-colored in red; Pvt1a (ex.1a) 
detecting Pvt1a isoform with 11 probes spanning exon 1a, labeled with Q670 and 
false-colored in red; Pvt1 (ex.1a-10) detecting total Pvt1 with 48 probes spanning 
exons 1a-10, labeled with Q570 and false-colored in green; Pvt1 (introns) detecting 
nascent Pvt1a with 31 probes spanning intron 1 upstream of exon 1b, labeled with 
Q670 and false-colored in red; and Myc (intron) detecting nascent Myc with 33 
probes spanning intron 1 of Myc, labeled with Q570 and false-colored in green. 
Pvt1a (ex.1a) and Pvt1b (ex.1b) probesets do not detect at the single molecule level. 
Images were captured using an Axio Imager 2 microscope system (Zeiss) with a 
PlanApo 63x 1.4 oil DIC objective lens (Zeiss). For KPR cells, z-stacks of 12 planes 
at 0.5 µm steps were acquired and used to generate maximum intensity projections. 
For WT MEFs, single plane images were acquired. All images were edited using 
Adobe Photoshop. 
 
DNA-Fluorescence in situ hybridization (FISH) 
DNA-FISH was performed as previously described (Chaumeil et al., 2008). 
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To generate probes, the following BAC clones were used: RP23-55F11 (Myc) and 
RP24-301E22 (Chr 6) (BACPAC Resources). BAC DNA was purified with a 
Nucleobond Xtra BAC kit (Takara Bio USA) and nick translated with a nick 
translation system (Invitrogen) and Alexa Fluor® 488-5-UTP or Alexa Fluor® 
594-5-UTP (Invitrogen) following manufacturer instructions. Final probes were 
ethanol precipitated with 7.5M ammonium acetate and stored in sterile TE at -
20°C.  
20 ng of nick-translated probe was precipitated with 3 µg of salmon sperm 
DNA (Invitrogen) and 1 µg of mouse COT1 DNA (Invitrogen) using 1/10th volume 
of sodium acetate (3M, pH 5.5) and 2.5 volumes of ethanol. Probes were stored 
overnight at -20°C, then centrifuged at 13K rpm for 30 min at 4°C, washed twice 
with 70% ethanol, and air dried. Pellets were resuspended in formamide (Millipore 
Sigma), incubated at 37°C for at least 10 min, and denatured for 7 min at 75°C. 
After denaturing, an equal volume of 2X hybridization buffer (4X SSC, 20% w/v 
dextran sulfate, 2 mg/mL BSA, 40 mM RVC) was added and probe-DNA mixtures 
were pre-annealed for 30 min to 1 hour at 37°C.  
Cells were plated on coverslips and fixed in 4% paraformaldehyde in PBS 
for 10 min at RT, followed by PBS washes. Cells were permeabilized in 0.5% Triton 
X-100 in PBS for 6 min, washed twice with 70% ethanol and stored in 70% ethanol 
at -20°C. Cover slips were dehydrated in an ethanol series (80%, 90%, 100%), air 
dried, and incubated in RNase A diluted in 2X SSC (100 µg/mL) for 1 hour at 37°C. 
Cover slips were washed three times with 2X SSC for 5 min and incubated in 50 
µg/mL pepsin diluted into prewarmed 0.01M HCl for 3 min at 37°C, followed by 
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two 5 min PBS washes and one in 1X PBS/MgCL2. After washing, cover slips were 
incubated in 1% formaldehyde (Thermo Scientific) in 1X PBS/MgCL2 for 10 min at 
RT. Cover slips were next washed in PBS for 5 min and dehydrated in an ethanol 
series (70%/90%/100%) and air dried. Cover slips were then denatured in 
prewarmed 50% formamide in 2X SSC for 30 min at 80°C, dehydrated in an ice-
cold ethanol series (70%/90%/100%), and incubated with denatured probe DNA 
overnight at 42°C in a dark chamber humidified with 50% formamide in 2X SSC. 
Following incubation, cover slips were washed three times with prewarmed 50% 
formamide in 2X SSC at 42°C for 5 min and three times with prewarmed 2X SSC 
at 42°C for 5 min.  Cover slips were mounted on slides with antifade mounting 
medium with DAPI (Vector Laboratories) and sealed with nail polish. Single plane 
images were captured using an Axio Imager 2 microscope system (Zeiss) with a 
PlanApo 63x 1.4 oil DIC objective lens (Zeiss). 
 
Subcellular fractionation  
Subcellular fractionation was performed as previously described (Conrad 
and Orom, 2017) with slight modifications. Briefly, cells were harvested by 
trypsinization, rinsed once in PBS and re-suspended in 1 mM EDTA in PBS. 1x106 
cells were set aside for whole cell (WC) RNA isolation using TRIzol (Invitrogen) 
following the manufacturer’s protocol. 3 x106 cells were lysed in 0.4 mL cell lysis 
buffer (10 mM TrisHCl pH 7.5, 0.15% NP-40, 150 mM NaCl, 100 U/mL RNase-IN 
(Promega) for 5 min on ice. Lysate was layered on a sucrose cushion (24% w/v 
sucrose, 150 mM NaCl, 10 mM TrisHCl pH 7.5,100 U/mL RNase-IN) and 
centrifuged for 10 min at 3,500g, yielding the cleared cytoplasmic fraction 
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(supernatant) and pelleted nuclei. Nuclear pellets were washed once in PBS 
supplemented with 1 mM EDTA, re-suspended in 0.25 mL glycerol buffer (50% 
glycerol, 20 mM Tris-HCl pH 7.5, 75 mM NaCl, 0.5 mM EDTA, 0.85 mM DTT, 100 
U/mL RNase-IN), and lysed by the immediate addition of an equal volume nuclear 
lysis buffer (10 mM HEPES pH 7.6, 7.5 mM MgCl2, 0.2 mM EDTA, 300 mM NaCl, 
1% NP-40, 1 mM DTT, 1M Urea, 100 U/mL RNase-IN) with 2 min incubation on 
ice. Centrifugation for 2 min at 18,800g yielded the nucleoplasmic and chromatin- 
associated fractions in the supernatant and pellet, respectively. Chromatin pellets 
were washed once in 1 mM EDTA in PBS and solubilized in 1 mL TRIzol reagent 
by syringing. RNA was extracted from the cytoplasmic and nucleoplasmic fractions 
using TRIzol-LS (Invitrogen) and from the chromatin-associated fraction using 
TRIzol following the manufacturer’s protocols. Subcellular RNA enrichment 
patterns were determined by qRT-PCR, normalizing fraction Ct values to WC Ct 
values. Cytoplasmically-enriched RNA Rn7s1 and chromatin-enriched RNA 
Kcnq1ot1 served as fractionation quality controls. Primer sequences can be found 
in Supplementary Table 2.  
 
Antisense knockdown  
1 µM Pvt1-targeting (ASO1, ASO2, and ASO3) or control (CON) antisense 
LNA Gapmers (Exiqon, Qiagen) were transfected into 1-3x106 MEFs using the 
Amaxa Mouse/Rat Hepatocyte Nucleofector Kit (Lonza, VPL-1004) and the 
Nucleofector 2b Device (Lonza). Knockdown of Pvt1 variants and the 
corresponding effects on p21 and Myc expression were assayed at 72 hours post-
transfection by qRT-PCR following the indicated treatments. The sequences of all 
 152 
ASOs are listed in Supplementary Table 1.  
 
Chromosome Conformation Capture (3C)  
Chromosome conformation capture was performed as described previously 
with minor modifications (Hagege et al., 2007). Briefly, cells were harvested by 
trypsinization, counted, washed once in PBS and 5-10x106 cells were crosslinked 
in 1% methanol-free formaldehyde (Thermo Scientific) diluted in PBS for 10 min 
at RT. The reaction was stopped by adding 1.425 ml of 1 M glycine. Cell pellets were 
frozen in a bath of dry ice covered in 100% EtOH and stored at -80°C, or were 
processed immediately. Cells were lysed in 5 ml cell lysis buffer (20 mM TrisHCl 
pH8.0, 85 nM KCl, 0.5% NP-40, 5 mM MgCl2, 0.1 mM EGTA) including 1x 
complete protease inhibitor (Roche). Cell nuclei were resuspended in 0.5 ml of 1.2x 
Cutsmart restriction buffer (New England Biolabs) and SDS was added to each 
tube to a final concentration of 0.3%. Following extraction with 2% Triton X-100, 
chromatin was digested overnight at 37°C with 400-800 U BamHI-HF (New 
England Biolabs). Ligations were performed in a total reaction volume of 6.125 mL 
of 1.15x ligation buffer (10x Ligation Buffer: 600 mM Tris-HCl pH7.5, 50 mM DTT, 
50 mM MgCl2, 10 mM ATP (New England Biolabs) using 100 U of T4 DNA ligase 
(New England Biolabs) with incubation at 16°C for 4 h, followed by further 
incubation at RT for 30 min. Reversal of crosslinking was performed by adding 
300 µg proteinase K (Roche) followed by incubation at 65°C overnight. DNA was 
extracted with phenol-chloroform followed by EtOH precipitation. The efficiency 
of restriction enzyme digestion was examined using qRT-PCR with primer sets 
spanning BamHI sites. The concentrations of 3C libraries were determined by 
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qRT-PCR and compared to a genomic DNA reference of known concentration. 
Samples were subsequently diluted to a concentration of 20 ng/µl and a total of 50 
ng was used for each qRT-PCR reaction. Interaction frequencies were determined 
using a unidirectional primer strategy with an anchor designed against the 
promoter of Myc (A1) and were normalized to a control region in the Myc-Pvt1 
locus. The primer sequences can be found in Supplementary Table 2. 
 
RNA-seq  
Total RNA was isolated in three biological replicates. PolyA selection and 
cDNA library preparation was performed using TruSeq Stranded mRNA Library 
Prep (Illumina). Paired-end 100 bp sequencing was performed on an Illumina 
HiSeq 4000 instrument. RNA-seq read files were merged from technical replicates 
and mapped to the mm10 genome assembly using Tophat (ver 2.0.14) (Trapnell et 
al., 2009) with gencode (vM10) annotation used as the transcriptome index. 
Additional transcripts were assembled using stringtie (1.2.4) (Pertea et al., 2015) 
and reads within exon sequences counted using HTSeq (HTSeq-0.6.1) counts 
(Anders et al., 2015). The differential expression analysis was performed with 
EdgeR (3.22.3) (using general linear model settings for biological triplicates with 
blocked matrix model for paired comparisons) (Robinson et al., 2010). For analysis 
of Myc targets, the Hallmark Gene Set in the Molecular Signature Database (Broad 
Institute) (Liberzon et al., 2015) was used and compared to randomly selected and 
expression matched genes with statistical significance of differential expression 




At approximately 60% cellular confluence, media was spiked with a final 
concentration of 100 µM s4U (Alfa Aesar) and grown in the dark for 1 hour. Cells 
were rinsed once with PBS, scraped from plates, suspended in 1 mL TRIzol 
(Invitrogen), and frozen overnight at -80°C. Total RNA was purified and treated 
with TimeLapse chemistry essentially as described (Schofield et al., 2018) with 
minor modifications. Briefly, following chloroform extraction and isopropanol 
precipitation (supplemented with 1 mM DTT) genomic DNA was depleted by 
treating with TURBO DNase (Invitrogen) and total RNA was extracted with acidic 
phenol:chloroform:isoamyl alcohol and EtOH precipitation. Isolated total RNA 
was mixed with 600 mM TFEA, 1 mM EDTA and 100 mM sodium acetate, pH 5.2 
in water. A solution of 10 mM NaIO4 was added and the reaction mixture was 
incubated at 45°C for 1 hr. Chemically treated RNA was purified using Agencourt 
RNAclean XP beads (1 equivalent volume, Beckman Coulter) according to 
manufacturer's instructions. Purified material was then incubated in a reducing 
buffer (10 mM DTT, 100 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA) at 37°C for 
30 min, followed by a second RNAclean bead purification. For each sample, 10 ng 
of total RNA input was used to prepare sequencing libraries from the Clontech 
SMARTer Stranded Total RNA-Seq kit Pico Input (Takara Bio USA) with 
ribosomal cDNA depletion. Paired-end 100 bp sequencing was performed on an 






At approximately 60% cellular confluence, media was spiked with s4U (1 µM 
final, Alfa Aesar) and cells were grown in the dark for 5 min. Total RNA and DNA 
isolation were performed as described above. Total RNA (50 µg) was biotinylated 
with MTSEA biotin-XX (Biotium), isolation and streptavidin enrichment 
essentially as described (Schofield et al., 2018). Enriched RNA was chemically 
treated as described above. Library construction and sequencing were performed 
essentially as described above. 
 
TimeLapse-seq mutational analysis 
Filtering and alignment to the mouse GRCm38.p5 were performed 
essentially as described previously (Schofield et al., 2018). Briefly, reads were 
filtered to remove duplicate sequences with FastUniq (Xu et al., 2012), trimmed of 
adaptor sequences with Cutadapt v1.16 (Martin, 2011) and aligned to GRCm38 
using HISAT2 v2.1.0 (Kim et al., 2015a) (with default parameters except -mp 4,2). 
Reads aligning to transcripts were quantified with HTSeq (Anders et al., 2015) 
htseq-count. SAMtools v1.5 (Li et al., 2009) was used to collect only read pairs with 
a mapping quality greater than 2 and concordant alignment (sam FLAG = 147/99 
or 83/163). Mutation calling was performed essentially as described previously 
(Schofield et al., 2018). Briefly, T-to-C mutations were only considered if they met 
several conditions. Mutations must have a base quality score greater than 40 and 
be more than 3 nucleotides from the read’s end. Sites of likely single-nucleotide 
polymorphisms (SNPs) and alignment artifacts were identified with bcftools or 
from sites of high mutation levels in the non-s4U treated controls and were not 
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considered in mutation calling. Browser tracks were made using STAR v2.5.3a 
(Dobin et al., 2013) and normalized across samples using scale factors calculated 
using RNA-seq reads using edgeR (Robinson et al., 2010) (calcNormFactors using 
method = ‘upperquartile’). 
 
Differential expression analysis 
Differential expression analysis of transcriptome-wide TimeLapse-seq and 
TT-TimeLapse-seq data was performed with DESeq2 (Love et al., 2014) essentially 
as described previously (Schofield et al., 2018). DESeq2 expression analysis was 
performed on TT-TimeLapse-seq and transcriptome-wide TimeLapse-seq data to 
determine changes in transcriptional activity and mRNA expression, respectively. 
 
Growth curve and colony assay  
To generate growth curves, Con-, DRE-, sg1-, or sg2-expressing KPR cells 
were grown in the presence or absence of Tam. Population doublings over 
indicated time course were plotted as the average of three independent 
experiments. For colony assays, 4x105 Con- or DRE -expressing KPR cells were 
plated in the presence of Tam in 6 cm dishes and monitored for colony formation. 
Plates were washed with PBS, fixed in 0.5% Crystal Violet; 25% MeOH for 10 
minutes and washed in ddH2O. The average of three biological replicates is shown.  
 
Tumor studies  
Lung tumorigenesis was initiated in cohorts of KC and KPC mice as 
described in (DuPage et al., 2009) by intratracheal infection with 1x105 pfu UGPC 
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lentiviruses . Mice were analyzed at 12 or 16 weeks post tumor initiation. For 
histological analyses, lungs were inflated with 4% paraformaldehyde, and fixed 
overnight in 4% paraformaldehyde, prior to dehydration in 70% ethanol. Fixed 
lungs were embedded in paraffin, sectioned, and stained with hematoxylin and 
eosin (H&E). Tumor burden scored as tumor area relative to total lung area was 
determined using the freehand selection tool and Measure feature in ImageJ on 
images acquired with an Axio Imager 2 microscope system (Zeiss) with a PlanApo 
10x 0.3 objective lens (Zeiss). Tumor grade was scored as previously described 
(DuPage et al., 2009; Nikitin et al., 2004). 
 
Immunohistochemistry  
Immunohistochemistry on paraffin sections was performed using the ABC 
Vectastain kit (Vector Labs) with an antibody to pHH3 Serine 10 (9701S, Cell 
Signaling Technologies). The staining was visualized with DAB (Vector Labs) and 
slides were counterstained with hematoxylin.  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
In relevant figures, figure legends convey the statistical details of 
experiments including statistical tests used and type and number (n) of biological 
replicates, while asterisks define degree of significance as described. All Student’s 
t-tests and Mann-Whitney U-tests were analyzed in two sided. All sequencing data 
were aligned to the mouse genome (GRCm38/mm10). All statistical analyses were 
performed and graphics were generated using Prism8 software. Tracking of Indels 
by DEcomposition (TIDE) analysis was used to estimate mutagenesis efficiency. 
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DATA AND SOFTWARE AVAILABILITY  
All software used in this work is listed in Supplementary Table 4. Data 
generated in (Olivero et al., 2020) are available through Gene Expression Omnibus 
(GEO) under accession number GEO: GSE126940. Some figures were created 

























Name Target Sequence 
Con N/A GCTCCCTTCAATCCAA 
ASO1 Pvt1 exon 1b GTAACTAGCACACATC 
ASO2 Pvt1 exon 1b TTTGCTCCTTCTAAAT 
ASO3 Pvt1 exon 1b GAGTCCATGTGACGTT 
   
SpCas9 dRNAs 
Name Target Sequence 
Con dTomato gCGAGTTCGAGATCGA 
A1 Pvt1a TSS GGAGATCGGGGACAC 
A2 Pvt1b TSS gATGGTCATAGCTAGT 
   
SpCas9 gRNAs 
Name Target Sequence 
Con dTomato GGCCACGAGTTCGAGATCGA 
RE Pvt1b p53RE gATATGGGCAGTGACAAGTTT 
p53 p53 ORF GTGTAATAGCTCCTGCATGG  
sg1 Gm26542 p53RE gTCTGAGGCCTGGGACTTGCC 
sg2 Gm26542 p53RE GGACTTGCTCAGTTCTTGGA 
sgALT1 Pvt1 exon 1b gAAACACAAACGCTTTCCCAC 
sgALT2 Pvt1 exon 1b gTTCTTAAAGCTCTAGCCAGT 
sgALT3 Pvt1 exon 1b gAAGTCCCACTTGGAGCTCCA 
sgALT4 Pvt1 exon 1b gTCTATCCTTGGAGCTCCAAG 
sgALT5 Pvt1 exon 1b GACTTCTTAAAAGATTTAGA 
sgALT6 Pvt1 exon 1b gTTAGAAGGAGCAAAGCTGTC 
sgALT7 Pvt1 exon 1b gAGGAAATCAGAAACGTCACA 
sgALT8 Pvt1 exon 1b gCGTCACATGGACTCCATGAC 
sgALT9 Pvt1 exon 1b GACTGGGAAAAACCTCGTGG 
sgALT10 Pvt1 exon 1b GGTGGCCTGCTCTCAGTGCT 
sgALT11 Pvt1 exon 1b GATGTGTGCTAGTTACATCT 
sgdeltaSS Pvt1 exon 1b 3’ end GTGTGCTAGTTACATCTCGG 
Puro Puromycin resistance gene gCGGGTGGCGAGGCGCACCGT 
   
in vivo SpCas9 gRNAs 
Name Target Sequence 
sgEx1a Pvt1 exon 1a gCTGGTCAAGCGGGCTCGGCA 
sgEx1b Pvt1 exon 1b gTCTATCCTTGGAGCTCCAAG 
   
HDR Templates 
Name Target Sequence 


























   
smRNA FISH Probes 
Name 3’ Modification Sequence 
PVT1_exons_1 Quasar 570 TCTGGGAATGCTAAGTTCGT 
PVT1_exons_2 Quasar 570 CCATGTGACGTTTCTGATTT 
PVT1_exons_3 Quasar 570 ACACATCCAAGCACTGAGAG 
PVT1_exons_4 Quasar 570 AAATCAGACCTCCGAGATGT 
PVT1_exons_5 Quasar 570 TTCAGGAAGTCTCCAGAGAG 
PVT1_exons_6 Quasar 570 CAGAATTACTCCCCAGGAAA 
PVT1_exons_7 Quasar 570 GGGTAGAGATACAATCCTCT 
PVT1_exons_8 Quasar 570 GCTCTCAGAAACACTGCATT 
PVT1_exons_9 Quasar 570 CTGGTTCTTCTGAGAGACTG 
PVT1_exons_10 Quasar 570 AGGCATCTCACAGCAAAGTA 
PVT1_exons_11 Quasar 570 TTATCACATTAGAGGACCCG 
PVT1_exons_12 Quasar 570 ACTTGGCATCTCTTAAGTCA 
PVT1_exons_13 Quasar 570 AGACTTCCATCTTTGCTATT 
PVT1_exons_14 Quasar 570 CAGCTGTCTTATAGGATTGC 
PVT1_exons_15 Quasar 570 TCTTAGGGTCAGTATCATGG 
PVT1_exons_16 Quasar 570 AGTATTCTAGCTTGGAGCTA 
PVT1_exons_17 Quasar 570 TTGTCACTCCATTTGGCAAA 
PVT1_exons_18 Quasar 570 TGCTTAAAGACCACAGAGGC 
PVT1_exons_19 Quasar 570 ATTGCTTTGGGTATTTTGGT 
PVT1_exons_20 Quasar 570 AATGTCTACTTGTTGGCCAA 
PVT1_exons_21 Quasar 570 TAGCAGAGTGGTTCAAAGGC 
PVT1_exons_22 Quasar 570 AGAATTTCAGAGGGCACTCG 
PVT1_exons_23 Quasar 570 AGACTTAGGGCATACAGGTA 
PVT1_exons_24 Quasar 570 CTGGATTCTGTAGCTATTCT 
PVT1_exons_25 Quasar 570 TAAAGCATCCAGGGCAGAAC 
PVT1_exons_26 Quasar 570 TGACTCCTGTTGGAAAACCA 
PVT1_exons_27 Quasar 570 CACGCTCATGTCCTTTAATA 
PVT1_exons_28 Quasar 570 GTTTAGCACTATCCATCTTT 
PVT1_exons_29 Quasar 570 TTGCTCTCCTTATGAAGAGG 
PVT1_exons_30 Quasar 570 GAAACCTTAAGCATGAGCCA 
PVT1_exons_31 Quasar 570 AGTGCACTCTTATACGTCAC 
PVT1_exons_32 Quasar 570 ATCTTAAGATGGCTTGGACC 
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PVT1_exons_33 Quasar 570 GAGATTCGGAACTGACAGGC 
PVT1_exons_34 Quasar 570 AAAGAGAACGTGTCCCTTGT 
PVT1_exons_35 Quasar 570 TCTATTGTAGGTTGTTCCTG 
PVT1_exons_36 Quasar 570 AAATCCAGGCTACTTCTCAG 
PVT1_exons_37 Quasar 570 GCCTCCAGAGAAAACGATGA 
PVT1_exons_38 Quasar 570 CAGGGCTCATGAGAACAGAG 
PVT1_exons_39 Quasar 570 CTTACCAGGAGAAGCATCAT 
PVT1_exons_40 Quasar 570 CAGCACATAGAACACAGGCA 
PVT1_exons_41 Quasar 570 GAAGATTGTGCCAGGAACTC 
PVT1_exons_42 Quasar 570 CAGATCCTGGTTTAGAACGG 
PVT1_exons_43 Quasar 570 CTGTCATCTTCTCTTCTTTG 
PVT1_exons_44 Quasar 570 TCCTTAATGTGCTACCACAA 
PVT1_exons_45 Quasar 570 GGATTCTACTTCACCATAGG 
PVT1_exons_46 Quasar 570 CCAAGGCATTATGAAGTGCA 
PVT1_exons_47 Quasar 570 AAAGTGTCTCAGGGAATCCT 
PVT1_exons_48 Quasar 570 TCAGTAAGTCACAGCTGTGA 
PVT1_intron_AE1up_1 Quasar 670 TTCCAGGGGATAAACTTGGA 
PVT1_intron_AE1up_2 Quasar 670 AATGCAAAAGCCACTTTCCT 
PVT1_intron_AE1up_3 Quasar 670 AAGGTTAACACGCGCTCGTG 
PVT1_intron_AE1up_4 Quasar 670 TCGAGTCTAGTGATGAGGAA 
PVT1_intron_AE1up_5 Quasar 670 ACACCCAAACTCTCTGGCAA 
PVT1_intron_AE1up_6 Quasar 670 TAGAGGCCATCCTGGGAAAT 
PVT1_intron_AE1up_7 Quasar 670 GCATAAATCCAGAATTACCT 
PVT1_intron_AE1up_8 Quasar 670 CTGAGGAAATGGGCTCTTGA 
PVT1_intron_AE1up_9 Quasar 670 CAAATCTGCGCTGATTGCAG 
PVT1_intron_AE1up_10 Quasar 670 TCGTAAATGAGGCCTCCAAA 
PVT1_intron_AE1up_11 Quasar 670 GACTAGACTCAGACTTCCAG 
PVT1_intron_AE1up_12 Quasar 670 AAGGATGGAGGGAGCATCAC 
PVT1_intron_AE1up_13 Quasar 670 GTTTTAGGAGATCACCTTCT 
PVT1_intron_AE1up_14 Quasar 670 GCACAGAAAGTTTCCTGACA 
PVT1_intron_AE1up_15 Quasar 670 CTTCCACGAACACAGGAACG 
PVT1_intron_AE1up_16 Quasar 670 TAGCAAGGATGAAGGCGTGG 
PVT1_intron_AE1up_17 Quasar 670 GTTAAAGCAACAAGCTATCC 
PVT1_intron_AE1up_18 Quasar 670 TAGCCAAGAAAGGGCCAATC 
PVT1_intron_AE1up_19 Quasar 670 CACTCATAGGTACAGCAGAA 
PVT1_intron_AE1up_20 Quasar 670 TGGAAGTCTGCACAGTTCTC 
PVT1_intron_AE1up_21 Quasar 670 CACATGTAGCTTCATGGCTG 
PVT1_intron_AE1up_22 Quasar 670 ATCCATGATGTGTCTACACA 
PVT1_intron_AE1up_23 Quasar 670 CAGATTATCACCCACTAGTA 
PVT1_intron_AE1up_24 Quasar 670 GAACGTTCTGGAGAGCTCAA 
PVT1_intron_AE1up_25 Quasar 670 GATTTCTCTCCTTAAGCTTC 
PVT1_intron_AE1up_26 Quasar 670 TTCTCCCTATACTCTCTTAA 
PVT1_intron_AE1up_27 Quasar 670 GTCAAATGACAACAACCCCT 
PVT1_intron_AE1up_28 Quasar 670 AACAGAGACCTGCATCCTTA 
PVT1_intron_AE1up_29 Quasar 670 CAACATCCTACCACATGCAC 
PVT1_intron_AE1up_30 Quasar 670 GTGAACAAGCCCAAACTTGT 
PVT1_intron_AE1up_31 Quasar 670 CTAGCTATGACCATAGGACT 
PVT1_Exon1a_1 Quasar 670 GTGGCCCGTGACGTCACG 
PVT1_Exon1a_2 Quasar 670 TGGTAGAGCGCGGGGCTG 
PVT1_Exon1a_3 Quasar 670 CGGCCACACGCGCTCTGC 
PVT1_Exon1a_4 Quasar 670 AGTGGGTCCATGTGCTCG 
PVT1_Exon1a_5 Quasar 670 TTGCCGAGCCCGCTTGAC 
PVT1_Exon1a_6 Quasar 670 CGTAGCTTCTCTTCATCC 
PVT1_Exon1a_7 Quasar 670 GCTCTGGGAATGCTAAGT 
 162 
PVT1_Exon1a_8 Quasar 670 GCGGATATCCACTCGGGG 
PVT1_Exon1a_9 Quasar 670 CTGCCAACATCCTTTCCA 
PVT1_Exon1a_10 Quasar 670 GACTCCGAGGTCACCGGG 
PVT1_Exon1a_11 Quasar 670 AGAGGGTGGATCCAGCCG 
PVT1_Exon1b_1 Quasar 670 GGCTAGAGCTTTAAGAAG 
PVT1_Exon1b_2 Quasar 670 ACACAAACGCTTTCCCAC 
PVT1_Exon1b_3 Quasar 670 TGGAGCTCCAAGGATAGA 
PVT1_Exon1b_4 Quasar 670 TCTTTTAAGAAGTCCCAC 
PVT1_Exon1b_5 Quasar 670 CAGCTTTGCTCCTTCTAA 
PVT1_Exon1b_6 Quasar 670 GACGTTTCTGATTTCCTG 
PVT1_Exon1b_7 Quasar 670 CCAGTCATGGAGTCCATG 
PVT1_Exon1b_8 Quasar 670 GGCCACCACGAGGTTTTT 
PVT1_Exon1b_9 Quasar 670 CATCCAAGCACTGAGAGC 
PVT1_Exon1b_10 Quasar 670 TCCGAGATGTAACTAGCA 
c-Myc intron_1 Quasar 570 AAAGACCACCAGATCTGTGC 
c-Myc intron_2 Quasar 570 TAACCGGCCGCTACATTCAA 
c-Myc intron_3 Quasar 570 CCCCAACTACTCTTGAGAAA 
c-Myc intron_4 Quasar 570 CATCTTGACAAGTCGCTCTA 
c-Myc intron_5 Quasar 570 CGCTTCAAAATGCATCCCGG 
c-Myc intron_6 Quasar 570 CCCATAGTAACCTCGGGAAC 
c-Myc intron_7 Quasar 570 AAGCAAGAATGTCCAACCGG 
c-Myc intron_8 Quasar 570 CCCTCAAAGGACACATATCA 
c-Myc intron_9 Quasar 570 GATTCCAAGGGCTTTCTTTG 
c-Myc intron_10 Quasar 570 TAATCCCTTCTCCAAAGACC 
c-Myc intron_11 Quasar 570 TCTCGCTCCCAAACGCAAAA 
c-Myc intron_12 Quasar 570 GGTAAGTCAGAAGCTACGGA 
c-Myc intron_13 Quasar 570 TTTAAATGCCCTCTCAGAGA 
c-Myc intron_14 Quasar 570 GTCAGAAATGCACCAAGCTG 
c-Myc intron_15 Quasar 570 TTAAAAGGCTCAGGGACGGG 
c-Myc intron_16 Quasar 570 GGGGGTCAGGCTTAAATTTT 
c-Myc intron_17 Quasar 570 CCAACATCAAGTCCTAGTGC 
c-Myc intron_18 Quasar 570 AATTTTGCTTCTCCTCACTG 
c-Myc intron_19 Quasar 570 TCAACGAATCGGTCACATCC 
c-Myc intron_20 Quasar 570 CAGTCTTCCTAGCAATTCAG 
c-Myc intron_21 Quasar 570 TTACGGAACCGCTCAGATCA 
c-Myc intron_22 Quasar 570 TACACTCTAAACCGCGACGC 
c-Myc intron_23 Quasar 570 ATAATAAGAGACACCTCCCT 
c-Myc intron_24 Quasar 570 GCTATCACAAGCCTCTCGAA 
c-Myc intron_25 Quasar 570 TGGAGGAGAGAGCTCAGTCT 
c-Myc intron_26 Quasar 570 CTTTTCTTTCCGATTGCTGA 
c-Myc intron_27 Quasar 570 AAGGAGAAAGGCGAGAGGCG 
c-Myc intron_28 Quasar 570 CTAAGAGCCGAGGCGCAAAG 
c-Myc intron_29 Quasar 570 GAGGCGACTGTAGGGAATAC 
c-Myc intron_30 Quasar 570 TCCTTCGAGCAGGGACTTAG 
c-Myc intron_31 Quasar 570 TACTATCAGTGACGCTCGTC 
c-Myc intron_32 Quasar 570 AGGCATGCACTCTTTTACTC 







Supplementary Table 2: qRT-PCR and PCR primer sequences 
 
qRT-PCR primers (mouse) 
Gene Forward sequence Reverse sequence 
Pvt1a (ex1a-2) ACTTAGCATTCCCAGAGCCC TGGAGGGCATCTTCTTACCG 
Pvt1b (ex1b-2) CCATGACTGGGAAAAACCTCG TGGAGGGCATCTTCTTACCG 
Pvt1b nascent (ex1b-int) CCATGACTGGGAAAAACCTCG CCAGCACAATAGCCCACAATG 
Pvt1 (ex4-5) CTGGGACACTGCCTGATTGA TCCTTCTGGAACGCTTAAAGG 
Myc TTCATCTGCGATCCTGACGAC CACTGAGGGGTCAATGCACTC 
p21 TCCACAGCGATATCCAGACA GGACATCACCAGGATTGGAC 
Rn7s1 CTGTAGTGCGCTATGCCGA GTTCACCCCTCCTTAGGCAA  
Kcnq1ot1 GGCCAGAAGCAGAGGTGATT CCGAGCCGTAACTGCAAAAC 
Gm26542 CCTTGGCTGACACCCGAACC CCGAGTTCGAGCGCGTCTTC 
Gapdh AGCTTGTCATCAACGGGAAG TTTGATGTTAGTGGGGTCTCG 
Pvt1 p53RE (ChIP) GGCTAAGGATGCAGGTCTC AAACGCTTTCCCACTGGCTA 
Myc promoter (ChIP) CGCGAGCAAGAGAAAATGGTC CTTTGGGAACTCGGGAGGG 
   
qRT-PCR primers (human) 
Gene Forward sequence Reverse sequence 
PVT1a (ex1a-2) TTCCAGTGGATTTCCTTGCGG CTGACAGGCACAGCCATCTTG 
PVT1b (ex1b-2) GCACAAGGGCCCAACTGGA CTGACAGGCACAGCCATCTTG 
MYC TCGGATTCTCTGCTCTCCTCG AGGTGATCCAGACTCTGACCT 
   
3C qRT-PCR primers 






















































































Pvt1 3'E.1 BamHI003 CCTGTCTCCTCCCCCATCCTGA
TAGTAC 
 
Pvt1 3'E.1 BamHI004 TGGTATGAGTATCCAAAGACAT
TGAGGACTC 
 
Pvt1 3'E.2 BamHI003 ACTAGAGTATGTCTGCCTTTTG
TGTGGGAC 
 






   
RT-PCR primers 
Name Forward sequence Reverse sequence 
Pvt1 (ex1a-5) TGGATATCCGCGTGGAAAGG TCCTTCTGGAACGCTTAAAGG 
Pvt1 (ex1b-5) CTCTAGCCAGTGGGAAAGCG TCCTTCTGGAACGCTTAAAGG 
   
Genotyping PCR primers 
Name Forward sequence Reverse sequence 
Pvt1a PAS TACCAGGCAGAGCGCGTG CTGGGCTCCAGAGTTTCCA 
Pvt1b PAS/TWI ACTTGCACAGTCCTATGGTCA CGTAAGGCACATCCTCACCT 
   
Mutagenesis efficiency PCR primers 
Name Forward sequence Reverse sequence 
Pvt1 p53RE GAAGTGCATGTGGTAGGATG GCACATCCTCACCTCCGAGA 
Pvt1 exon 1b GCCTGTTTTGCATATGGGCAG ACAAGGCAGTCCCATACAGTC 
Pvt1 exon 1b 3’ end CAGTGGGAAAGCGTTTGTG AGCAAGAAACAGCCACCCTT 
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Supplementary Table 3: Key plasmids and recombinant DNA used in this work 
Name Source Identifier 
pCMV-dR8.2 
dvpr (Stewart et al., 2003) Addgene #8455 
pCMV-VSV-G (Stewart et al., 2003) Addgene #8454 
pWZL Hygro S. Lowe, unpublished Addgene #18750 
BRD001 Broad Institute N/A 
BRD004 Broad Institute N/A 
UGPC (Olivero et al., 2020) N/A 
lenti-SAM-hygro (Olivero et al., 2020) N/A 
Myc BAC BACPAC Resources Center Cat#RP23-55F11 

































Supplementary Table 4: Software and algorithms used in this work 
 
Resource Source Location 
GraphPad Prism, 
version 8.2.1 for 
MacOS 
N/A www.graphpad.com 






Biorender N/A www.biorender.com 




stringtie (v1.2.4)  (Pertea et 
al., 2015) 
https://ccb.jhu.edu/software/stringtie/ 
HTSeq (v0.6.1)  (Anders et 
al., 2015) 
https://htseq.readthedocs.io/en/release_0.11.1/ 





FastUniq (Xu et al., 
2012) 
http://sourceforge.net/projects/fastuniq/ 
Cutadapt (v1.16)  (Martin, 
2011) 
https://cutadapt.readthedocs.io/en/stable/ 
HISAT2 (v2.1.0)  (Kim et al., 
2015a) 
https://ccb.jhu.edu/software/hisat2/index.shtml 
SAMtools (v1.5)  (Li et al., 
2009) 
http://samtools.sourceforge.net 
STAR (v2.5.3a)  (Dobin et 
al., 2013) 
https://github.com/alexdobin/STAR  
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